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“A Parisian tailor, not yet old, having dined and left his house had walked 
hardly 40 paces when he suddenly fell to the ground and expired.  His body 
was opened and no disease was found except the three semilunar cusps 
leading to the aorta were bony”  
 Théophile Bonet, 1679 
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ABSTRACT 
BACKGROUND 
Aortic stenosis affects not only the valve but also the myocardium.  In 
response to the increased afterload, left ventricular hypertrophy initially 
occurs as a compensatory response to maintain wall stress and cardiac 
output but ultimately, decompensation and heart failure ensues.  The 
transition from adaptation to decompensation is driven by myocyte death 
and myocardial fibrosis. The aims of the thesis are to investigate 
cardiovascular magnetic resonance assessment of disease severity and 
myocardial fibrosis, and explore its relationship with other biomarkers of 
disease activity and clinical outcome in patients with aortic stenosis. 
 
METHODS AND RESULTS 
The conventional assessment of aortic stenosis relies heavily on two-
dimensional and Doppler echocardiography but there are inherent 
limitations in echocardiography that can affect the severity classification.  I 
demonstrated that cardiovascular magnetic resonance offered a more 
accurate estimation of left ventricular volumes and mass, and excellent 
myocardial characterization.  Indeed, inaccurate stroke volume estimation by 
Doppler echocardiography and inconsistent thresholds in current guidelines 
accounted for more than 40% of patients with discordant small-area, low-
gradient aortic stenosis.  These data may explain the variable prognosis 
reported in this unique group of patients, and argue for more accurate 
assessment of borderline cases with cardiovascular magnetic resonance.   
 
Late gadolinium enhancement imaging detects focal areas of established 
myocardial fibrosis.  In many conditions, including aortic stenosis, a more 
diffuse form of fibrosis predominates, which is potentially reversible and not 
readily identified by late gadolinium enhancement.  Recently several 
myocardial T1 mapping approaches have been developed to quantify diffuse 
fibrosis. Using a standardized and systematic approach, I compared several 
commonly used T1 mapping techniques and identified that extracellular 
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volume had the best profile (reproducibility and discriminatory potential) for 
the identification of diffuse fibrosis in patients with aortic stenosis.   
 
Cardiac troponin is a structural protein present in the cardiac myocytes.  
Recent advances in assay technology have substantially improved 
sensitivity, allowing quantification of troponin concentrations with a high 
degree of precision in everyone.  In more than 250 patients with aortic 
stenosis, I demonstrated that cardiac troponin I concentrations were 
independently associated with markers of left ventricular decompensation 
(hypertrophy and fibrosis) and predicted clinical outcome in patients with 
aortic stenosis. This suggests that myocardial fibrosis detected by 
cardiovascular magnetic resonance is consequent on myocardial injury 
secondary to left ventricular decompensation. 
 
Left ventricular hypertrophy with strain pattern on a 12-lead 
electrocardiogram is associated with poor outcome in patients with aortic 
stenosis, but the mechanism of this electrocardiographic pattern has not been 
described.  In more than 300 patients with aortic stenosis, I demonstrated 
that these characteristic repolarization abnormalities were a highly specific 
marker of focal mid-wall myocardial fibrosis (specificity of 99% and 
sensitivity of 54%).  Moreover, the prognostic value of this 
electrocardiographic pattern was again confirmed with markedly worse 
long-term outcomes in these patients.  
 
CONCLUSION 
I have demonstrated that cardiovascular magnetic resonance can assist in the 
assessment of disease severity in patients with aortic stenosis and discordant 
echocardiographic findings. Moreover, I have validated the assessment of 
diffuse myocardial fibrosis, as well as, demonstrated the close association 
between myocardial fibrosis and biomarkers of myocardial injury and 
electrocardiographic strain pattern that predicted an adverse outcome in 
patients with aortic stenosis. 
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1.1 OVERVIEW 
Calcific aortic stenosis is the most common valvular heart condition in 
developed countries, displaying an increasing prevalence with age (1).  
Aortic stenosis is characterized by progressive narrowing of the aortic valve, 
driven by a complex, active and highly regulated process of inflammation, 
fibrosis and calcification that leads to leaflet thickening and immobility (2,3). 
In response to the narrowed valve, left ventricular hypertrophy occurs 
initially to restore wall stress and cardiac performance, but ultimately this 
process decompensates and patients progress towards heart failure, 
symptoms and adverse clinical outcomes (4).   
 
Contemporary guidelines advocate aortic valve replacement in patients with 
severe aortic stenosis and evidence of left ventricular decompensation 
defined by either the presence of symptoms or an impaired ejection fraction 
less than 50% (5,6).  Echocardiography is the imaging modality of choice for 
assessing aortic stenosis: two dimensional imaging allows direct 
visualization of the valvular apparatus and cardiac chambers and Doppler 
techniques provide non-invasive assessment of haemodynamics (7). 
However, echocardiography is inherently limited, particularly in patients 
with poor acoustic windows and is more operator-dependent compared to 
other imaging modalities.  Moreover, current approaches of assessing left 
ventricular decompensation also have crucial limitations.  Aortic stenosis 
commonly occurs in elderly patients with comorbidities (such as coronary 
artery disease, hypertension and chronic lung diseases) that may confound 
symptom presentation and contribute to adverse cardiovascular outcomes.  
Importantly, an impaired ejection fraction occurs late in the disease process 
when myocardial damage may not be reversible.  Whilst the risk of sudden 
cardiac death during the asymptomatic phase is relative low (~1% per year 
in large prospective series (8,9)), it is not negligible.  Indeed, recent studies 
have suggested improved outcomes with early aortic valve replacement in 
asymptomatic patients with preserved systolic function (10,11).  
 
	   18	  
A more thorough understanding of the mechanism of left ventricular 
decompensation is essential to identify patients with aortic stenosis who may 
benefit from early aortic valve replacement.   
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1.2 THE ASSESSMENT AND CLASSIFICATION OF AORTIC 
STENOSIS 
The severity of aortic stenosis is classified using aortic valve area, mean 
transvalvular gradient and peak aortic jet velocity, with thresholds 
established from a variety of haemodynamic and natural history data (Table 
1.1) (5-7).   
 
TABLE 1.1.  CLASSIFICATION OF AORTIC STENOSIS SEVERITY 
Severity Aortic Valve Area (cm2) 
Mean Pressure 
Gradient (mmHg) 
Peak Aortic Jet 
Velocity (m/s) 
Mild > 1.5 < 20 2.0 to 2.9 
Moderate 1.0 to 1.5 20 to 39 3.0 to 3.9 
Severe < 1.0 > 40 > 4 
 
A normal aortic valve measured between 3.0 and 4.0 cm2 and serious 
consequences occurred when valve area was reduced by more than 25% of 
the normal area; thus an aortic valve area of 1.0 cm2 (corresponding to an 
indexed aortic valve area of 0.6 cm2/m2, assuming a body surface area of 1.75 
m2) was defined as severe aortic stenosis in adults (12).  Although this 
threshold of 1.0 cm2 was established from invasive cardiac catheterization, 
this was subsequently confirmed with valve areas estimated from the 
continuity equation and echocardiography (9,12,13).   
 
Using the continuity equation, the calculated aortic valve area is based on the 
ratio between Doppler stroke volume and post-aortic valve flow.  However, 
estimation of stroke volume by Doppler echocardiography assumes a 
circular and geometrically regular left ventricular outflow tract and a laminar 
flow profile, which is frequently not the case.  In addition, the severity 
thresholds based on aortic valve areas and mean transvalvular gradients in 
current guidelines are inherently discordant: theoretical models have 
suggested an aortic valve area of 1.0 cm2 corresponds more closely to a mean 
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transvalvular gradient of 30 to 35 mmHg, whilst the current recommended 
threshold of 40 mmHg corresponds to an aortic valve area of 0.8 to 0.9 cm2 
(14,15).  The combination of these factors can have a significant impact on the 
assessment and classification of patients with aortic stenosis, particularly in 
patients with small aortic valve area, low transvalvular gradient aortic 
stenosis and preserved systolic ejection fraction (paradoxical low-flow low-
gradient severe aortic stenosis).  The outcomes associated with these patients 
have been variable in different studies, presumably reflecting a 
heterogeneous population and highlighting the limitations of current 
assessment and classification.  
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1.3 LEFT VENTRICULAR HYPERTROPHY: ADAPTATION TO HEART 
FAILURE 
In conditions associated with left ventricular pressure overload such as aortic 
stenosis, myocyte size and myocardial wall thickness increase to restore wall 
stress (σ) according to the LaPlace’s Law: σ = [P x r] / 2h where P is left 
ventricular pressure, r is left ventricular radius and h is the myocardial wall 
thickness.  The changes in ventricular pressure, radius and wall thickness are 
initially adaptive, maintaining cardiac output and systolic function (16).  
 
There is significant heterogeneity in the magnitude of hypertrophy that 
patients develop in response to similar degrees of aortic valve narrowing.  
Indeed, multiple studies have shown only a weak correlation between the 
severity of aortic valve narrowing and left ventricular mass: approximately 
10 to 20% of patients with severe aortic stenosis have no evidence of left 
ventricular hypertrophy (17-22).  Sex-related differences partially explain this 
variation, with women having smaller ventricles and lower myocardial mass 
compared to men (23-27), potentially as a consequence of differences in sex-
related hormones and overall body mass (24,27).  However, other clinical 
factors are also known to influence the magnitude of the hypertrophic 
response: age, the metabolic syndrome, obesity, ACE I/D polymorphisms, 
and importantly concomitant hypertension that imposes an additional load 
to the left ventricle (19,28-32).  In order to account for both the arterial and 
valvular load on the left ventricle, a measure of the global left ventricular 
haemodynamic load (valvulo-arterial impedance, ZVA) has been proposed, 
with ZVA values >3.5 to 4.5 mmHg/mL/m2 providing incremental prognostic 
value in patients with moderate and severe aortic stenosis (33,34).  
 
As left ventricular hypertrophy increases, it will ultimately decompensate.  
This is characterized by progressive impairment in left ventricular 
performance and the development of symptoms (17,20,35) (Figure 1.1).  The 
pathologic transition from ventricular adaptation to decompensation is 
driven primarily by two processes: myocyte death and myocardial fibrosis 
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(36).  Myocyte death is predominantly in the form of proteosomal-mediated 
autophagy and oncosis (cellular and organelle swelling associated with 
increased membrane permeability), which occurs alongside more 
conventional forms of apoptosis.  This cell death is believed to be activated 
by neurohumoral mediators such as angiotensin II and norepinephrine (37-
40), and by progressive myocardial ischaemia. The latter relates to increased 
myocardial oxygen demand (due to the increased myocardial mass and 
afterload) and reduced coronary flow reserve (due to impaired 
microcirculatory perfusion and inadequate expansion of coronary capillary 
density despite the absence of coronary artery disease) (41,42). 
 
Myocardial fibrosis is one of the histological hallmarks of end-stage heart 
failure (43,44).  The pathogenesis of myocardial fibrosis is complex and the 
distribution varies, depending on the underlying pathology, although it 
generally exists in two predominant forms.  Replacement fibrosis commonly 
occurs late in the disease process, is not believed to be reversible and is 
characterized by a more localized distribution corresponding to areas of 
myocyte loss.  By contrast, interstitial fibrosis is more diffusely distributed, 
reflecting the more uniform and progressive accumulation of collagen in the 
interstitium, and is thought to be potentially reversible with targeted therapy 
(45-49).  Both types of fibrosis are present in aortic stenosis, occupying up to 
30% of the myocardium (16,50,51) and leading to progressive impairment of 
myocardial relaxation and contraction. 
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FIGURE 1.1.  PATHOPHYSIOLOGY OF LEFT VENTRICULAR 
HYPERTROPHY AND THE TRANSITION TO HEART FAILURE IN AORTIC 
STENOSIS 
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1.4 MARKERS OF LEFT VENTRICULAR HYPERTROPHY 
Left ventricular hypertrophy is commonly assessed using the 12-lead 
electrocardiogram and echocardiography.  By both methods, the presence of 
left ventricular hypertrophy in patients with aortic stenosis is associated with 
worse symptoms, impaired systolic function and an adverse prognosis 
(8,20,52,53).  Data from the recent Simvastatin and Ezetimibe in Aortic 
Stenosis substudy reported an independent association between 
electrocardiographic left ventricular hypertrophy with strain and 
cardiovascular events in more than 1500 patients and 4 years of follow-up 
(8).  However, the mechanism associated with this electrocardiographic 
strain was not known until recently.  Electrocardiographic left ventricular 
hypertrophy with strain pattern was demonstrated to be a marker of an 
exaggerated hypertrophic response.  Although these tests are non-invasive, 
inexpensive and well tolerated, an electrocardiogram is relatively insensitive 
in detecting left ventricular hypertrophy (54) and echocardiography relies 
heavily upon suitable acoustic windows, experience of the operator and a 
series of geometrical and mathematical assumptions (55).  This may limit 
accurate measurements, particularly in subjects with distorted left ventricles 
or asymmetrical ventricular hypertrophy.   
 
On the other hand, assessment by cardiovascular magnetic resonance is 
independent of geometric assumptions, providing highly accurate and 
reproducible measures of the left ventricle.  Indeed, cardiovascular magnetic 
resonance is accepted as the non-invasive reference gold-standard for 
estimating left ventricular mass, volumes and ejection fraction (56,57) and it 
is being increasingly used to investigate the hypertrophic response in aortic 
stenosis.  Consistent with previous electrocardiographic and 
echocardiographic data, indexed left ventricular mass assessed using 
cardiovascular magnetic resonance demonstrated an increased trend of 
predicting all-cause mortality in patients with moderate to severe aortic 
stenosis (58).   
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Traditionally, four patterns of ventricular hypertrophy based on myocardial 
wall thickness, left ventricular volume and mass have been described: 
normal geometry, concentric remodeling, concentric hypertrophy and 
eccentric hypertrophy (55).  Recently, high spatial resolution cardiovascular 
magnetic resonance demonstrated the presence of asymmetric patterns of 
ventricular remodeling and hypertrophy in more than one in four patients 
with aortic stenosis (18).  However, it remains unclear how patients 
transition between these different patterns, how they relate to the 
progression to heart failure and what the clinical consequences of these 
patterns might be. 	  
 
Although the European Society of Cardiology had suggested aortic valve 
replacement be considered in patients with excessive left ventricular 
hypertrophy (Class IIb; Level of evidence: C) (5), the extent at which left 
ventricular hypertrophy is considered excessive in a patient is challenging to 
define.  Instead, much of current evidence and ongoing research has focused 
on markers of ventricular decompensation secondary to maladaptive and 
advanced myocardial hypertrophy. 
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1.5 MARKERS OF DECOMPENSATION: LEFT VENTRICULAR 
PERFORMANCE 
1.5.1 Systolic Function 
Left ventricular ejection fraction is the conventional marker of global systolic 
dysfunction.  Current guidelines recommend aortic valve replacement in 
patients with severe aortic stenosis and a reduced ejection fraction <50% 
(5,6).  However, left ventricular ejection fraction is not sensitive to detect 
mild degrees of left ventricular systolic dysfunction (59,60).  Moreover, the 
evidence for using ejection fraction as an indication for aortic valve 
replacement is weak. Indeed, this recommendation is largely based upon 
limited retrospective studies that demonstrated an improvement in left 
ventricular function following aortic valve replacement in patients with 
severe aortic stenosis and impaired ejection fraction (61,62). 
 
Another limitation of using the ejection fraction is its tendency to 
overestimate myocardial systolic function in the presence of advanced 
concentric hypertrophy. This is because the associated increases in 
myocardial wall thickness and filling pressures, alongside reductions in 
ventricular volumes can result in a normal or even supra-normal ejection 
fraction despite significant impairment in intrinsic myocardial contractility 
(59,63,64). By contrast, echocardiographic assessment of mid-wall fractional 
shortening and longitudinal function better reflect such contractility.  They 
have been associated with the presence of symptoms and the magnitude of 
the left ventricular afterload in aortic stenosis, although their prognostic 
significance remains to be established (65-68). In addition, novel myocardial 
deformation imaging (strain and strain rate) using two-dimensional speckle 
tracking echocardiography has been proposed as an alternative and highly 
sensitive technique for the assessment of intrinsic myocardial contractility 
(69,70).  This approach measures the magnitude of myofibril contraction in 
the left ventricle, which varies in direction according to the different 
myocardial layers.  Indeed, multi-directional strain imaging has 
demonstrated that myocardial dysfunction is present despite preserved 
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ejection fraction and interestingly, it progresses in a step-wise fashion from 
subendocardial dysfunction in mild aortic stenosis (abnormal longitudinal 
deformation), to mid-wall dysfunction in moderate aortic stenosis (abnormal 
circumferential deformation), and eventually transmural dysfunction in 
severe disease (abnormal radial deformation) (67,71,72). This technique also 
appears to provide prognostic information, with impaired longitudinal 
myocardial strain and strain rate predicting an adverse outcome in 
asymptomatic patients with aortic stenosis (34).  
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1.5.2 Diastolic Function 
Impaired left ventricular relaxation occurs in aortic stenosis as a result of left 
ventricular hypertrophy and myocardial fibrosis (16,73-75), frequently 
preceding reductions in ejection fraction.  Current studies examining 
diastolic dysfunction in aortic stenosis have largely relied on Doppler mitral 
inflow and myocardial tissue velocities (52,76-78), with limited data using 
myocardial strain and strain rate imaging.  These echocardiographic 
measures of diastolic dysfunction are associated with worse symptomatic 
status (52,78), and predict adverse cardiovascular events (34,76,79).  They 
therefore hold potential as early markers of left ventricular decompensation 
although their relationship with the more sensitive assessment of systolic 
dysfunction such as strain and strain rate imaging is not well understood 
and there is some inconsistency with respect to their prognostic value (77). 
 
Measurement of the left atrial size is an alternative method for assessing 
diastolic function that has been the subject of several small-scale studies 
(34,79).  It is also closely linked with the development of atrial fibrillation, 
which in the context of aortic stenosis is associated with advanced 
hypertrophy, an impaired ejection fraction and an increased risk of heart 
failure and cerebrovascular events (80).   
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1.5.3 Role of Exercise Stress Testing 
The prompt identification of symptoms is crucial in the effective 
management of patients with aortic stenosis, given the poor prognosis 
associated with their development (4).  However, it should be noted that the 
cardinal symptoms established by Ross and Braunwald (angina, exertional 
dyspnoea, pre-syncope and syncope) were based on young patients with 
bicuspid or rheumatic disease (average age of 63 years at time of death) 
compared to the older patients who present today with calcific aortic stenosis 
and comorbidities.  The assessment of symptoms in contemporary clinical 
practice is therefore frequently challenging.  Under reporting is common, 
and patients may unconsciously limit their activities to minimize symptoms.  
In these situations, exercise stress testing performed under close supervision 
and with careful monitoring of blood pressure and electrocardiographic 
changes may be helpful in unmasking otherwise latent symptoms.  However, 
in a meta-analysis of 7 studies and 491 patients with asymptomatic severe 
aortic stenosis, the sensitivity, specificity, positive and negative predictive 
values for an adverse cardiac event after an abnormal exercise stress test 
were only modest at 75%, 71%, 66% and 79% respectively (81).  Nevertheless, 
both the American Heart Association/American College of Cardiology and 
European Society of Cardiology guidelines recommend that aortic valve 
replacement be considered in patients who develop exercise-limiting 
symptoms or an abnormal blood pressure response (defined as an increase in 
systolic blood pressure of <20 mmHg) on exercise stress testing (5,6,82,83).   
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1.5.4 Brain Natriuretic Peptide 
Interest has surrounded the use of the blood biomarkers brain natriuretic 
peptide (BNP) and the related N-terminal fragment of proBNP (NT-proBNP) 
in aortic stenosis. These are endogenous cardiac hormones released in 
response to increased left ventricular wall stress and are therefore elevated in 
patients with left ventricular dysfunction. Several studies have demonstrated 
that their levels increase as patients transition from hypertrophy to heart 
failure and that they hold promise in assessing patients with equivocal 
symptoms and severe disease (84-87). 
 
The value of measuring BNP and NT-proBNP in patients who are 
asymptomatic is less certain.  In many studies, BNP and NT-proBNP 
demonstrated a better association with clinical outcomes than traditional 
measures of aortic stenosis severity (88-91). However, two recent studies 
have questioned their prognostic value, failing to demonstrate an 
incremental prognostic value when other clinical and echocardiographic 
measures of aortic stenosis were also considered (86,92).  Of note, patients in 
the latter two studies were older (79 to 83 years versus 68 to 74 years), hinting 
at an important limitation of these biomarkers.  Both BNP and NT-proBNP 
increase substantially with advancing age independent of aortic valve 
disease (93,94) and this lack of specificity in the elderly (the population most 
commonly affected by aortic stenosis) makes the selection of appropriate 
thresholds difficult.  Moreover, BNP and NT-proBNP lack sensitivity and 
levels only increase in the later stages of left ventricular decompensation 
when symptoms and other markers of left ventricular dysfunction are 
already apparent. 
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1.6 MARKERS OF DECOMPENSATION: MYOCARDIAL FIBROSIS  
Myocardial fibrosis is one of the key mediators in the transition from 
compensatory left ventricular hypertrophy to heart failure, occurring early 
and crucially, before significant deterioration in cardiac diastolic/systolic 
function (50,95) (Figure 1.2).  Therefore, there is considerable interest in 
novel biomarkers associated with this transition so that high-risk patients 
with aortic stenosis may be identified and offered prompt valvular 
replacement before heart failure ensues. 
 
Myocardial biopsy remains the gold standard of diagnosing myocardial 
fibrosis.  However, it is invasive, susceptible to sampling errors and unable 
to assess the fibrotic burden of the whole heart.  Alternatively, 
echocardiography and circulating markers of collagen metabolism have been 
used as indirect measures of myocardial fibrosis but collagen markers lack 
specificity and integrated backscatter echocardiographic techniques are 
prone to artifacts (less than half of the patients have suitable backscatter 
signal for analysis) and have poor reproducibility (96-98). 
 
Multiparametric cardiovascular magnetic resonance offers high-resolution 
whole-heart imaging and excellent myocardial characterization, providing a 
more accurate diagnosis than localized invasive myocardial biopsy.  In 
addition, cardiovascular magnetic resonance allows serial assessment of 
myocardial remodeling and fibrosis over time.  Currently, two approaches 
are used: late gadolinium enhancement, for direct visualization and 
quantification of focal replacement fibrosis, and novel myocardial T1 
mapping, for assessing more diffuse patterns of myocardial fibrosis.   
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FIGURE 1.2. MARKERS OF LEFT VENTRICULAR HYPERTROPHY AND 
VENTRICULAR DECOMPENSATION IN AORTIC STENOSIS  
 
(Abbreviations: BNP brain natriuretic peptide; NT-proBNP N-terminal 
fragment of proBNP; ECG electrocardiogram; EF ejection fraction; LGE late 
gadolinium enhancement; TDI tissue Doppler imaging; hs cTnI/T high 
sensitivity cardiac troponin I/T; MRI cardiovascular magnetic resonance) 
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1.6.1 Late Gadolinium Enhancement 
In cardiovascular magnetic resonance, the pixel signal intensity is based on 
the relaxation of hydrogen protons in a static magnetic field.  One of the 
relaxation parameters is T1, the time constant (measured in milliseconds) 
corresponding to approximately 63% of its longitudinal recovery.  T1 
relaxation times depend on the underlying tissue composition: for example, 
T1 is shortest in fat and longest in water. 
 
Extracellular gadolinium-based contrast agents distribute only in the 
intravascular and the extracellular space.  After intravenous injection, 
gadolinium contrast diffuses into the extracellular space (‘wash in’).  As a 
result of redistribution and renal excretion, the blood concentration of 
gadolinium falls and the contrast is ‘washed out’ from the extracellular space 
into the blood pool.   In the normal myocardium, contrast concentration in 
the extracellular space equilibrates rapidly with the blood pool.  In regions of 
myocardial fibrosis, extracellular space is expanded because of excessive 
collagen deposition.  As a result, gadolinium volume of distribution is 
increased and wash out is prolonged (99).  The combination of these effects 
causes a significant difference in contrast concentration between normal and 
abnormal myocardium during the equilibrium phase following contrast 
administration. 
 
In the presence of gadolinium-based contrast agents, T1 relaxation in regions 
of fibrosis is considerably shorter compared with surrounding normal 
myocardium.  Using the conventional inversion-recovery gradient echo 
sequences, maximum difference in signal intensity between normal and 
abnormal myocardium is achieved at the “null” point – the inversion time 
where normal myocardium appears dark (100).  This technique can therefore 
identify areas of replacement fibrosis in the myocardium which appear 
bright in the mid-wall of the left ventricle, in contrast to the surrounding 
black-appearing normal myocardium (Figure 1.3) (44,101,102).  Importantly, 
this pattern of fibrosis can be differentiated from that observed with prior 
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myocardial infarction, which can also be observed in patients with aortic 
stenosis.   
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FIGURE 1.3. LATE GADOLINIUM ENHANCEMENT AND MYOCARDIAL 
T1 MAP 
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Several studies have investigated the role of late gadolinium enhancement.  
A recent study of 143 patients with moderate to severe aortic stenosis 
demonstrated the presence of replacement fibrosis was an independent 
predictor of mortality, providing incremental prognostic value over and 
above that of the ejection fraction.  Indeed, patients with myocardial fibrosis 
had an 8-fold increase in all-cause mortality compared to those without 
fibrosis despite similar aortic stenosis severity and coronary artery disease 
burden (58).  Similar findings have also been observed in patients following 
aortic valve replacement, with the presence of replacement fibrosis being 
associated with adverse ventricular remodeling and worse peri-operative 
and long-term outcomes following aortic valve replacement (51,103-106).  
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1.6.2 Myocardial T1 Mapping 
As discussed earlier, the predominant form of myocardial fibrosis in aortic 
stenosis is actually interstitial not replacement fibrosis.  As a consequence of 
its diffuse distribution, this form of fibrosis is not detected by late 
gadolinium enhancement, which relies on regional differences in signal 
intensity between normal and fibrotic regions (44).  Instead, novel 
myocardial T1 mapping is an emerging technique to quantify this form of 
fibrosis  (Figure 1.3) (107).   
 
Current methods differ principally in magnetization preparation pulse 
sequences and image acquisition timings, with the Modified Look-Locker 
Inversion-recovery sequence being the most widely studied (107-110).  The 
Modified Look-Locker Inversion-recovery sequence uses 17 heartbeats 
within one breath-hold to acquire 11 images with different inversion times 
during mid-diastole.  Thereafter, the images were combined and the T1 in 
each individual voxel was estimated using a non-linear curve-fitting 
algorithm and a Look-Locker correction method (111) (Figure 1.4).    
 
To date four major T1 measures have been assessed and validated against 
histology with promising results.  The major strengths and limitations are 
discussed in Table 1.2.  Although prospective outcome data associated with 
myocardial T1 mapping are lacking in aortic stenosis, they have been 
established in other cardiovascular patient populations (112-114).  
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FIGURE 1.4. MODIFIED LOOK-LOCKER INVERSION-RECOVERY 
SEQUENCE IMAGE ACQUISITION 
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1.6.3 High-sensitivity Cardiac Troponin 
A plasma biomarker that appears to be released early during the transition 
from hypertrophy to heart failure is cardiac troponin.  Increased cardiac 
troponin concentrations have traditionally been considered to be a highly 
specific marker of myocardial necrosis in patients with acute coronary 
syndromes (115).  However recent advances in assay sensitivity allow 
quantification of plasma cardiac troponin with a high degree of precision at 
extremely low plasma concentrations (116).  This allows the detection of 
myocardial injury in a wide range of cardiac conditions aside from acute 
coronary syndromes, including aortic stenosis.  As previously discussed, 
myocyte death is one of the key factors driving left ventricular 
decompensation in aortic stenosis, and this provides a clear rationale for 
troponin as a cheap and potentially widely available biomarker of this 
process.  
 
In a recent study, high-sensitivity plasma cardiac troponin T concentrations 
were detectable in all 57 patients with moderate and severe aortic stenosis.  
Moreover, these concentrations correlated positively with left ventricular 
wall thickness, ventricular mass and the severity of aortic stenosis but 
interestingly did not appear related to concomitant coronary artery disease.  
Furthermore, the highest quartile of high-sensitivity troponin T 
concentrations was associated with worst 2-year survival rates (117).  
Although early data is encouraging, larger studies are needed to investigate 
the potential clinical role for high-sensitivity cardiac troponin and the 
mechanism of its release in aortic stenosis.  
	   41	  
1.7 THESIS AIMS AND HYPOTHESES  
The aims of the thesis are: 
1. To compare stroke volume estimation using echocardiography with the 
standard reference of using cardiovascular magnetic resonance and 
establish the optimal threshold for severe aortic stenosis 
 
2. To characterize the temporal and regional T1 profiles of the 
myocardium and to identify the optimal approach based upon its 
reproducibility and ability to differentiate asymptomatic patients with 
aortic stenosis from healthy volunteers 
 
3. Using a high-sensitivity assay and cardiovascular magnetic resonance, 
to establish the determinants and long-term prognosis associated with 
plasma cardiac troponin I concentrations in patients with aortic stenosis 
 
4. To investigate the association between electrocardiographic strain 
pattern and extent of ventricular hypertrophy and myocardial fibrosis 
assessed using cardiovascular magnetic resonance; and to examine the 
prognosis associated with this electrocardiographic pattern in patients 
with aortic stenosis 
The hypotheses of the thesis are: 
1. Combination of left ventricular outflow tract area underestimation and 
inconsistent thresholds influence the classification of aortic stenosis 
severity, and contribute to patients with small aortic valve area, low 
transvalvular gradient aortic stenosis (Chapter 3) 
 
2. Among the commonly used T1 measures, extracellular volume fraction 
has the best profile (reproducibility and ability to differentiate patients 
with aortic stenosis from healthy volunteers) and therefore, holds the 
most potential to assess diffuse myocardial fibrosis in aortic stenosis 
(Chapter 4) 
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3. Detection of myocardial injury by high-sensitivity troponin assays 
provide an early indication of left ventricular decompensation and it is 
associated with long-term cardiovascular events in patients with aortic 
stenosis (Chapter 5) 
 
4. Left ventricular hypertrophy with strain on an electrocardiogram is a 
marker of left ventricular decompensation and it predicts adverse 
cardiac events in patients with aortic stenosis (Chapter 6) 
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2.1 PATIENT POPULATION 
Stable adults with mild to severe aortic stenosis (including those with planned 
aortic valve replacement) and who were able to provide informed consent 
were eligible for the studies.  These patients were prospectively recruited from 
the Edinburgh Heart Centre, United Kingdom.  The exclusion criteria were: 
(1) other significant valvular heart disease (defined as moderate or worse in 
severity); (2) significant co-morbidities with limited life expectancy (such as 
advanced malignancy, end-stage heart failure); (3) contraindications for 
cardiovascular magnetic resonance such as implantable cardiac devices, renal 
impairment with glomerular filtration rate <30 mL/min/1.73 m2, ocular 
metallic foreign bodies, cranial aneurysmal clips and women who were 
pregnant or lactating; (4) acquired or inherited cardiomyopathies (including 
previous myocarditis).  The presence of coronary artery disease was defined 
by previous infarction, clinical symptoms of angina (in those with mild or 
moderate aortic stenosis), evidence of myocardial ischemia or >50% luminal 
stenosis in a major epicardial vessel. 
 
Written informed consent was obtained from all participants.  All studies had 
received ethical approval from the South East Scotland Research Ethics 
Committee and the research was conducted in accordance with the 
Declaration of Helsinki.  Where appropriate, studies were registered with 
clinicaltrials.gov (NCT01755936). 
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2.2 ECHOCARDIOGRAPHY 
Comprehensive transthoracic echocardiography was performed in all 
patients (iE33, Philips Medical Systems, Best, the Netherlands) by a research 
ultrasonographer (Audrey White) and a cardiologist certified in 
echocardiography (Dr Calvin Chin).  The severity of aortic stenosis was 
assessed and classified according to the European Association of 
Echocardiography/American Society of Echocardiography guidelines (7).   
 
Left ventricular outflow tract diameter was measured in the parasternal 
long-axis view, at the insertion of the aortic cusps from the inner edge of the 
septal endocardium to the inner edge of the anterior mitral leaflet in mid-
systole.  Left ventricular outflow tract velocity-time integral was measured in 
the apical 5-chamber view using pulsed-wave Doppler just proximal to the 
aortic valve, careful to obtain a laminar spectral tracing to avoid 
contamination from flow across the aortic valve.  The peak aortic jet velocity 
and mean transvalvular gradient were derived from the aortic valve velocity-
time integral, using continuous-wave Doppler.  The highest aortic jet velocity 
and mean transvalvular gradient were determined in multiple acoustic 
windows using standard S51 and D2cwc probes (Philips Medical Systems, 
Best, the Netherlands), and corroborated by the 2 operators.  The mean of 3 
readings (5 if the patient had atrial fibrillation) was recorded.  Aortic valve 
area was calculated with the continuity equation (Aortic valve area = 
Doppler stroke volume/aortic valve velocity-time integral; Doppler stroke 
volume = left ventricular outflow tract area x left ventricular outflow tract 
velocity-time integral).   In our centre, we were able to achieve excellent 
reproducibility in the assessment of aortic stenosis severity (intra- and inter-
observer reproducibility of 4.9% and 6.9% for aortic valve area, respectively) 
(118). 
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Diastolic function was determined using the standard measures (119).  Trans-
mitral early and late diastolic velocities and deceleration time of early filling 
velocity were measured at the tips of the mitral valve leaflets using pulsed-
wave Doppler.  The mean early diastolic velocities of the medial and lateral 
mitral annulus were measured using pulsed-wave tissue Doppler imaging.  
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2.3 CARDIOVASCULAR MAGNETIC RESONANCE 
 
Cardiovascular magnetic resonance was performed at 3T (MAGNETOM 
Verio, Siemens AG, Healthcare Sector, Erlangen, Germany) according to a 
standardized protocol.  Localizer scans were first performed to ascertain the 
anatomical position of the heart and to plan subsequent examinations.  Rapid 
axial views of the entire thorax were performed with an ultra fast spin echo 
sequence in a single breath hold (Half-fourier Acquisition Single-shot Turbo 
Spin Echo; HASTE).  Double-oblique sections of the heart were performed 
with a high-resolution balanced steady-state free precision sequence (True 
Fast-Imaging with Steady state Precision; TrueFISP) to obtain the standard 
long axis two-chamber, three-chamber, four-chamber and axial view of the 
aortic valve (FIGURE 2.1).  Short-axis cine images extending from the mitral 
valve to the left ventricular apex (8 mm parallel slices with 2 mm spacing; 
temporal resolution ≤ 45 ms) were used for the assessment of left ventricular 
volumes, mass and function. 
 
In this study, diffuse myocardial fibrosis is assessed using myocardial T1 
mapping, performed using the Modified Look-Locker Inversion-recovery 
(flip angle 35°; minimum TI 100 ms; TI increment of 80 ms; time delay of 150 
ms; heart beat acquisition scheme of 3-3-5) with built-in motion correction 
(109,110,120).  A gradient echo field map and associated shim were 
performed to minimize off-resonance frequency artifact.  Short axis T1 maps 
of the basal, mid-cavity and apical slices were acquired before and at 20 min 
following the administration of 0.1 mmol/kg of gadobutrol (Gadovist, Bayer 
Pharma AG, Germany).  The basal slice was defined as the first complete ring 
of myocardium below the left ventricular outflow tract, and the mid-cavity 
slice as the most basal slice to include both papillary muscles.  The apical 
slice was selected between the apex and the mid-cavity on the image least 
affected by trabeculations and partial volume averaging.  The acquisition 
sequence and the commonly used T1 measures have been described in detail 
in Chapter 1.  In a recent study, we had compared the commonly used T1 
measures and demonstrated pre- and post-contrast T1 had excellent intra- 
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and inter-observer reproducibility (intra-class coefficient >0.95) and good 
scan-rescan reproducibility (intra-class coefficient 0.56 to 0.72).  On the other 
hand, both partition coefficient and extracellular volume fraction had the 
best reproducibility profile (intra-class coefficient of >0.95 and a variability of 
< 2.5% for inter-, intra-observer and scan-rescan reproducibilities) (121).   
 
Late gadolinium enhancement was performed between 8 and 15 min 
following gadobutrol administration.  Two approaches were used: an 
inversion-recovery fast gradient-echo sequence and a phase-sensitive 
inversion-recovery sequence in two phase-encoding directions to 
differentiate true enhancement from artifact (100,122).  The inversion time for 
the inversion-recovery fast gradient-echo sequence was optimized for each 
slice to achieve satisfactory nulling of the myocardium. 
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FIGURE 2.1. PLANNING THE BASIC CARDIAC VIEWS 
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2.4 HIGH SENSITIVITY CARDIAC TROPONIN I 
Plasma cardiac troponin I concentrations were determined using a high-
sensitivity assay (ARCHITECT STAT, Abbott Laboratories, Abbott Park, IL, 
USA).  The ARCHITECT STAT assay uses the chemiluminescent 
microparticle immunoassay technology.  In the first step, the sample and 
anti-troponin I antibody coated paramagnetic microparticles are combined.  
Cardiac troponin I present in the sample binds to the anti-troponin I coated 
microparticles.  After washing, the acridinium-labeled anti-troponin 
conjugate is added in the second step.  Following another wash, pre-trigger 
and trigger solutions are added to the reaction, resulting in a 
chemiluminescent reaction (Figure 2.2).  This reaction is measured in relative 
light units by the ARCHITECT i System optics and the cardiac troponin I 
concentration is reported based on a standard calibration curve established 
with known concentrations (123).   
 
The lower limit of detection of this assay is 1.2 ng/L (116) and the 99th centile 
from a healthy reference population is 26 ng/L, with a 10% inter-assay 
coefficient of variation at 4.7 ng/L (123). Precision profiling of the assay was 
also performed in our centre (248 samples in 18 healthy controls).  The inter-
assay coefficient of variation for duplicate samples was 10% at 6 ng/L and 
20% at 1.5 ng/L. 
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FIGURE 2.2. BIOLOGICAL PRINCIPLES OF THE HIGH-SENSITIVITY 
TROPONIN I ASSAY 
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2.5 ELECTROCARDIOGRAM 
In all patients, a standard resting 12-lead electrocardiogram (10 mm/mV at 
25 mm/s) was acquired in supine position using the same machine (Philips 
Pagewriter TC50, Philips Medical Systems, Massachusetts, USA).  
Electrocardiograms were performed on the day of cardiovascular magnetic 
resonance imaging, and interpreted according to the recommendations by 
the American Heart Association/American College of Cardiology 
Foundation/Heart Rhythm Society (124).  Poor quality electrocardiograms 
were repeated.  Electrocardiographic left ventricular hypertrophy was 
diagnosed using the Romhilt-Estes system (score ≥5) (125) and QRS 
duration, PR and QT intervals were determined based on the Philips DXL 
ECG Algorithm (126). 
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2.6  COMPUTED TOMOGRAPHY 
Patients in the Outcome Cohort (Chapters 5 and 6) also underwent 
computed tomography of the aortic valve.  This cohort consisted of patients 
from the Scottish Aortic Stenosis Lipid Lowering, Impact on Regression 
(SALTIRE) and the imaging methodology had been described previously 
(127).  Computed tomography was performed using a double-helix scanner 
(Twin II Flash, Philips Medical Systems, Massachusetts, USA).  The aortic 
valve was scanned with 2.7-mm slices, increments of 1.4 mm during 
inspiratory breath-holding sessions.  The images were analysed by a single 
operator using an automated software (Picker Cardiac Scoring), involving a 
modified Agatston scoring method with a threshold of 90 Hounsfield units to 
compensate for non-gated imaging (127). Computed tomography aortic valve 
calcium score had an excellent reproducibility of 0.07 log arbitrary units 
(128). 
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2.7 IMAGE ANALYSIS 
The quantification of left ventricular volumes, function and mass was 
performed using the Argus Ventricular Function software (Siemens AG 
Healthcare Sector, Erlangen, Germany).  Papillary muscles and minor 
trabeculations were included in the volume measurements (and excluded in 
left ventricular mass measurements) during both phases of the cardiac cycle, 
indexed to body surface area.  Normal indexed volumes, ejection fraction 
were defined using sex- and age-specific ranges (129).  Left ventricular mass 
was calculated from the total end-diastolic myocardial volume multiplied by 
the specific gravity of the myocardium (1.05 g/mL). 
 
The presence of myocardial enhancement was independently determined by 
two experienced operators (Dr Calvin Chin and Dr Marc Dweck).  The extent 
of mid-wall late gadolinium enhancement was quantified using QMASS 
software (Medis medical Imaging Systems, Leiden, the Netherlands) using a 
signal intensity threshold of > 2 standard deviations above the mean value in 
an adjacent normal region of myocardium.  Areas of inversion artifact, or 
contamination by blood pool or epicardial fat, were excluded.    
 
The quality of T1 map data was examined using the individual inversion 
recovery images.  All segments affected by off-resonance, excessive breathing 
motion artifacts not corrected by the inline motion correction, and 
mistriggering were excluded from the analysis.  To minimize partial volume 
effects from surrounding tissues and blood pool, we standardized the 
windowing and placement of regions of interest around the mid-cavity 
myocardium using a pre-defined protocol (121).  The regions of interest were 
first drawn on the short-axis pre-contrast motion-corrected myocardial T1 
maps and then copied onto each of the corresponding 20 min post-contrast 
T1 maps with stringent adjustments applied to avoid blood pool and artifacts 
(OsiriX version 4.1.1, Geneva, Switzerland) (Figure 2.3).  Extracellular 
volume fraction (ECV) values were calculated:  
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λ = ΔR1myocardium/ΔR1blood-pool, where R1=1/T1 [1] 
 ECV = (1-haematocrit) x λ   [2] 
 
Haematocrit was determined at the time of cardiovascular magnetic 
resonance. 
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FIGURE 2.3.  METHOD OF ASSESSING MYOCARDIAL T1 
 
 
	   57	  
2.8 SAMPLE SIZE CALCULATIONS AND STATISTICAL ANALYSIS 
From our previous study, the all-cause mortality rates (regardless of aortic 
valve replacement) in patients with and without mid-wall fibrosis were 
143/1000 patient-years and 15.7/1000 patient-years, respectively (58).  A 
sample size of 150 patients with aortic stenosis would be needed to detect an 
absolute survival rate difference of 13% with a power of 0.80 and a two-sided 
Type I error of 0.05.  The prevalence of mid-wall fibrosis was assumed to be 
about 30% (58).     
 
The distribution of all continuous variables was assessed for normality using 
the Shapiro-Wilk test.  Continuous variables were presented as mean ± 
standard deviation or median [inter-quartile range] as appropriate.  
Comparison for normally distributed data was performed using Student’s t-
test or analysis of variance with post hoc Bonferroni adjustment.  The Mann-
Whitney U test and Kruskal-Wallis with post hoc Dunn tests were used for 
non-parametric data comparisons.  Categorical variables were expressed as 
percentages and compared using the χ2 test.  The correlation between 
continuous data was assessed with the Pearson correlation. 
 
Standard statistical analyses were performed using GraphPad Prism 
(GraphPad Software, Inc., San Diego, CA, USA) and SPSS Version 19 (SPSS, 
Inc., Chicago, IL, USA), unless otherwise stated.  A two-sided P <0.05 was 
considered statistically significant. 
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3.1 SUMMARY 
AIMS:  Discordance between small aortic valve area (AVA, <1.0 cm2) and 
low mean pressure gradient (MPG, <40 mmHg) affects a third of patients 
with moderate or severe aortic stenosis.  We hypothesized that this is largely 
due to inaccurate echocardiographic measurements of the left ventricular 
outflow tract area (LVOTarea) and stroke volume alongside inconsistencies in 
recommended thresholds. 
 
METHODS:  133 patients with mild to severe aortic stenosis and 33 control 
individuals underwent comprehensive echocardiography and cardiovascular 
magnetic resonance (CMR).  Stroke volume and LVOTarea were calculated 
using both echocardiography and CMR, and the effects on AVA estimation 
assessed.  The relationship between AVA and MPG measurements was then 
modeled with non-linear regression and consistent thresholds for these 
parameters calculated.  Finally the impact of these modified AVA 
measurements and novel thresholds on the number of patients with small-
area low-gradient aortic stenosis was investigated.  
 
RESULTS:  Compared to CMR, echocardiography underestimated LVOTarea 
(n=40, -0.7 [95%CI -2.6 to 1.3] cm2), stroke volumes (-6.5 [95%CI -28.9 to 16.0] 
mL/m2) and consequently, AVA (-0.23 [95%CI -1.01 to 0.59] cm2).  Moreover 
an AVA of 1.0 cm2 corresponded to MPG of 24 mmHg based on 
echocardiographic measurements and 37 mmHg after correction with CMR-
derived stroke volumes.  Based on conventional measures, 56 patients had 
discordant small-area low-gradient AS.  Using CMR-derived stroke volumes 
and the revised thresholds, a 48% reduction in discordance was observed 
(n=29).  
 
CONCLUSIONS:  Compared to CMR, echocardiography underestimates 
LVOTarea, stroke volume and therefore AVA.  The thresholds based on 
current guidelines are also inconsistent.  The combination of these factors 
explain >40% of patients with discordant small-area low-gradient aortic 
stenosis.  
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3.2 INTRODUCTION 
Discordant small aortic valve area (small-area; aortic valve area <1.0 cm2), 
low mean pressure gradient (low-gradient; mean pressure gradient <40 
mmHg) aortic stenosis occurs in about 30% of patients with aortic stenosis 
evaluated using echocardiography (130,131).  This has classically been 
attributed to patients with low flow states, such as those with reduced left 
ventricular ejection fractions (7).  However, in recent years, it has been 
recognized that small-area low-gradient aortic stenosis can also be observed 
in the presence of a preserved ejection fraction: so-called “paradoxical low-
flow, low-gradient severe aortic stenosis”.  The outcomes associated with 
such patients have been variable in different studies (132-135), presumably 
reflecting a heterogeneous population and highlighting the uncertainty with 
regards to the actual severity of aortic stenosis in this subgroup. 
 
Using the continuity equation, the aortic valve area is calculated based upon 
the ratio between the Doppler stroke volume and the post-aortic valve flow.  
Doppler stroke volume relies crucially on accurate estimation of the left 
ventricular outflow tract area (LVOTarea) according to the formula: Doppler 
stroke volume = LVOTarea x LVOT flow.  On two-dimensional 
echocardiography the LVOTarea is derived from left ventricular outflow tract 
diameter measurements made on the parasternal long-axis view and the 
assumption that the left ventricular outflow tract is circular. However recent 
experience from transcatheter aortic valve replacement sizing has 
demonstrated that the left ventricular outflow tract is frequently elliptical not 
circular and as a consequence, measurements made by echocardiography 
underestimate the true LVOTarea (136,137).  The implication is therefore that 
echocardiography might also underestimate the left ventricular stroke 
volume and aortic valve area.  
 
In addition, it is widely acknowledged that the severity thresholds for aortic 
valve area and mean transvalvular gradient recommended by current 
guidelines are inherently inconsistent (15,130), with theoretical models 
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suggesting an aortic valve area of 1.0 cm2 corresponds more closely to a 
mean pressure gradient of 30 to 35 mmHg than the recommended threshold 
of 40 mmHg (14,15).   
 
We hypothesized that the combination of LVOTarea underestimation and 
inconsistent thresholds might influence the classification of aortic stenosis 
severity, and contribute to the number of patients with discordant small-area 
low-gradient aortic stenosis.  The aims of the study were firstly to compare 
stroke volume estimation by echocardiography with the gold-standard non-
invasive cardiovascular magnetic resonance (CMR) assessment and to 
establish the optimal thresholds for severe aortic stenosis.  Subsequently, we 
then sought to investigate whether correcting for these two factors might 
impact on the number of patients with discordant small-area low-gradient 
aortic stenosis. 
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3.3 METHODS 
3.3.1 Study Population 
Patients with mild to severe aortic stenosis were prospectively recruited from 
the Edinburgh Heart Centre.  The exclusion criteria have been described in 
Chapter 2.  In addition, control individuals without aortic stenosis were 
recruited from the local community.   
 
The study was conducted in accordance with the Declaration of Helsinki, 
and approved by the local ethics committee.  Written informed consent was 
obtained in all subjects. 
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3.3.2 Echocardiography 
Standard echocardiographic techniques to assess severity of aortic stenosis 
have been carefully described in Chapter 2.  Specifically, the left ventricular 
outflow diameter was measured at the insertion of the aortic cusps, from the 
inner edge of the septal endocardium to the inner edge of the anterior mitral 
leaflet in mid-systole (Figure 3.1A), because the cross-sectional shape is 
believed to more circular at this level (7).  Doppler stroke volume was 
estimated (LVOTarea x left ventricular outflow tract velocity-time integral) 
and used to calculate the AVA with the continuity equation (stroke 
volume/aortic valve velocity-time integral).  Normal stroke volume by 
echocardiography was defined as ≥35 mL/m2 (138).  In a further analysis, we 
had also estimated stroke volume according to the Teichholz method (139) 
and the effects on aortic stenosis classification.  In addition, the severity of 
aortic valve calcification was assessed in the short-axis view of the aortic 
valve using a score of 1 to 4 (140), and corroborated between the two 
operators.  Valvuloarterial impedance, a measure of global afterload, was 
calculated as [systolic blood pressure + mean pressure gradient]/CMR stroke 
volume. 
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FIGURE 3.1. ESTIMATION OF THE LEFT VENTRICULAR OUTFLOW 
TRACT (LVOT) AREA USING ECHOCARDIOGRAPHY AND 
CARDIOVASCULAR MAGNETIC RESONANCE 
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3.3.3 Cardiovascular Magnetic Resonance 
All participants underwent cardiovascular magnetic resonance at 3T 
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen, Germany) 
according to the protocol specified in Chapter 2.  Papillary muscles and 
minor trabeculations were included in the volume measurements during 
both phases of the cardiac cycle (Figure 3.1B) and stroke volume was 
measured as the difference between the end-diastolic and end-systolic left 
ventricular volumes (given the absence of significant mitral regurgitation), 
indexed to body surface area.  Normal indexed left ventricular volumes, 
stroke volumes and ejection function were defined using sex- and age-
specific ranges (129).  Left ventricular mass was calculated from the total 
end-diastolic myocardial volume (excluding papillary muscles and minor 
trabeculations) multiplied by the specific gravity of the myocardium 
(1.05g/mL). 
 
In 40 patients, additional co-axial short-axis cine slices were acquired from 
the level of the aortic valve.  The LVOTarea was planimetered at the base of 
the aortic valve (the slice which all three cusps were first observed to 
disappear) in mid-systole and comparisons were made with the LVOTarea 
estimated from the left ventricular outflow tract diameter on two-
dimensional echocardiography (Figure 3.1C).   
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3.3.4 Curve Fitting and Statistical Analysis 
In patients with normal stroke volumes, the relationship between aortic 
valve area and mean pressure gradient was modeled according to the Gorlin 
equation, aortic valve area = c/√mean pressure gradient (GraphPad Prism 5, 
GraphPad Software Inc., San Diego, CA, USA).  No rules were set for the 
initial value for the modeling parameter, c.  We generated two curve-fitting 
models with aortic valve area derived using Doppler stroke volume and 
cardiovascular magnetic resonance stroke volume.  Comparison between 
echocardiographic and cardiovascular magnetic resonance indices of stroke 
volume, LVOTarea and aortic valve area was assessed using the Bland-Altman 
analyses.  Fixed and proportional biases with 95% limits of agreement were 
reported.  Standard statistical methods as described in Chapter 2 were also 
used and a two-sided P<0.05 was considered statistically significant. 
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3.4 RESULTS 
A total of 133 patients with mild to severe aortic stenosis (aortic valve area 
0.98±0.40 cm2; mean pressure gradient 33±20 mmHg; peak aortic velocity 
3.8±0.9 m/s) and 33 control individuals were recruited.  The median interval 
between echocardiography and cardiovascular magnetic resonance was 9 
[interquartile range: 5 to 29] days.  Compared to control individuals, patients 
with aortic stenosis had higher ejection fractions (64±4 and 67±7%, 
respectively; P=0.02) despite similar left ventricular end-diastolic volumes 
(75±13 and 72±16 mL/m2, respectively; P=0.34) and stroke volumes (47±8 
and 48±10 mL/m2, respectively; P=0.59) (Table 3.1 and Table 3.2).  
 
In this study, 40 patients with mild to severe aortic stenosis were randomly 
selected and planimetry of the LVOTarea was performed on cardiovascular 
magnetic resonance to investigate the effects of accurate LVOTarea 
measurement on stroke volume estimation.  The characteristics of these 40 
patients were similar to the entire cohort of patients with aortic stenosis 
(Table 3.3). 
	   68	  
TABLE 3.1. BASELINE CHARACTERISTICS OF PATIENTS WITH 














Clinical Characteristics    
Age, years 54±23 68±12 <0.01 
Males, n (%) 18 (55) 89 (67) 0.40 
Hypertension, n (%) 9 (27) 85 (64) <0.01 
Diabetes Mellitus, n (%) 0 18 (14) - 
Coronary artery disease, n (%) 3 (9) 44 (33) 0.01 
Atrial fibrillation, n (%) 0 3 (2) - 
Echocardiography    
Left ventricular outflow tract (LVOT) diameter, cm 2.05±0.17 2.07±0.24 0.66 
LVOT cross-sectional area, cm2 3.30±0.55 3.39±0.85 0.60 
LVOT velocity time integral, cm 20.9±3.7 23.5±4.4 0.01 
Doppler stroke volume, mL 70±19 79±19 <0.01 
Doppler stroke volume (indexed), mL/m2 38±8 42±10 <0.01 
    
Aortic valve area, cm2 2.36±0.59 0.98±0.40 <0.01 
Aortic valve area (indexed), cm2/m2 1.26±0.26 0.52±0.21 <0.01 
Mean pressure gradient, mmHg 4±1 33±20 <0.01 
Peak aortic velocity, m/s 1.4±0.2 3.8±0.9 <0.01 
Dimensionless index 0.72±0.10 0.28±0.09 <0.01 
Aortic valve calcium score 1 [1,1] 3 [3,4] <0.01 
Valvuloarterial impedance, mmHg•ml-1•m-2 3.2±0.7 4.0±1.0 0.34 
    
End-diastolic volume, mL¶ 93±25 87±26 0.17 
End-diastolic volume (indexed), mL/m2 ¶ 50±13 46±13 0.12 
End-systolic volume, mL¶ 41±14 38±14 0.29 
End-systolic volume (indexed), mL/m2 ¶ 22±7 20±7 0.16 
Stroke volume, mL¶ 51±16 49±14 0.48 
Stroke volume (indexed), mL/m2 ¶ 28±8 26±7 0.16 
Ejection fraction, %¶ 56±9 57±7 0.49 
    
Mild mitral regurgitation, n (%) 2 (6) 19 (14) 0.37  
Mild aortic regurgitation, n (%) 2 (6) 57 (43) <0.01 















Cardiovascular Magnetic Resonance    
End-diastolic volume, mL 140±32 135±35 0.47 
End-diastolic volume (indexed) (EDVi), mL/m2 75±13 72±16 0.34 
End-systolic volume, mL 51±15 46±18 0.14 
End-systolic volume (indexed), mL/m2 27±7 24±9 0.08 
Stroke volume, mL 89±19 90±22 0.81 
Stroke volume (indexed), mL/m2 47±8 48±10 0.59 
Ejection fraction, % 64±4 67±7 0.02 
Left ventricular mass (indexed) (LVMi), g/m2 67±15 89±22 <0.01 
LVMi/EDVi, g/mL 0.90±0.13 1.25±0.26 <0.01 
¶ Estimated using the Teichholz formula 
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TABLE 3.2. CHARACTERISTICS OF PATIENTS WITH AORTIC 
STENOSIS CLASSIFIED BASED ON AORTIC VALVE AREA ESTIMATED 






 (n=44) (n=56) (n=28) 
 
P value 
CLINICAL CHARACTERISTICS    
Age, years 65±13 72±10 68±11 0.02a 
Males, n (%) 32 (72) 34 (61) 19 (68) 0.44 
Height, cm 169±9 163±8 168±8 <0.01a,b 
Body mass index, kg/m2 29±5 29±5 27±4 0.13 
Body surface area, m2 1.9±0.2 1.8±0.2 1.9±0.2 0.07 
Hypertension, n (%) 27 (61) 40 (71) 16 (57) 0.36 
Diabetes Mellitus, n (%) 9 (20) 6 (11) 3 (11) 0.32 
Coronary artery disease, n (%) 14 (32) 15 (27) 12 (43) 0.33 
Atrial fibrillation, n (%) 0 3 (5) 0 - 
     
Systolic blood pressure, mmHg 147±20 154±20 147±22 0.19 
ECHOCARDIOGRAPHY    
Left ventricular outflow tract (LVOT) 
diameter, cm 
2.19±0.21 1.96±0.19 2.08±0.24 <0.01a,b 
LVOT cross-sectional area, cm2 3.79±0.75 3.05±0.57 3.43±0.78 <0.01a 
LVOT velocity time integral, cm 24.5±4.2 23.0±4.5 22.7±4.3 0.15 
Doppler stroke volume, mL 92±18 70±13 78±19 <0.01a,c 
Doppler stroke volume (indexed), mL/m2 48±10 38±7 42±10 <0.01a,c 
     
Aortic valve area, cm2 1.38±0.38 0.79±0.15 0.69±0.17 <0.01a,c 
Aortic valve area (indexed), cm2/m2 0.72±0.20 0.43±0.08 0.37±0.09 <0.01a,c 
Mean pressure gradient, mmHg 20±8 29±9 54±17 <0.01a,b,c 
Peak aortic velocity, m/s 3.0±0.5 3.7±0.5 4.8±0.6 <0.01 a,b,c 
Dimensionless index 0.36±0.09 0.26±0.05 0.20±0.04 <0.01 a,b,c 
Aortic valve calcium score 3 [2,3] 3 [3,4] 4 [4,4] <0.01 a,b,c 
Valvuloarterial impedance, mmHg•ml-1•m-2 3.6±0.8 4.9±1.1 5.0±1.2 <0.01a,c 
     
 








 (n=44) (n=56) (n=28)  
ECHOCARDIOGRAPHY (CONTINUED)    
End-diastolic volume, mL¶ 94±21 82±26 83±23 0.03a 
End-diastolic volume (indexed), mL/m2 ¶ 49±10 45±13 44±12 0.15 
End-systolic volume, mL¶ 42±12 36±14 35±14 0.04 
End-systolic volume (indexed), mL/m2 ¶ 22±6 19±7 19±7 0.11 
Stroke volume, mL¶ 53±12 46±13 48±13 0.04a 
Stroke volume (indexed), mL/m2 ¶ 28±6 25±7 26±7 0.25 
Ejection fraction, %¶ 56±7 57±7 59±8 0.40 
     
Mild mitral regurgitation, n (%) 3 (7) 9 (16) 7 (25) 0.10 
Mild aortic regurgitation, n (%) 18 (41) 27 (48) 12 (43) 0.24 
CARDIOVASCULAR MAGNETIC RESONANCE    









     
End-diastolic volume, mL 142±30 126±25 139±40 0.03a 
End-diastolic volume (indexed) (EDVi), 
mL/m2 
74±13 69±13 74±19 0.17 
End-systolic volume, mL 47±17 43±15 47±20 0.38 
End-systolic volume (indexed), mL/m2 25±8 23±8 25±10 0.75 
Stroke volume, mL 95±19 83±16 92±26 <0.01a 
Stroke volume (indexed), mL/m2 49±8 45±8 49±12 0.08 
Ejection fraction, % 67±7 66±7 67±7 0.84 
Left ventricular mass (indexed) (LVMi), g/m2 85±18 85±21 99±25 <0.01b,c 
LVMi/EDVi, g/mL 1.17±0.23 1.24±0.24 1.38±0.28 <0.01b,c 
π5 patients were classified with large-area high-gradient aortic stenosis 
¶ Estimated using the Teichholz formula 
‡ Planimetered left ventricular outflow tract area was performed in 40 patients.  One patient 
was classified with large-area high-gradient aortic stenosis 
a P<0.05 between non-severe and small-area low-gradient aortic stenosis  
b P<0.05 between small-area low-gradient and severe aortic stenosis 
c P<0.05 between non-severe and severe aortic stenosis 
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TABLE 3.3. BASELINE CHARACTERISTICS OF THE 40 PATIENTS 
WITH PLANIMETERED LEFT VENTRICULAR OUTFLOW TRACT AREA 
















Age, years 68±12 69±12 0.64 
Males, n (%) 27 (68) 83 (63) 0.56 
Body surface index, m2 1.9±0.2 1.9±0.2 1.00 
Systolic blood pressure, mmHg 151±21 150±21 0.79 
Heart rate, per min 64±10 64±11 1.00 
Mean pressure gradient, mmHg 37±24 32±16 0.13 
Peak aortic jet velocity, m/s 4.0±1.1 3.7±0.8 0.06 
Aortic valve area, cm2 1.0±0.3 1.0±0.4 1.00 
End-diastolic volume (indexed) (EDVi), mL/m2 75±21 72±16 0.34 
Indexed end-systolic volume, mL/m2 25±12 24±9 0.57 
Indexed stroke volume, mL/m2 50±12 48±10 0.29 
Ejection fraction, % 67±8 67±7 1.00 
Left ventricular mass (indexed) (LVMi), g/m2 95±28 88±21 0.09 
LVMi/EDVi, g/mL 1.29±0.28 1.25±0.26 0.40 
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3.4.1 Doppler and Cardiovascular Magnetic Resonance Stroke Volume 
Doppler stroke volume correlated only weakly with cardiovascular magnetic 
resonance stroke volume measurements (r2=0.12, P<0.001; Figure 3.2A) and 
underestimated the stroke volume by more than 6 mL/m2 compared to 
cardiovascular magnetic resonance (-6.5 mL/m2, 95% confidence interval: -
28.9 to 16.0 mL/m2; Figure 3.2B).  Similar results were observed after 
excluding the 19 patients in the cohort with mild mitral regurgitation 
(r2=0.14, P<0.001; mean difference -6.1 mL/m2, 95% confidence interval: -28.2 
to 16.0 mL/m2).  This in part appears to be due to underestimation of the 
LVOTarea by echocardiography when compared with planimetered LVOTarea 
measurements (-0.7 cm2, 95% confidence interval: -2.6 to 1.3 cm2; Figure 3.3).  
Indeed, when we subsequently recalculated stroke volume using the 
planimetered LVOTarea, an excellent correlation with cardiovascular magnetic 
resonance stroke volumes was observed (r2=0.87, P<0.001; Figure 3.2C) 
without significant fixed or proportional biases (-1.3 mL/m2, 95% confidence 
interval: -9.9 to 7.3 mL/m2; Figure 3.2D).  Moreover, this effect translated 
into an underestimation of the aortic valve area when calculated using 
echocardiography-derived stroke volumes compared with cardiovascular 
magnetic resonance measured stroke volumes (-0.23 cm2, 95% confidence 
interval: -1.01 to 0.59 cm2; Figure 3.4). As previously described the 
explanation for echocardiographic underestimation of the LVOTarea appears 
related to its elliptic shape.  Indeed, the mean ellipticity ratio (ratio of the 
maximum to minimum left ventricular outflow tract diameter) was 1.2±0.1, 
with only 28% of these patients having a circular left ventricular outflow 
tract (defined as ellipticity ratio of 1.0).  Of note, we achieved excellent intra-
observer (r2=1.00, P<0.001; mean difference 0.5±2.7%) and inter-observer 
(r2=0.98, P<0.001; mean difference 1.1±5.4%) agreement in the planimetered 
left ventricular outflow tract measurements using cardiovascular magnetic 
resonance. 
 
	   74	  




	   75	  
FIGURE 3.3. LEFT VENTRICULAR OUTFLOW TRACT (LVOT) AREA 
CORRELATION AND BLAND-ALTMAN ANALYSIS 
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3.4.2 Consistent Aortic Valve Area and Mean Pressure Gradient 
Cutoffs 
Based on measurements derived from Doppler stroke volume, a mean 
pressure gradient of 40 mmHg corresponded to an aortic valve area of 0.77 
cm2, whilst an aortic valve area of 1.0 cm2 corresponded to a mean pressure 
gradient of only 24 mmHg (aortic valve area = 4.85/√mean pressure 
gradient; r2=0.73; Figure 3.5A).  When cardiovascular magnetic resonance 
stroke volume measurements were used to calculate the aortic valve area, a 
mean pressure gradient of 40 mmHg corresponded to an aortic valve area of 
0.97 cm2 and an aortic valve area of 1.0 cm2 corresponded to a mean pressure 
gradient of 37 mmHg (aortic valve area = 6.13/√mean pressure gradient; 
r2=0.81, Figure 3.5B).  
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FIGURE 3.5. RELATIONSHIP BETWEEN AORTIC VALVE AREA AND 
MEAN PRESSURE GRADIENT 
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3.4.3 Discordant Small-area Low-gradient Aortic Stenosis 
Using the conventional echocardiographic estimation of mean pressure 
gradient and aortic valve area, and the thresholds for severe disease based on 
current guidelines (aortic valve area of 1.0 cm2 and mean pressure gradient 
of 40 mmHg) (141),(5), 56 patients with aortic stenosis (42%) had discordant 
small-area low-gradient aortic stenosis (Figure 3.6A).   
 
Using a step-wise approach, we first assessed the impact of using aortic 
valve area measurements derived from cardiovascular magnetic resonance 
stroke volumes on this proportion of patients with discordant small-area 
low-gradient aortic stenosis.  This resulted in 20 patients being reclassified as 
having non-severe aortic stenosis (median aortic valve calcium score 3; 
valvuloarterial impedance 3.7±0.7 mmHg/mL/m2), leaving 36 with small-
area low-gradient aortic stenosis (Figure 3.6B).  Subsequently when we used 
the revised thresholds established above (aortic valve area of 1.0 cm2 and 
mean pressure gradient of 37 mmHg), a further 7 patients were reclassified 
with severe disease (all had aortic valve calcium score of 4 and 
valvuloarterial impedance 4.5±1.2 mmHg/mL/m2). This left only 29 patients 
with discordant small-area low-gradient aortic stenosis, a reduction of 48% 
compared to the original classification (Figure 3.6C).  Of these, three patients 
had impaired systolic function and two had a low stroke volume due to 
small left ventricular cavity volumes. The remainder appeared to consist of 
patients with moderate to severe disease with values for a wide range of 
parameters that were intermediate between concordant moderate and severe 
disease (Table 3.4). This included the aortic valve calcium score, which was 3 
in 48% and 4 in 52% of patients.  
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FIGURE 3.6. RECLASSIFICATION OF AORTIC STENOSIS SEVERITY 
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TABLE 3.4. CHARACTERISTICS OF PATIENTS WITH DISCORDANT 
SMALL-AREA LOW-GRADIENT AORTIC STENOSIS AFTER 
CORRECTION FOR STROKE VOLUME UNDERESTIMATION AND 




low-gradient Severe   
  
(n=61) (n=29) (n=33) 
P value 
CLINICAL CHARACTERISTICS        
Age, years 66±13 73±9 72±9 <0.01a,c 
Male, n (%) 44 (72) 15 (52) 20 (61) 0.15 
Height, cm 168±9 161±9 165±8 <0.01a 
Body mass index, kg/m2 29±5 30±5 27±3 0.09 
Body surface area, m2 1.9±0.2 1.8±0.2 1.8±0.2 0.02 
Hypertension, n (%) 38 (62) 21 (72) 22 (67) 0.64 
Diabetes mellitus, n (%) 11 (18) 3 (10) 4 (12) 0.56 
Coronary artery disease, n (%) 18 (30) 7 (24) 17 (52) 0.04 
Atrial fibrillation, n (%) - 3 (10) - - 
       
Systolic blood pressure, mmHg 149±21 151±22 151±23 0.91 
ECHOCARDIOGRAPHY        
Left ventricular outflow tract (LVOT) 
diameter, cm 
2.14±0.21 1.94±0.21 2.02±0.25 <0.01a,c 
LVOT cross-sectional area, cm2 3.64±0.73 3.01±0.63 3.28±0.82 <0.01a 
LVOT velocity time integral, cm 23.6±4.2 23.3±5.1 23.7±4.4 0.93 
Doppler stroke volume, mL 86±19 69±14 77±20 <0.01a 
Doppler stroke volume (indexed), mL/m2 45±10 38±8 42±10 <0.01a 
     
Aortic valve area, cm2 1.24±0.41 0.76±0.16 0.71±0.19 <0.01a,c 
Aortic valve area (indexed), cm2/m2 0.65±0.22 0.42±0.10 0.39±0.10 <0.01 a,c 
Mean pressure gradient, mmHg 21±8 30±5 55±24 <0.01a,b,c 
Peak aortic velocity, m/s 3.1±0.6 3.7±0.3 4.8±0.9 <0.01a,b,c 
Dimensionless index 0.34±0.09 0.26±0.05 0.21±0.05 <0.01a,b,c 
Aortic valve calcium score 3 [2,3]  4 [3,4] 4 [4,4] <0.01a,b,c 
Valvuloarterial impedance, mmHg•ml-1•m-2  4.0±1.0 4.8±1.2 4.9±1.3 <0.01a,c 
     





low-gradient Severe P value   
  
(n=61) (n=29) (n=33)  
ECHOCARDIOGRAPHY (CONTINUED)        
End-diastolic volume, mL¶ 93±25 77±25 83±24 <0.01a 
End-diastolic volume (indexed), mL/m2 ¶ 49±12 42±13 45±13 0.09 
End-systolic volume, mL¶ 42±14 31±13 35±14 <0.01a 
End-systolic volume (indexed), mL/m2 ¶ 22±7 17±7 20±7 0.02a 
Stroke volume, mL ¶ 52±13 45±13 45±11 0.02 
Stroke volume (indexed), mL/m2 ¶ 27±6 25±7 25±7 0.27 
Ejection fraction, % ¶ 56±6 60±7 57±9 0.05a 
     
Mild mitral regurgitation, n (%) 7 (11) 4 (14) 7 (21) 0.44 
Mild aortic regurgitation, n (%) 24 (39) 16 (56) 16 (48) 0.34 
CARDIOVASCULAR MAGNETIC RESONANCE        







     
End-diastolic volume, mL 142±28 117±18 127±35 <0.01a,c 
End-diastolic volume (indexed) (EDVi), 
mL/m2 74±14 65±9 70±17 0.01
a 
End-systolic volume, mL 47±16 39±10 45±22 0.12 
End-systolic volume (indexed), mL/m2 25±8 22±5 25±11 0.28 
Stroke volume, mL 95±18 78±13 83±21 <0.01a,c 
Stroke volume (indexed), mL/m2 50±9 43±7 45±10 <0.01a 
Ejection fraction, % 67±7 67±6 66±9 0.63 
Left ventricular mass (indexed) (LVMi), g/m2 86±21 81±18 93±20 0.06 
LVMi/EDVi, g/mL 1.18±0.22 1.25±0.23 1.37±0.30 <0.01c 
π10 patients were classified with large-area high-gradient aortic stenosis 
¶ Estimated using the Teichholz formula 
‡ Planimetered left ventricular outflow tract area was performed in 40 patients.  Four 
patients were classified with large-area high-gradient aortic stenosis 
a P<0.05 between non-severe and small-area low-gradient aortic stenosis  
b P<0.05 between small-area low-gradient and severe aortic stenosis 
c P<0.05 between non-severe and severe aortic stenosis 
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3.4.4 Stroke Volume Estimation and Aortic Stenosis Classification 
Using the Teichholz Formula 
In a further analysis, we assessed an alternate echocardiographic method for 
estimating stroke volumes using the Teichholz formula (139).  Results were 
similar with the correlation between echocardiography-estimated and 
cardiovascular magnetic resonance derived stroke volumes remaining weak 
(r2=0.16, P<0.001), and 51% of patients classified as having discordant small-
area low-gradient aortic stenosis.  
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3.4.5 Evaluation of Aortic Stenosis Classification Using Indexed Aortic 
Valve Area and the Dimensionless Index  
We investigated thresholds of severe aortic stenosis using indexed aortic 
valve area, and the effects on classification using an indexed aortic valve area 
of 0.6 cm2/m2 and mean pressure gradient of 40 mmHg.   
 
Using Doppler stroke volume, an indexed aortic valve area of 0.6 cm2/m2 
corresponded to a mean pressure of 18 mmHg while an indexed valve area 
of 0.6 cm2/m2 corresponded to a mean pressure gradient of 27 mmHg with 
cardiovascular magnetic resonance derived stroke volume (Figure 3.7).  The 
use of indexed aortic valve area did not reduce the number of patients with 
discordant small-area low-gradient aortic stenosis with either Doppler stroke 
volume [61 patients (46%) compared with the 56 patients (42%) using non-
indexed aortic valve area] or cardiovascular magnetic resonance derived 
stroke volumes [52 patients (39%) compared with the 36 patients (27%) using 
non-indexed aortic valve area]. 
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FIGURE 3.7. AORTIC STENOSIS CLASSIFICATION USING INDEXED 
AORTIC VALVE AREA 
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Using a dimensionless index (DI) threshold of <0.25 and mean pressure 
gradient of <40 mmHg, 26 patients were classified with discordant low-DI 
low-gradient aortic stenosis (20%).  This appears to support out conclusion 
that discordant small-area low-gradient aortic stenosis is largely influenced 
by LVOTarea estimation. 
 
However, this result has to be interpreted with caution.  The use of 
dimensionless index has limitations precisely because it does not take into 
account the LVOTarea, which is the key factor to consider when determining 
the severity of aortic stenosis (7,142).  This is perhaps best illustrated with an 
example: 
 
 Aortic valve area = LVOTd2 x 0.785 x DI; DI = LVOTVTI/AVVTI 
 
In a patient with a LVOT diameter (LVOTd) of 2.0cm and DI of 0.25 (severe 
aortic stenosis), this would translate to an aortic valve area of 0.79 cm2 
(severe aortic stenosis).  However, in another patient with LVOTd of 2.5cm 
and the same DI of 0.25, this increases the aortic valve area to 1.23 cm2 
(moderate aortic stenosis).  This example illustrates that a DI threshold of 
0.25 may not be appropriate in all patients: in patients with large left 
ventricular outflow tract, a smaller dimensionless index threshold for severe 
disease may be needed (142).  Indeed, amongst the 26 patients with 
discordant low-DI low-gradient aortic stenosis, 9 patients (35%) had an aortic 
valve area > 1.0 cm2 and they had a larger mean left ventricular outflow tract 
diameter (measured on echocardiography) compared to the other 17 patients 
(2.2±0.2 versus 1.9±0.2 cm; P=0.03).   
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3.4.6 Comparison of Doppler, MRI Volumetric and Phase Contrast 
Stroke Volume Estimation 
An exploratory analysis was performed in 10 patients with aortic stenosis to 
compare Doppler, MRI volumetric (cine) and phase contrast stroke volume.  
Through plane phase contrast velocity mapping was positioned orthogonal to 
the ascending aorta at the level of the bifurcation of the main pulmonary 
artery.  An initial velocity encoding level of 100 cm/s was selected and 
increased in increments of 50 cm/s if aliasing occurs.  The total forward flow 
during systole is computed using the Argus software (Siemens AG Healthcare 
Sector, Erlangen, Germany). 
 
The results are shown in Table 3.5.  In these 10 patients, there was no 
correlation between Doppler indexed stroke volume and MRI-derived indexed 
stroke volume (r=0.32; P=0.37) and between Doppler indexed stroke volume 
and MRI phase contrast indexed stroke volume (r=0.20; P=0.58).  On the 
other hand, MRI-derived stroke volume and MRI phase contrast 
demonstrated excellent correlation (r=0.87; P=0.001; Figure 3.8) and 
agreement (2.4mL/m2; 95% CI -6.8 to 11.6 mL/m2; Figure 3.8).   
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#1 34 49 41 Severe 
#2 33 33 32 Severe 
#3 45 34 28 Moderate 
#4 35 35 36 Moderate 
#5 46 37 32 Severe 
#6 54 36 29 Severe 
#7 50 48 45 Mild 
#8 45 42 38 Moderate 
#9 36 30 32 Severe 
#10 49 52 59 Mild 
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FIGURE 3.8. CORRELATION AND BLAND-ALTMAN ANALYSIS 
BETWEEN MRI VOLUMETRIC AND PHASE CONTRAST STROKE 
VOLUME 
 
Stroke volumes derived using MRI volumetric estimation and phase contrast 
demonstrated excellent correlation (A) and narrow limits of agreement (B). 
  
	   90	  
3.5 DISCUSSION 
In this study, we have systematically demonstrated that echocardiography 
underestimates the LVOTarea, the left ventricular stroke volume, and as a 
consequence, the aortic valve area.  Moreover we have demonstrated that 
there are inconsistencies in the guideline thresholds of severity with an aortic 
valve area of 1.0 cm2 corresponding to a mean pressure gradient of 24 mmHg 
based on standard echocardiographic measures and 37 mmHg when 
cardiovascular magnetic resonance derived stroke volumes are used. Finally 
we have shown that if we correct for these two factors using more accurate 
cardiovascular magnetic resonance estimation of the stroke volume to 
calculate aortic valve area and revised thresholds, more than 40% of the 
patients with small-area low-gradient aortic stenosis were reclassified as 
having concordant measurements.  
 
Two-dimensional and Doppler echocardiography assessments are the 
predominant methods used worldwide to assess the severity of aortic 
stenosis.  However, the echocardiographic estimation of the aortic valve area 
relies on accurate measurement of stroke volume.  Unfortunately as 
demonstrated in this study, echocardiography frequently underestimates the 
stroke volume when compared to non-invasive gold-standard measurements 
made using cardiovascular magnetic resonance.  As a consequence, 
echocardiography would also appear to underestimate the aortic valve area. 
Our data provide explanations for these observations.  A subgroup of 40 
patients had co-axial short-axis cine images of their left ventricular outflow 
tract.  This allowed accurate and reproducible planimetered measurements 
of the LVOTarea to be compared to the derived measurements made using 
two-dimensional echocardiographic diameter measurements. Similar to 
previous studies (136,137), we have demonstrated that such 
echocardiographic measures underestimate the true LVOTarea in part due to 
the fact that the left ventricular outflow tract is frequently elliptical not 
circular.  Indeed, when Doppler stroke volumes were corrected using the 
more accurate planimetered measurements of the LVOTarea, a good 
correlation with cardiovascular magnetic resonance derived stroke volumes 
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was subsequently observed.  Further to our analyses, we have also explored 
using other echocardiographic indices such as indexed aortic valve area and 
the dimensionless index.  Unfortunately, these techniques were also 
associated with inherent limitations related to the LVOTarea measurements.  
  
Inconsistencies in the MPG and AVA thresholds recommended by the 
current guidelines are well described (15,130,142).  Consistent with previous 
reports (15,130), our echocardiography data confirmed an aortic valve area of 
1.0 cm2 corresponded to a mean pressure gradient of only 24 mmHg, 
significantly lower than the threshold of 40 mmHg stated in current 
guidelines. Interestingly this improved to 37 mmHg when cardiovascular 
magnetic resonance stroke volume measurements were used to calculate 
aortic valve area, much closer to the recommended threshold though still 
discrepant.  
 
Multiple previous studies have shown that a third of patients with moderate 
and severe aortic stenosis have discordant disease severity according to their 
aortic valve areas and mean pressure gradients.  Interest has surrounded this 
group given its ubiquity and the uncertainty in the outcome associated with 
these patients.  Indeed whilst some studies have suggested that patients with 
small-area low-gradient aortic stenosis have a prognosis similar to those with 
moderate disease, others have indicated the exact opposite and that their 
outcomes are more akin to those with severe disease (132-135).  
 
In the final part of the study, we investigated whether the underestimation of 
the aortic valve area by echocardiography and inconsistencies in the 
guideline thresholds might explain the ubiquity of patients with small-area 
low-gradient aortic stenosis and help resolve the true severity of their 
disease.  We demonstrated that correcting for these two factors reduced the 
number of patients with a small-area low-gradient by over 40%.  Of the 
remaining 29 subjects, 3 had low flow due to an impaired ejection fraction 
and 2 had low flow due to small LV cavity size.  The remainder appeared to 
genuinely sit on the borderline between moderate and severe disease with 
parameters that were intermediate between those observed in concordant 
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severe and non-severe groups.  Our data would therefore indicate that 
discordance in the assessment of aortic stenosis severity can be reduced by 
correcting for aortic valve area underestimation and inconsistent thresholds, 
but further studies are now needed to investigate the long-term outcomes of 
patients reclassified using this approach.  
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3.5.1 Study Limitations 
In this study, assessment of the planimetered LVOTarea on cardiovascular 
magnetic resonance was only available in 40 patients. However, this was felt 
to be a large enough sample size to assess the inaccuracies associated with 
left ventricular outflow tract diameter measurements and the data is 
consistent with the large and expanding literature investigating LVOTarea 
measurements for the sizing of transcatheter aortic valve bioprostheses (137).  
Moreover, the baseline characteristics were similar between these 40 patients 
and the entire cohort of patients with aortic stenosis.  We also used 
echocardiography to assess aortic valve calcification. Whilst this provides 
important prognostic information (140), computed tomography gives a more 
sensitive quantification of aortic valve calcification and has recently been 
shown to provide differentiation as to the true severity of patients with 
small-area low-gradient aortic stenosis (131,143).  Phase contrast 
cardiovascular magnetic resonance is an alternate method to estimate stroke 
volume, but this technique is associated with its own problems particularly 
in patients with aortic stenosis where complex aortic flow in the ascending 
aorta can result in measurement inaccuracy.  This is a particular problem at 
3T.  Finally, we were not able to perform both echocardiography and 
cardiovascular magnetic resonance on the same day because many of our 
elderly patients could not tolerate both procedures on the same visit.  
However, no patient experienced any cardiac events or changes in 
medications between the two scans and after correcting for inaccuracies in 
the LVOTarea, an excellent agreement was observed between cardiovascular 
magnetic resonance and echocardiography-derived stroke volumes. This 
would argue against any significant variability in stroke volumes between 
the scans.  
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3.6 CONCLUSIONS 
Echocardiography underestimates the aortic valve area because of an 
underestimation of the LVOTarea and stroke volume, compared to 
cardiovascular magnetic resonance.  These factors, along with inconsistent 
aortic valve area and mean pressure gradient cutoffs in the current 
guidelines, account for more than 40% of patients with discordant small-area 
low-gradient aortic stenosis.   
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4.1 SUMMARY 
AIMS: To determine the optimal T1 mapping approach to assess myocardial 
fibrosis at 3T 
 
METHODS: T1 mapping was performed at 3T using the modified look-
locker-inversion sequence in 20 healthy volunteers and 20 patients with 
aortic stenosis.  Pre- and post-contrast myocardial T1, the partition coefficient 
(λ; ∆Rmyocardium/∆Rblood, where ∆R=1/post-contrast T1 – 1/pre-contrast T1) and 
extracellular volume fraction (ECV; λ x [1-haematocrit]) were assessed.  After 
establishing the optimal time-point and myocardial region for analysis, we 
compared the reproducibility of these T1 measures and their ability to 
differentiate asymptomatic patients with aortic stenosis from healthy 
volunteers. 
 
RESULTS: There was no segmental variation across the ventricle in any of 
the T1 measures evaluated.  λ and ECV did not vary with time, while post-
contrast T1 was relatively constant between 15-30min.  Thus, mid-cavity 
myocardium at 20min was used for subsequent analyses.  ECV displayed 
excellent intra-, inter-observer, and scan-rescan reproducibility (intraclass 
correlation coefficients (ICC) 1.00, 0.97 and 0.96 respectively), as did λ (ICC 
0.99, 0.94, 0.93 respectively).  Moreover, ECV and λ were both higher in 
patients with aortic stenosis compared to controls (ECV 28.3±1.7 versus 
26.0±1.6%, P<0.001; λ 0.46±0.03 versus 0.44±0.03, P=0.02), with the former 
offering improved differentiation.  By comparison, scan-rescan 
reproducibilities for pre- and post-contrast myocardial T1 were only modest 
(ICC 0.72 and 0.56) with no differences in values observed between cases and 
controls (both P>0.05).   
 
CONCLUSIONS: ECV appears to be the most promising measure of diffuse 
myocardial fibrosis at 3T based upon their superior reproducibility and 
ability to differentiate disease from health.  
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4.2 INTRODUCTION 
Myocardial fibrosis is a common pathological finding in a wide range of 
cardiovascular diseases and has been associated with an adverse prognosis 
(58,144,145).  Using cardiovascular magnetic resonance (CMR), the late 
gadolinium enhancement technique has become widely used to evaluate 
focal myocardial fibrosis.  However in many conditions, including aortic 
stenosis, a more diffuse form of fibrosis predominates, which crucially is 
reversible and therefore a potential target for novel therapeutic strategies 
(36,47,96,146).  Late gadolinium enhancement imaging has inherent 
limitations in assessing diffuse fibrosis because it relies upon detecting a 
difference in signal intensity between normal and fibrotic regions (44).  
Consequently, it has difficulty in discriminating areas of diffuse myocardial 
fibrosis, which tend to have an even distribution. 
 
Recently, several T1 mapping approaches have been developed to quantify 
diffuse fibrosis.  The first approach measures intrinsic myocardial T1 on the 
basis that T1 relaxation times are longer in regions of fibrosis (pre-contrast 
T1) (110,147,148). Alternatively, myocardial T1 can be measured following 
gadolinium administration, which accumulates in fibrotic areas on account 
of the increased extracellular volume (post-contrast T1) (149,150).  However, 
post-contrast T1 is potentially confounded by individual variations in 
gadolinium kinetics and by the precise timing of imaging (44).  As a result, 
investigators have proposed methods to correct for these factors using either 
blood-pool T1 values to derive the partition coefficient (151), or plasma 
volume to calculate the contrast volume of distribution in the myocardium.  
The latter is commonly referred to as the myocardial extracellular volume 
fraction (152-157).  Each of these approaches have been validated against the 
extent of myocardial fibrosis on histology (149,150,152,154,155,157).  
However, the optimal technique remains uncertain due to a lack of consistent 
acquisition sequences and disease states studied, whilst direct comparative 
studies are relatively lacking (157).  In addition, there is insufficient 
reproducibility data (particularly scan-rescan) and few studies have been 
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performed at 3T (158-161), which may offer potential improvements 
compared to 1.5T (162).  
 
Therefore, the purpose of this study was to perform a systematic and 
comprehensive assessment to determine the optimal T1 approach at 3T.  In 
particular, we aimed to characterize the temporal and regional T1 profiles of 
the myocardium; and to identify the optimal technique based upon its 
reproducibility and ability to differentiate asymptomatic patients with aortic 
stenosis from healthy volunteers.  Patients with advanced symptoms and 
focal scarring were excluded so as to focus on patients in whom diffuse 
myocardial fibrosis is most likely to be of clinical interest.  
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4.3  METHODS 
4.3.1 Study Population 
Twenty asymptomatic patients with mild to severe aortic stenosis were 
recruited from outpatient clinics at the Edinburgh Heart Centre.  Twenty 
healthy volunteers were recruited from the community and the University of 
Edinburgh.  All individuals had normal renal function and a left ventricular 
ejection fraction within the normal range.  In addition to the exclusion 
criteria stated in Chapter 2, patients with aortic stenosis and presence of focal 
late gadolinium enhancement were excluded in this study.  Exclusion criteria 
for healthy volunteers were: (1) hypertension, (2) diabetes mellitus,  (3) 
coronary artery disease (previous myocardial infarction, evidence of 
myocardial ischemia, or >50% luminal stenosis in a major epicardial vessel) 
(4) valvular heart disease, (5) cardiomyopathy or previous myocarditis and 
(6) the presence of focal late gadolinium enhancement. 
 
All clinical assessments and imaging studies were carried out at the 
Wellcome Trust Clinical Research Facility and the Clinical Research Imaging 
Centre, Edinburgh.  Studies were performed with the approval of the local 
research ethics committee, and with the written informed consent from each 
participant. 
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4.3.2 Imaging Protocols and Analysis 
The echocardiographic and cardiovascular magnetic resonance imaging 
protocols for assessing aortic stenosis severity, cardiac function and 
myocardial morphology (including myocardial fibrosis assessment with late 
gadolinium enhancement and novel myocardial T1 mapping) have been 
described in detail in Chapter 2.  Furthermore, cardiovascular magnetic 
resonance imaging was performed at additional time-points to assess 
temporal changes in T1 measures (Figure 4.1). 
 
Myocardial T1 values were assessed at multiple time-points to establish the 
optimal time-point for post-contrast T1 mapping.  This was defined at the 
flattest point on the T1 relaxation curve at which variation in T1 values with 
time was at a minimum.  Mid-cavity motion-corrected T1 maps were 
analyzed using a dedicated workstation (OsiriX version 4.1.1, Geneva, 
Switzerland).  To minimize partial volume effects from surrounding tissues 
and blood-pool, we standardized the windowing and placement of regions 
of interest around the mid-cavity myocardium using a pre-defined protocol 
(Figure 4.2).  The regions of interest were first drawn on the pre-contrast T1 
maps and then copied onto each of the corresponding post-contrast T1 maps 
with stringent adjustments applied to avoid blood-pool and artifact (Figure 
4.2A).  This approach ensured consistency in the placement of regions of 
interest across the different time points, allowing us to investigate the 
temporal variation in our T1 measures.  
 
Myocardial partition coefficient (λ) and extracellular volume fractions (ECV) 
were also calculated at all time-points.  These measures were derived from 
pre- and post-contrast myocardial T1 values corrected for blood-pool T1 
(measured at the mid-cavity, Figure 4.2) and haematocrit (sampled at the 
time of CMR), according to: 
 
 λ = ΔR1myocardium/ΔR1blood-pool, where R1=1/T1 [1] 
 ECV = (1-haematocrit) x λ   [2] 
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Using a standardized approach, the basal, mid-cavity and apical T1 maps 
were divided into segments according to the standard 17-segment model 
recommended by the American College of Cardiology/American Heart 
Association (163).  We excluded the true apex because it was not possible to 
avoid partial volume effects.  Regions of interest were drawn in each of the 
16 segments on the pre-contrast T1 map and subsequently, copied onto the 
post-contrast T1 map at the optimal time-point established from the above 
analysis (Figure 4.2B).  Pre- and post-contrast myocardial T1, partition 
coefficient and extracellular volume fraction values were assessed in each 
segment of the left ventricle.  
 
We established the reproducibility of our image analysis technique and of 
the different T1 measures from a random sample of 5 healthy volunteers and 
5 patients with aortic stenosis.  In assessing intra-observer reproducibility, a 
single observer repeated analysis after an interval of more than two weeks to 
minimize recall bias.  For inter-observer reproducibility, two independent 
observers performed separate blinded analyses.   Scan-rescan reproducibility 
was assessed in 10 healthy volunteers.  Repeat scans were performed at least 
7 days after the first scan, and haematocrit samples were collected on both 
scan days.  Images were analyzed as above by a single observer. 
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FIGURE 4.1. CARDIOVASCULAR MAGNETIC RESONANCE IMAGING 
AND MYOCARDIAL T1 MAPPING PROTOCOL 
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FIGURE 4.2. METHODOLOGY FOR MEASURING MYOCARDIAL T1 AT 
MULTIPLE TIME-POINTS AND IN MULTIPLE SEGMENTS OF THE LEFT 
VENTRICLE 
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4.3.3 Statistical Analysis 
Sample size estimation was not performed because this is an exploratory 
study to optimize a novel technique and determine the T1-derived measure 
with the most potential to assess diffuse myocardial fibrosis. 
 
In all T1-derived measures, we compared the values across all the segments 
using one-way analysis of variance (ANOVA) with post-hoc Bonferroni 
adjustment.  We examined the potential influence of heart rate and age on T1 
measures using univariate linear analysis, and adjusted the effects of age and 
haematocrit using multivariate linear regression.  Reproducibility analysis 
(intra-, inter-observer, and scan-rescan) was performed using intraclass 
correlation coefficients (ICC).  ICC values between 0.50 and 0.75 indicated 
moderate reliability, and values >0.75 good reliability.  For clinical measures, 
excellent intraclass correlation coefficients of >0.90 are required to ensure 
sufficient reliability (164).  Fixed and proportional biases with 95% limits of 
agreement were assessed using Bland-Altman analyses.   
 
The standard statistical analyses described in Chapter 2 and Bland-Altman 
analyses were performed using GraphPad Prism (GraphPad Software, Inc., 
San Diego, CA, USA).  Univariate and multivariate linear regression, and 
ICC were performed using SPSS version 19 (SPSS, Inc., Chicago, IL, USA).  A 
two-sided P<0.05 was considered statistically significant. 
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4.4 RESULTS 
Patients with aortic stenosis were older than healthy volunteers (median age 
75 versus 55 years, P<0.01) and there were an equal number of males and 
females (Table 4.1).  On average they had moderate aortic stenosis (mean 
aortic valve area 1.2±0.6 cm2; peak aortic valve velocity 3.3±0.9 m/s) with an 
increased left ventricular mass index and indices of diastolic dysfunction 
compared to healthy volunteers (Table 4.1).  
 
A total of 1215 myocardial segments were analyzed (606 in healthy 
volunteers and 609 in patients with aortic stenosis) and 5.1% of segments 
were rejected because of artifacts. 
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TABLE 4.1. BASELINE CLINICAL, ECHOCARDIOGRAPHIC AND 




Stenosis P value 
CLINICAL CHARACTERISTICS 
Males, n (%) 
Median age, years [IQR] 
Hypertension, n (%) 
Diabetes Mellitus, n (%) 
Coronary artery disease, n (%) 
 
Systolic blood pressure, mmHg 






























Aspirin, n (%) 
ACEI/ARB, n (%) 
Beta blockers, n (%) 














Aortic valve area, cm2 
Mean pressure gradient, mmHg 
Peak velocity, m/sec 
Mean e’, cm/s 
















CARDIOVASCULAR MAGNETIC RESONANCE 
Indexed end-diastolic volume (EDVi), mL/m2 
Indexed end-systolic volume, mL/m2 
Stroke volume, mL/m2 

















(Abbreviations: EDV, end diastolic volume; ESV: end systolic volume; IQR, 
interquartile range; ACEI angiotensin-converting enzyme inhibitors; ARB 
angiotensin receptor blockers). 
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4.4.1 Influence of Heart Rate and Age on T1 Measures 
Across the range of heart rates in our study, there was no correlation 
between heart rate and pre-contrast myocardial T1 (r=-0.23, P=0.16), 
suggesting that incomplete restoration of magnetization due to fast heart 
rates and long T1 values was not an important factor.  In healthy volunteers 
(age range 19 to 75) there was no correlation between age and any of the T1 
measures investigated (pre-contrast myocardial T1, r=-0.09, P=0.70; post-
contrast myocardial T1, r=-0.25, P=0.29; λ, r=0.16, P=0.52; and ECV, r=0.25, 
P=0.29).    
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4.4.2 Effects of Time on Post-Contrast T1 Values 
Post-contrast T1 values in the blood-pool and myocardium were lower than 
pre-contrast values, and demonstrated an exponential return to baseline with 
time (Figure 4.3 and Table 4.2).  In particular, the initial 15 min post-contrast 
was characterized by rapid changes in T1 values but thereafter the relaxation 
curve appeared to plateau such that subsequent changes were minimal.  
Indeed, T1 values at 20 min did not differ significantly from those at 15 and 
30 min (Figure 4.3).  On this basis, 20 min was the time-point used for 
subsequent comparisons.  
 
Interestingly, λ or ECV values were constant at all time-points evaluated, 
reflecting a constant relationship between the myocardial and blood-pool T1 
relaxation times (Figure 4.3).   
 
	   109	  
FIGURE 4.3. VARIATION OF DIFFERENT T1 MEASURES WITH TIME 
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TABLE 4.2. PRE- AND POST-CONTRAST T1, PARTITION COEFFICIENT 





Stenosis P value 
Pre-contrast 
Myocardial T1, ms 











Myocardial T1, ms 
Blood-pool T1, ms 
Myocardial ΔR1, ms-1x103 
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4.4.3 Regional Variation in T1 Measures 
In healthy volunteers, there was no variation in any of the T1 measures 
across the 16 segments of the left ventricle (P>0.1 in all measures; all pairwise 
comparisons Bonferroni corrected), with similar results demonstrated in 
patients with aortic stenosis (Figure 4.4).  Specifically, there were no 
differences across any of the myocardial slices or between segments within 
the same slice (P>0.1 for all measures; all pairwise comparisons Bonferroni 
corrected).  Indeed, T1 measures in the mid-cavity were representative of 
those assessed across the entire left ventricular myocardium (λ 0.46±0.03 
versus 0.46±0.03, P=1.00; ECV 28.4±1.7 versus 28.3±1.9%, P=0.61).  Thus, the 
mid-cavity myocardium was used for subsequent comparisons.   
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FIGURE 4.4. VARIATION IN THE DIFFERENT T1 MEASURES ACROSS 
THE LEFT VENTRICULAR MYOCARDIUM IN PATIENTS WITH AORTIC 
STENOSIS 
 
There were no differences in the pre- (A) or post-contrast (B) myocardial T1, 
partition coefficient (C), and the extracellular volume fraction (D) across the 
16 segments.  Intra-class coefficients values were >0.90 for each myocardial 
segment.  
 
Results presented in mean ± standard deviation 
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4.4.4 Comparison of T1 Measures 
Intra-, and inter-observer reproducibilities were excellent for pre- and post-
contrast T1 values, with no fixed or proportional biases and narrow limits of 
agreement (Table 4.3).  However, scan-rescan reproducibilities for pre- and 
post-contrast T1 values were modest (ICC 0.72 and 0.56 respectively).  
Conversely, all measures of reproducibility were excellent for λ and ECV.  
ICC values were >0.90 with no fixed biases and narrow confidence limits 
(Table 4.3).  The scan-rescan variability was ±3%.  Furthermore, the ICC 
values for both λ and ECV were >0.90 in each of the 16 myocardial segments.  
 
Pre-contrast myocardial T1 values were similar in healthy volunteers and 
patients with aortic stenosis (1180±28 versus 1191±34ms, P=0.29) as were 
post-contrast T1 values (672±56 versus 663±43ms, P=0.59; Figure 4.5A; Table 
4.4).  However, λ and ECV values were higher in patients with aortic stenosis 
compared to healthy volunteers (λ 0.46±0.03 versus 0.44±0.03, P=0.02; ECV 
28.3±1.7 versus 26.0±1.6%, P<0.001; Figure 4.5B; Table 4.4), with the latter 
appearing to offer better differentiation.  The absolute increase in ECV values 
in patients with aortic stenosis was 2.1% compared to healthy volunteers 
(95% CI: 0.6 to 3.6%, P=0.009) after adjustment for age and hematocrit levels. 
Moreover a correlation was observed between ECV and diastolic function 
(ECV and E/e’ r=0.63, P<0.01; ECV and e’ r=-0.50, P<0.01), providing indirect 
support for increased myocardial fibrosis in patients with aortic stenosis.  
The other T1-related measures did not demonstrate such an association 
(P>0.05 for all). 
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FIGURE 4.5. ABILITY OF THE T1 MEASURES TO DIFFERENTIATE 
PATIENTS WITH AORTIC STENOSIS FROM HEALTHY VOLUNTEERS 
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TABLE 4.4. MYOCARDIAL T1, PARTITION COEFFICIENT AND 













1 1221 726 0.494 28.2 
2 1153 676 0.466 26.1 
3 1167 635 0.514 29.8 
4 1201 684 0.504 31.8 
5 1136 689 0.452 28.4 
6 1202 673 0.479 27.8 
7 1192 679 0.479 27.2 
8 1179 656 0.421 27.4 
9 1238 705 0.451 29.8 
10 1190 753 0.435 27.3 
11 1172 747 0.460 25.6 
12 1142 617 0.444 27.2 
13 1195 585 0.461 27.5 
14 1223 623 0.456 30.6 
15 1194 632 0.483 28.2 
16 1269 659 0.427 30.4 
17 1193 607 0.419 26.4 
18 1140 652 0.417 26.8 
19 1211 684 0.483 28.2 
20 1200 582 0.474 31.0 
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4.4.5 Analysis of T1 Measures in Patients with Focal Late Gadolinium 
Enhancement 
A separate analysis of T1 measures was performed in patients who were 
excluded because of the presence of focal replacement myocardial fibrosis 
identified on late gadolinium enhancement (n=9).  Regions of interest were 
placed around areas of late gadolinium enhancement as well as the remote 
myocardium (defined as an adjacent myocardial segment on the same short 
axis slice without evidence of late enhancement and then copied onto 
corresponding pre- and post-contrast T1 maps.  T1-related measures were 
then calculated for both regions. 
 
Among the 9 patients with aortic stenosis and focal late gadolinium 
enhancement, 5 had an infarct and 4 had a mid-wall pattern of enhancement.  
The partition coefficient and extracellular volume fraction values were 
higher in regions of focal enhancement compared to the myocardium remote 
to the mid-wall enhancement (λ 0.69±0.16 versus 0.48±0.04, P=0.02; ECV 
46.6±8.5% versus 30.9±2.3%, P=0.006) but surprisingly, there was no 
difference in pre- and post-contrast T1 values (Figure 4.6).  Furthermore, 
extracellular volume fraction values were also increased in the remote 
myocardium of patients with mid-wall late gadolinium enhancement 
compared to those without late enhancement (30.9±2.7 versus 28.3±1.7%, 
P<0.01).  This was not observed with respect to pre- and post-contrast T1 nor 
partition coefficient values.   
 
The study was not powered to investigate T1-related measures in the remote 
myocardium in patients with mid-wall late enhancement.  However, the 
increased extracellular volume fraction values in these regions support the 
concept that mid-wall fibrosis represents the end-stage of the myocardial 
fibrotic response.   
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FIGURE 4.6. ANALYSIS OF T1 MEASURES IN PATIENTS WITH LATE 
GADOLINIUM ENHANCEMENT 
 
Results were presented in box-and-whiskers plots (Tukey): the central box 
represents the interquartile range, with the median indicated by the line 
within the box.  The whiskers extend to the most extreme values within the 
1.5 interquartile ranges. 
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4.5 DISCUSSION 
Using a standardized methodology and patient cohort, we have 
systematically compared commonly used T1 measures at multiple time-
points and in multiple regions across the left ventricle.  We have shown that 
pre-contrast T1 was limited by an inability to differentiate patients with 
aortic stenosis from healthy volunteers, while post-contrast myocardial T1 
lacked sufficient scan-rescan reproducibility.  By comparison, partition 
coefficient and in particular extracellular volume fraction demonstrated 
excellent reproducibility and were increased in patients with aortic stenosis 
compared to healthy volunteers.  
 
Over recent years, multiple T1-derived parameters have been derived to 
assess diffuse myocardial fibrosis.  We have attempted to optimize and 
compare these different techniques at 3T using a standardized technique 
with meticulous attention paid to avoid blood-pool and artifact.  This 
approach demonstrated excellent reproducibility, with respect to the entire 
ventricle and within individual myocardial segments, indicating that both 
global and regional T1 can be measured.  Furthermore, pre- and post-
contrast T1, partition coefficient and extracellular volume fraction values did 
not vary across segments in the left ventricle.  This is as anticipated given the 
diffuse distribution of interstitial fibrosis. 
 
We have also characterized the temporal variation of T1 measures.  Post-
contrast T1 demonstrated the characteristic exponential increase back to 
baseline following gadolinium administration.  The rate of this recovery 
appears to be determined by the blood concentration of gadolinium 
(equilibrium between blood-pool and myocardial T1 occurred as early as 2 
min), which depends on its volume of distribution and renal clearance. 
Whilst the first 15 min following injection were characterized by large 
variations in myocardial and blood-pool T1 values, a plateau phase ensued 
between 15 and 30 min during which T1 values were relatively constant.  We 
therefore investigated whether meaningful comparisons could be made 
between serial scans using post-contrast T1 values at 20 min.  Unfortunately 
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the scan-rescan reproducibility of post-contrast T1 was modest.  This is likely 
the consequence of inter-day variation in gadolinium pharmacokinetics 
relating to glomerular filtration rate, the patient’s volume status and diet. 
Such variation will have had a major impact on our post-contrast T1 values 
potentially obscuring any differences attributable to diffuse fibrosis.  Indeed 
this is the likely explanation for the lack of difference in values between 
patients with aortic stenosis and healthy volunteers. Whilst complex kinetic 
models have been developed in an attempt to correct for some of these 
factors these are based upon multiple assumptions and data acquired at 1.5 
not 3T (165). 
 
An alternate T1 technique is therefore necessary to overcome variations in 
gadolinium kinetics.  One approach is pre-contrast myocardial T1.  In this 
study, pre-contrast myocardial T1 demonstrated improved scan-rescan 
reproducibility; but, like post-contrast T1, was unable to differentiate 
patients with aortic stenosis from healthy volunteers. This probably reflects 
the reduced sensitivity of pre-contrast techniques that rely on the inherent T1 
properties of healthy myocardium and fibrosis.  By comparison a recent 
study demonstrated that pre-contrast myocardial T1 values (using the 
shortened modified MOLLI sequence) were higher in patients with severe 
aortic stenosis compared to healthy volunteers (147).  Most likely this reflects 
the more advanced disease state in their study population.  Indeed there was 
no increase in values amongst their patients with moderate stenosis, who 
had a similar degree of hypertrophy to our cohort (81±18 versus 82±17 g/m2). 
 
A second approach is to correct post-contrast myocardial T1 values for 
variation in the pharmacokinetics of gadolinium.  Partition coefficient 
appears to be an effective method by using a ratio of myocardial and blood-
pool T1 values.  Indeed, partition coefficient demonstrated excellent 
reproducibility, indicating that inter-day variation in gadolinium kinetics can 
be accounted for by this approach.  Furthermore, partition coefficient values 
are increased in patients with aortic stenosis compared to healthy volunteers.  
This probably reflects the improved sensitivity of contrast-enhanced 
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techniques, based on the accumulation of gadolinium in regions of fibrosis 
and the resultant shortening of T1 (44).  
 
Extracellular volume fraction translates partition coefficient into a percentage 
of the myocardium affected by diffuse fibrosis and is in many ways easier to 
conceptualize.  Furthermore, it corrects for the effects of plasma volume, 
which can vary considerably from day to day (perhaps accounting for some 
of the scan-rescan variation in pre- and post-contrast T1 values). Extracellular 
volume fraction demonstrated excellent reproducibility in this study and 
appears to further improve the differentiation between patients with aortic 
stenosis and healthy volunteers.  
 
Both partition coefficient and extracellular volume fraction appear to possess 
all the necessary attributes for the measurement of diffuse fibrosis at 3T.  
Interest surrounds such techniques in the assessment of novel anti-fibrotic 
agents in aortic stenosis (3) and our scan-rescan reproducibility will be of use 
when estimating the required sample sizes for such studies. These will 
require the excellent reproducibility provided by partition coefficient and 
extracellular volume fraction to ensure that any difference detected between 
scans is attributed to the intervention. Moreover, the slowly progressive 
nature of fibrosis means that any treatment differences are likely to be small, 
so that the improved sensitivity of partition coefficient and extracellular 
volume fraction in particular over pre-contrast T1 will also be important.  
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4.5.1 Study Limitations 
By design we did not recruit patients with end-stage aortic stenosis, as we 
believe that T1 mapping will be more relevant to those with less severe 
disease in whom myocardial fibrosis is more likely to be reversible with 
novel anti-fibrotic therapies.  Unfortunately, this has limited our ability to 
validate the various T1 measures against histology.  However, good 
correlations for each technique have previously been established with 
histology, and supported in this study by increased extracellular volume 
fraction and partition coefficient in regions of late gadolinium enhancement.  
Furthermore, we have demonstrated a close association between 
extracellular volume fraction and markers of diastolic dysfunction.  It is 
therefore reasonable to assume that our T1-derived measures are markers of 
diffuse myocardial fibrosis particularly as we have carefully excluded 
individuals with pathologies that might have confounded our results.  
 
The patients with aortic stenosis were significantly older than healthy 
volunteers in our study, but the differences in extracellular volume fraction 
and partition coefficient values between patients with aortic stenosis and 
healthy volunteers were independent of age.  This is also consistent with 
previous studies (152,166).  
 
Scan-rescan reproducibility was only assessed in healthy volunteers, but not 
patients with aortic stenosis.  However, both patients with aortic stenosis and 
healthy volunteers demonstrated similar T1 relaxation profiles in the 
myocardium and blood-pool.  Furthermore, we did not observe any 
proportional bias in healthy volunteers.  Therefore, we are confident the 
scan-rescan reproducibility in patients with aortic stenosis should be similar 
to that in healthy volunteers.        
   
	   123	  
4.6 CONCLUSIONS 
In the cardiovascular magnetic resonance assessment of diffuse myocardial 
fibrosis, pre- and post-contrast myocardial T1 have limitations.  By contrast, 
partition coefficient and in particular extracellular volume fraction 
demonstrate excellent reproducibility and an ability to differentiate patients 
with aortic stenosis from healthy volunteers.  Among all the T1-derived 
measures evaluated, extracellular volume fraction appears to have the most 
potential in assessing diffuse myocardial fibrosis at 3T. 
 




HIGH-SENSITIVITY TROPONIN I 
CONCENTRATIONS ARE A MARKER OF AN 
ADVANCED HYPERTROPHIC RESPONSE AND 








Chin CW*, Shah AS*, McAllister DA, Joanna Cowell S, Alam S, Langrish JP, 
Strachan FE, Hunter AL, Maria Choy A, Lang CC, Walker S, Boon NA, 
Newby DE, Mills NL, Dweck MR. High-sensitivity troponin I concentrations 
are a marker of an advanced hypertrophic response and adverse outcomes in 
patients with aortic stenosis.  Eur Heart J. 2014;35(34):2312-2321. 
* Equal contributions as first authors 
 
	   125	  
5.1 SUMMARY 
AIMS:  High-sensitivity cardiac troponin I (cTnI) assays hold promise in 
detecting the transition from hypertrophy to heart failure in aortic stenosis. 
We sought to investigate the mechanism for troponin release in patients with 
aortic stenosis and whether plasma cTnI concentrations are associated with 
long-term outcome.  
 
METHODS: Plasma cTnI concentrations were measured in two patient 
cohorts using a high-sensitivity assay.  First, in the Mechanism Cohort, 122 
patients with aortic stenosis (median age 71, 67% male, aortic valve area 
1.0±0.4cm2) underwent cardiovascular magnetic resonance and 
echocardiography to assess left ventricular (LV) myocardial mass, function 
and fibrosis.  In the separate Outcome Cohort, 131 patients originally 
recruited into the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact of 
REgression (SALTIRE) study, had long-term follow up for the occurrence of 
aortic valve replacement and cardiovascular deaths.  
 
RESULTS: The indexed LV mass and measures of replacement fibrosis (late 
gadolinium enhancement) were associated with cTnI concentrations 
independent of age, sex, coronary artery disease, aortic stenosis severity and 
diastolic function.  Over a median follow-up of 10.6 years (1,178 patients-
years), 24 patients died from a cardiovascular cause and 60 patients had an 
aortic valve replacement.  Plasma cTnI concentrations were associated with 
aortic valve replacement or cardiovascular death (HR 1.77; 95% CI 1.22-2.55) 
independent of age, sex, systolic ejection fraction, and aortic stenosis severity. 
 
CONCLUSIONS: In patients with aortic stenosis, plasma cTnI concentration 
is associated with advanced hypertrophy and replacement myocardial 
fibrosis as well as AVR or cardiovascular death. 
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5.2 INTRODUCTION 
Aortic stenosis is the commonest form of valvular heart disease in the 
western world and its prevalence is expected to double in the next two 
decades (1). Current guidelines advocate aortic valve replacement in patients 
with symptoms and severe valve narrowing (5,141).  However, there is a poor 
correlation between the severity of stenosis and symptom onset making the 
management of asymptomatic patients controversial (5). This apparent 
discrepancy might in part be explained by heterogeneity in the hypertrophic 
response to aortic stenosis, which itself is an independent marker of an 
adverse prognosis (3,53,58).  
 
Hypertrophy occurs in response to the increased afterload imposed by aortic 
valve narrowing on the left ventricle. Initially, this restores wall stress and 
maintains cardiac performance but decompensation ultimately ensues and 
patients develop symptoms, adverse events and the need for surgery. The 
transition from hypertrophy to heart failure is characterized by progressive 
cardiomyocyte death and replacement fibrosis (36). Myocardial fibrosis can 
be detected using two cardiovascular magnetic resonance techniques: late 
gadolinium enhancement (replacement fibrosis) and T1 mapping (diffuse 
interstitial fibrosis) with data indicating that the former provides useful 
prognostic information (51,58). However to date, a marker of myocyte cell 
death has been lacking.  
 
Cardiac troponin is a structural protein present in cardiac muscle, with 
plasma troponin concentrations considered a highly specific marker for 
myocardial injury (115). Recent advances in assay technology have greatly 
improved sensitivity, now allowing quantification of troponin with a high 
degree of precision at extremely low plasma concentrations (116).  
 
In this study, we hypothesized that detection of myocardial injury by high-
sensitivity troponin assays may provide an early indicator of left ventricular 
decompensation and be associated with future adverse events in patients 
with aortic stenosis.  
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5.3 METHODS 
Two cohorts of stable patients with aortic stenosis were recruited from 
cardiology outpatient clinics across 3 centers in Southeast Scotland.  First we 
determined the association between plasma cardiac troponin I (cTnI) 
concentrations and left ventricular functional and structural abnormalities on 
cardiovascular magnetic resonance (Mechanism Cohort), and second we 
examined the prognostic role of plasma cTnI concentrations in patients with 
aortic stenosis (Outcome Cohort).  The study was conducted in accordance 
with the Declaration of Helsinki, and approved by the local research ethics 
committee.  Written informed consent was obtained from all participants. 
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5.3.1 Patient Populations 
Mechanism Cohort: Patients in the Mechanism Cohort were recruited 
prospectively as stated in Chapter 2.  In addition, thirteen age- and sex-
matched healthy volunteers without clinically significant heart disease were 
recruited from the local community.  
 
Outcome Cohort: This cohort comprised patients recruited into the Scottish 
Aortic Stenosis and Lipid Lowering Trial, Impact of REgression (SALTIRE) 
study.  The study design, inclusion and exclusion criteria have been described 
previously (127). In brief, from March 2001 to April 2002, 155 patients with 
asymptomatic aortic stenosis were randomly assigned to receive either 
atorvastatin 80 mg or placebo once daily.  Patients were excluded if they were 
already on a statin, if aortic valve replacement was planned or if they had 
moderate or severe left ventricular systolic impairment.  Only patients with 
plasma samples available for cTnI analysis were included in the present 
analysis.  
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5.3.2 Blood Sampling and Analysis 
In the Mechanism Cohort, brain natriuretic peptide (BNP) concentration was 
analyzed with the Triage BNP assay (Biosite, Inc., San Diego, California).  The 
inter-assay coefficient of variation was 10% at 28.8 pg/ml, with a detection 
range of 5 to 1300 pg/ml (167).  In the Outcome Cohort, N-terminal proBNP 
(NT-proBNP) concentration was measured using the Elecysys 2010 analyzer 
(Roche Diagnostics Ltd, Lewes, UK).  This assay has <0.001% cross-reactivity 
with bioactive BNP, and the inter-assay coefficients of variation range from 
0.9 to 5.5% (168).   
 
Plasma cTnI concentrations were determined by the ARCHITECT STAT high-
sensitivity cTnI assay (Abbott Laboratories, Abbott Park, Illinois) in both 
cohorts.  The method of detection and sensitivity of the assay have been 
provided in greater detail in Chapter 2.  Precision profiling of the assay was 
performed in 248 samples across 18 healthy controls (Figure 5.1).  
Concentrations lower than the detection limit were assigned a value of 1.2 
ng/L. 
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FIGURE 5.1. ANALYTICAL VARIABILITY OF HIGH-SENSITIVITY 
CARDIAC TROPONIN I ASSAY 
 
 
Precision profiling of the ARCHITECTSTAT high-sensitivity troponin I assay 
was performed in 248 samples across 18 healthy controls.  The inter-assay 
coefficient of variation (CV) for duplicate samples is 10% at 6 ng/L and 20%  
at 1.5 ng/L. 
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5.3.3 Imaging Protocol in the Mechanism and Outcome Cohorts   
All participants in both cohorts underwent echocardiography to assess aortic 
stenosis severity and diastolic function according to the protocol described in 
Chapter 2.  Patients in the Mechanism Cohort also underwent cardiovascular 
magnetic resonance at 3T to assess left ventricular volumes, mass and 
function.  Furthermore, assessment of myocardial fibrosis was performed 
using both conventional late gadolinium enhancement and novel myocardial 
T1 mapping techniques as detailed in Chapter 2. 
 
In addition to echocardiography, patients in the Outcome Cohort also 
underwent computed tomography calcium scoring of the coronary arteries 
and aortic valve was performed on ECG-gated non-contrast scans using a 
double helix scanner (Twin II Flash, Philips Medical Systems).  All images 
were analyzed by a single operator using the Picker Cardiac Scoring software 
as previously described (127).  
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5.3.4 Follow-up in the Outcome Cohort 
Clinical outcomes were obtained and adjudicated by two independent 
investigators blinded to plasma cTnI and BNP concentrations.  All in-hospital 
and community deaths were captured in a comprehensive national database: 
the General Register of Scotland.  Cardiovascular death was based on the 
cause of death stated on the death certificate.  We defined cardiovascular 
death as death due to myocardial infarction, sudden cardiac death, heart 
failure, stroke, death due to cardiovascular procedures and death due to 
other cardiovascular causes.  Each death was classified as cardiac or non-
cardiac by two independent investigators and any discrepancy resolved by 
consensus.  All events were confirmed by independent review of each 
patient’s electronic healthcare record where available.  Surgical aortic valve 
replacement (no patients underwent transcatheter aortic valve implantation 
in the follow-up period) was determined from individual patient medical 
records.  All patients in the Outcome Cohort were managed in the tertiary 
cardiac center, where patients are reviewed at a multi-disciplinary meeting 
prior to undergoing cardiac surgery.  Only patients with established 
indications were referred for aortic valve replacement according to the 
European Society of Cardiology recommendations (5,169).     
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5.3.5 Statistical Analysis 
We assessed the association of plasma cTnI concentrations with measures of 
aortic stenosis and ventricular remodeling using univariate and multivariable 
linear regression models.  Plasma cTnI concentrations were log-transformed 
as this variable was highly skewed.  Kaplan-Meier analysis was performed 
across tertiles of cTnI concentrations.  To accommodate competing risks, the 
association between time to aortic valve replacement or cardiovascular deaths 
and plasma cTnI concentrations (log-transformed [base 2]) was modeled as a 
composite endpoint in Cox proportional hazard models.  Furthermore, we 
examined whether relative change in cTnI concentrations at 1 year (cTnI at 1 
year – baseline cTnI, both log transformed) was associated with increased 
odds of an event at 3-year, and 5-year follow-up independent of baseline cTnI 
concentrations.  Survival analyses and all other analyses were performed 
using R version 2.15.2 (Vienna, Austria) and SPSS Version 19 (SPSS, Inc., 
Chicago, IL, USA), respectively.   
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5.4 RESULTS 
We recruited 122 patients into the Mechanism Cohort (71 [65-77] years, 67% 
males, aortic valve area 1.0±0.4 cm2) and analyzed 131 patients in the 
Outcome Cohort (69 [62-75] years, 70% males, aortic valve area 1.1±0.4 cm2) 
(Tables 5.1 and 5.2).  Thirteen healthy volunteers were recruited, who were 
well matched in terms of age (65 [57-75] years) and sex (62% male) compared 
to the other groups and did not have any history of diabetes mellitus, 
hypertension or coronary artery disease.   
 
Plasma cTnI concentrations above the lower limit of detection of 1.2 ng/L 
were present in 98% of our patients with aortic stenosis and increased in both 
cohorts compared to the healthy volunteers (Mechanism Cohort 6.6 [3.8-12.0] 
ng/L; Outcome Cohort 7.6 [5.7-13.2] ng/L; healthy volunteers 3.2 [1.3-11.0] 
ng/L).  There were 10 patients (8.1%) in the Mechanism Cohort and 10 
patients (7.6%) in the Outcome Cohort with plasma cTnI concentrations 
above 26 ng/L (the 99th centile derived from the healthy reference 
population).  There was no difference in renal function across tertiles of cTnI 
in patients with aortic stenosis (Figure 5.2). 
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FIGURE 5.2. DISTRIBUTION OF HIGH-SENSITIVITY PLASMA CARDIAC 
TROPONIN I CONCENTRATIONS IN THE MECHANISM AND OUTCOME 
COHORTS OF PATIENTS WITH AORTIC STENOSIS 
 
Plasma cardiac troponin I concentrations were above the limit of detection in 
98% of our patients with aortic stenosis in both cohorts, and exceeded the 
recommended diagnostic threshold for myocardial infarction (> 26ng/L) in 8%.  
The distribution of plasma troponin I concentrations were similar in the two 
cohorts of patients. 
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TABLE 5.1. BASELINE CHARACTERISTICS OF PATIENTS WITH 










CLINICAL CHARACTERISTICS   
Age, years 65 [57,75] 71 [65,77] 0.13 
Male sex, n (%) 8 (62) 82 (67) 0.76 
Diabetes mellitus, n (%) 0 14 (11) - 
Hypertension, n (%) 0 78 (63) - 
Coronary artery disease, n (%) 0 41 (33) - 
SBP, mmHg 148±12 149±20 0.35 
NYHA class, n (%) 
     I 
     II 











    
Creatinine, µmol/l 69±8 78±17 0.06 
Cardiac troponin I concentration, ng/L 3.2 [1.3,11.0] 6.6 [3.8,12.0] 0.03 
Brain natriuretic peptide, pg/ml 10.3 [5.6,18.1] 26.4 [10.6,53.9] 0.009 
ECHOCARDIOGAPHY   
Peak aortic jet velocity, m/s 1.4±0.2 3.7±0.9 <0.001 
Mean pressure gradient, mmHg 4±1 32±18 <0.001 
Aortic valve area, cm2 2.4±0.7 1.0±0.4 <0.001 
Valvulo-arterial impedance, mmHg/ml•m2 4.5±1.1 4.5±1.2 0.96 
Mean e’, cm/s 8.1±2.7 6.2±1.9 0.001 
Mean E/e’ 7.9±2.2 14.8±8.1 0.003 
CARDIOVASCULAR MAGNETIC RESONANCE   
Indexed end-diastolic volume (EDVi), ml/m2 73±13 72±14 0.71 
Indexed end-systolic volume, ml/m2 27±7 24±9 0.28 
Indexed stroke volume, ml/m2 46±7 48±9 0.68 
Ejection fraction, % 64±3 67±7 0.12 
Indexed left ventricular mass (LVMi), g/m2 70±14 89±22 0.004 
LVMi/EDVi, g/ml 0.96±0.13 1.26±0.28 <0.001 
Extracellular volume fraction, % 25.9±1.6 27.7±2.5 0.01 
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CLINICAL CHARACTERISTICS    
Age, years 67±10 64±12 69±10 70±9 0.03 
Male sex, n (%) 91 (70) 24 (57) 32 (71) 35 (79) 0.08 
Diabetes Mellitus, n (%) 4 (3) 1 (2) 1 (2) 2 (5) - 
Hypertension, n (%) 66 (50) 18 (43) 22 (49) 26 (59) 0.31 
Coronary artery disease, n (%) 22 (16) 6 (14) 7 (16) 9 (21) 0.72 
Systolic blood pressure, mmHg 145±20 139±17 148±21 146±19 0.07 
NYHA class, n (%) 
    I 















      
Creatinine, µmol/l 91±21 86±17 92±20 95±25 0.12 









ECHOCARDIOGRAPHY    
Peak aortic jet velocity, m/s 3.4±0.7 3.4±0.6 3.4±0.6 3.5±0.7 0.45 
Mean pressure gradient, mmHg 26±11 25±10 25±10 28±13 0.35 
Aortic valve area (AVA), cm2 1.1±0.4 1.0±0.4 1.1±0.4 1.0±0.4 0.72 
Indexed AVA, cm2/m2 0.5±0.2 0.5±0.2 0.6±0.2 0.5±0.2 0.66 
Left ventricular mass (LVM), g 357±107 327±111 350±102 393±100 0.02 
Indexed LVM, g/m2 180±50 165±54 172±49 196±49 0.06 
Fractional shortening, % 40±8 42±9 42±8 37±6 0.004 
Ejection fraction (EF), % 70±10 72±11 72±9 66±8 0.007 
Left ventricular hypertrophy, n (%) 109 (95) 34 (81) 36 (80) 39 (89) 0.49 
Impaired EF <50%, n (%) 4 (3) 1 (2) 2 (4) 2 (5) 0.84 
COMPUTED TOMOGRAPHY    
Coronary calcium score, log AU 1.6±1.3 1.5±1.3 1.5±1.3 1.8±1.1 0.53 
Aortic valve calcium score, log AU 3.6±0.6 3.6±0.5 3.6±0.5 3.7±0.8 0.61 
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5.4.1 Mechanism for Increased Cardiac Troponin I Concentrations 
In the Mechanism Cohort, patients with aortic stenosis had an increased left 
ventricular mass index compared to healthy controls, although there was no 
difference in left ventricular volumes or ejection fraction (Table 5.1). 
Furthermore, these patients had higher extracellular volume fraction values 
(27.7±2.5 versus 25.9±1.6%, P=0.01), and 35 patients (28%) had a mid-wall 
pattern of late gadolinium enhancement: an observation not seen among the 
healthy volunteers (Figure 5.3).  
 
Plasma cTnI concentrations correlated with left ventricular mass index, 
independent of coronary artery disease status (r=0.50, P<0.001; Figure 5.4).  A 
weaker correlation was also observed between plasma cTnI concentrations 
and peak aortic jet velocity (r=0.32, P<0.001).  Furthermore, patients with 
aortic stenosis and mid-wall late gadolinium enhancement had a two-fold 
increase in plasma cTnI concentrations compared to those without (9.5 [5.7, 
20.3] ng/L versus 4.3 [3.3, 7.9] ng/L, P=0.02; Figure 5.5). 
 
With univariate analysis, age, mean pressure gradient, mean e’, the left 
ventricular mass index, and measures of both diffuse and replacement 
fibrosis were all associated with plasma cTnI concentrations (Table 5.3; all 
P<0.05).  However, only age, left ventricular mass index and extent of late 
gadolinium enhancement (%) were independently associated with plasma 
cTnI concentrations (Model 1; Table 5.3).  
 
Interestingly, there was no difference in plasma cTnI concentrations between 
patients with and without coronary artery disease (6.9 [4.0, 13.5] ng/L versus 
6.2 [3.5, 10.0] ng/L, P=0.28).  This was supported by data from the Outcome 
Cohort where no correlation was observed between the coronary calcium 
scores and plasma cTnI concentrations (r=-0.03, P=0.71).  
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FIGURE 5.3. COMPARISON OF TWO PATIENTS WITH SEVERE AORTIC 
STENOSIS 
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FIGURE 5.4. CORRELATION BETWEEN INDEXED LEFT VENTRICULAR 
MASS AND PLASMA CARDIAC TROPONIN I CONCENTRATIONS 
 
	   141	  
FIGURE 5.5. CARDIAC TROPONIN I CONCENTRATIONS IN PATIENTS 
WITH AND WITHOUT MID-WALL FIBROSIS 
 
Results were presented in box-and-whiskers plots (Tukey): the central box 
represents the interquartile range, with the median indicated by the line 
within the box.  The whiskers extend to the most extreme values within the 
1.5 interquartile ranges. 
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5.4.2 Prognostic Value of Cardiac Troponin I Concentrations  
Patients in the Outcome Cohort were stratified by tertiles of plasma cTnI 
concentration (Table 5.2).   In comparison to the lowest tertile, patients in the 
highest tertile were older (70±9 versus 64±12 years, P=0.03) and had an 
increased ventricular mass (393±100 versus 327±111g, P=0.02).  However, 
there were no differences in co-morbidity, severity of aortic stenosis or 
coronary calcium scores across the tertiles (P>0.1 for all; Table 5.2).  
 
Over a median of 10.6 years follow-up (1,178 patient-years), 60 patients had 
an aortic valve replacement, 24 died from a cardiovascular cause and 47 died 
from non-cardiovascular causes.  Ten-year event-free survival rate for aortic 
valve replacement or cardiovascular deaths differed across the tertiles of cTnI 
concentrations (log rank test for trend, P=0.016, Figure 5.6). Plasma cTnI 
concentration was associated with an increased risk of aortic valve 
replacement or cardiovascular deaths in unadjusted analysis (HR 1.65 per 
two-fold increment in cTnI concentration; 95%CI 1.15 to 2.38, P=0.007) with 
minimal attenuation in the effect estimate after adjusting for age, sex and 
ejection fraction (Table 5.4).  Moreover, this association persisted after further 
adjustment for severity of aortic stenosis (HR 1.77; 95%CI 1.22 to 2.35, 
P=0.002) as well as the coronary artery and aortic valve calcium scores (HR 
2.10; 95%CI 1.22 to 3.61, P=0.007).  
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FIGURE 5.6. TEN-YEAR EVENT FREE SURVIVAL FOR COMPOSITE 
ENDPOINT FOR AORTIC VALVE REPLACEMENT OR 
CARDIOVASCULAR DEATHS 
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TABLE 5.4. HAZARD RATIOS PREDICTING TIME TO VALVE 




(95% confidence interval) 
P 
value 
Model 1 1.65 (1.15 to 2.38) 0.007 
Model 2 1.61 (1.11 to 2.35) 0.01 
Model 3 1.63 (1.11 to 2.38) 0.01 
Model 4 1.77 (1.22 to 2.55) 0.002 
Model 5 2.10 (1.22 to 3.61) 0.007 
 
Model 1: Unadjusted  
Model 2: Adjusting for age and sex  
Model 3: Model 2 and systolic ejection fraction  
Model 4: Model 2 and mean pressure gradient 
Model 5: Model 2 and coronary and aortic valve calcium score 
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5.4.3 Mechanism and Prognosis Associated with BNP Concentrations 
Serum BNP concentrations were higher in patients with aortic stenosis 
compared with healthy volunteers (26.4 [10.6,53.9] versus 10.3 [5.6,18.1] 
ng/ml, P=0.009; Table 1).  In patients with aortic stenosis, BNP concentrations 
increased with age, disease severity, diastolic dysfunction, left ventricular 
mass index, myocardial fibrosis, the presence of coronary artery disease and 
symptoms (all p<0.05; Figure 5.7). However on multivariable analysis, only 
age was significantly associated with BNP concentrations (P<0.001; Table 
5.5).   
 
In the Outcome Cohort, NT-proBNP was not associated with aortic valve 
replacement or cardiovascular deaths in both unadjusted (HR 1.15 per two-
fold increment in NT-proBNP concentration; 95%CI 0.86 to 1.53, P=0.34) and 
adjusted analyses (Table 5.6).  Importantly, NT-proBNP concentration did 
not modify the association between troponin and time to aortic valve 
replacement or cardiovascular deaths (HR 1.60; 95% CI 1.10 to 2.34, P=0.01). 
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FIGURE 5.7. BRAIN NATRIURETIC PEPTIDE CONCENTRATIONS IN 
PATIENTS WITH AORTIC STENOSIS 
 
In patients with aortic stenosis, brain natriuretic peptide (BNP) concentration 
was increased across NHYA functional class and in those with coronary 
artery disease (CAD). 
Results were presented in box-and-whiskers plots (Tukey): the central box 
represents the interquartile range, with the median indicated by the line 
within the box.  The whiskers extend to the most extreme values within the 
1.5 interquartile ranges. 
 
	   148	  
 
	   149	  
 
TABLE 5.6. HAZARD RATIOS FOR TIME TO VALVE REPLACEMENT OR 
CARDIOVASCULAR DEATH FOR N-TERMINAL PRO-BRAIN 
NATRIURETIC PEPTIDE CONCENTRATIONS 
Model Hazard ratio 
(95% confidence interval) 
P 
value 
Model 1 1.15 (0.86 to 1.53) 0.34 
Model 2 1.14 (0.80 to 1.60) 0.47 
Model 3 1.13 (0.80 to 1.60) 0.49 
 
Model 1:  Unadjusted 
Model 2: Adjusting for age and sex 
Model 3: Model 2 and dyspnea (NYHA >1) 
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5.4.4 Exploratory Analysis of 1-year Change in Cardiac Troponin I 
Concentrations and Outcomes  
Among a subset of patients in whom troponin was measured more than once 
and who were event-free at one year, we explored the association between 
both baseline troponin and change in troponin from baseline to year 1 with 
the odds of valve surgery or death during subsequent follow-up. 
 
Serial plasma cardiac troponin I concentrations were available for 69 patients 
(52%).  There was a strong correlation between baseline and one-year cTnI 
concentrations (r=0.87, P<0.001).  Sixteen patients (23%) had an event within 3 
years and 25 (41%) had an event within 5 years of follow-up.  Associations in 
the same direction were evident for both 3-year and 5-year events for both 
baseline troponin (two fold increase OR 1.73 [1.11-2.89], P=0.02 and OR 1.39 
[0.95-2.16], P=0.23, respectively) and difference in troponin from baseline 
(two fold increase OR 3.19 [1.33-8.62], P=0.01 and 1.58 [0.75-3.78], P=0.23, 
respectively), although only the associations for 3-year event rates were 
statistically significant. 
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5.5 DISCUSSION 
This is the first dataset to explore mechanisms and outcomes associated with 
cTnI concentrations using a high-sensitivity assay in patients with aortic 
stenosis. In more than 250 patients with aortic stenosis, we have 
demonstrated that levels are detectable in 98% of subjects and increased 
compared to age and sex-matched healthy volunteers.  Plasma cTnI 
concentrations were not associated with the presence of co-existent coronary 
artery disease or the severity of valve narrowing on multivariable analysis.  
Instead, plasma cTnI concentrations demonstrated a close association with 
the magnitude of left ventricular hypertrophy and the presence of mid-wall 
myocardial fibrosis. Moreover, high-sensitivity plasma cTnI concentration 
showed an independent association with long-term risk of aortic valve 
replacement or cardiovascular deaths.  We therefore believe that high-
sensitivity plasma cTnI concentrations hold potential as an objective marker 
of left ventricular decompensation in patients with aortic stenosis and as a 
potential early trigger to aortic valve replacement.  
 
Aortic stenosis is defined not only by the development of progressive valve 
narrowing but also by the left ventricular hypertrophic response that ensues. 
Whilst this initially restores wall stress, decompensation due to progressive 
cell death and fibrosis ultimately occurs and patients transition from 
hypertrophy to heart failure (3).  Because of the associated adverse prognosis, 
current guidelines recommend surgery in patients with severe stenosis and 
evidence of such decompensation, detected either on the basis of symptom 
development or an ejection fraction <50%. Unfortunately, symptoms are often 
frequently difficult to assess whilst an ejection fraction <50% occurs late in the 
disease process and is often irreversible.  There is therefore emerging interest 
in developing novel, objective biomarkers of decompensation for patients 
with aortic stenosis.  Data from our study suggests that troponin has the 
potential to be such a marker.  
 
To date elevated cardiac troponin has been considered the sine qua non for the 
diagnosis of myocardial infarction (170).  However, marked improvements in 
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assay sensitivity now allow quantification of plasma cTnI concentrations in 
the majority of the healthy population (116).  In our study, cTnI was 
detectable in 98% of patients with aortic stenosis, and exceeded the 
recommended diagnostic threshold for myocardial infarction in 7.9%.  
Patients with stable coronary disease have been reported to have higher 
plasma troponin concentrations, with elevated levels being associated with 
long-term cardiovascular risk (171). However, in our cohort of patients with 
aortic stenosis, there were no differences in plasma troponin concentrations 
between those with and without coronary artery disease. Instead, plasma 
troponin concentrations were independently associated with an advanced 
hypertrophic response and replacement myocardial fibrosis. Indeed, the latter 
occurred over and above the effects of left ventricular mass, supporting our 
hypothesis that cTnI release relates to the myocardial injury that accompanies 
ventricular decompensation and myocardial fibrosis. 
 
The poor prognosis associated with increased troponin concentrations offers 
further support for this model.  At ten years, more than a half of patients in 
the highest tertile of plasma cTnI had undergone an aortic valve replacement 
or died from cardiovascular disease.  Moreover, plasma cTnI concentrations 
were associated with aortic valve replacement or cardiovascular deaths, 
independent of the burden of coronary atherosclerosis (as assessed using 
coronary calcium scoring) as well as age, sex, systolic ejection fraction, 
echocardiographic measures of aortic stenosis severity and the aortic valve 
calcium score.  
 
A recent study demonstrated an association between high-sensitivity cardiac 
troponin T concentrations and echocardiographic measures of left ventricular 
modeling in aortic stenosis (117).  Our data confirms and extends these 
findings using cardiovascular magnetic resonance, which has allowed us to 
investigate the remodeling response in greater detail and crucially assess the 
relationship with myocardial fibrosis, thereby providing additional 
mechanistic data.  We therefore believe that the plasma cTnI concentration 
measured by a high-sensitivity assay has considerable potential as an early 
biomarker of left ventricular decompensation and as a powerful prognostic 
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tool in patients with aortic stenosis.  Moreover, this test is inexpensive and 
easy to perform making any future transition into routine clinical practice 
readily achievable. However, considerable overlap was observed between 
patients with aortic stenosis and our control cohort. This is perhaps 
unsurprising given cTnI is released as a consequence of a wide range of 
myocardial insults. A future strategy where asymptomatic aortic stenosis 
patients with elevated or increasing plasma troponin concentrations 
subsequently proceed to cardiovascular magnetic resonance for confirmation 
of myocardial fibrosis and left ventricular decompensation is therefore 
attractive.  Large-scale prospective studies are now required to investigate 
the use of these two biomarkers in the management and risk stratification of 
patients with aortic stenosis and whether the above approach might identify 
asymptomatic patients who would benefit from early surgery.  
 
In contrast to troponin, BNP did not have prognostic value in our study.  
BNP is an endogenous cardiac hormone released in response to increasing 
left ventricular wall stress and most commonly used in the assessment of 
patients with heart failure.  It is therefore only likely to be released late in the 
transition from hypertrophy to heart failure, making it of limited value in 
detecting signs of early decompensation in asymptomatic patients. Given 
that this is the group in whom novel biomarkers of left ventricular 
decompensation are most likely to be useful, we believe that troponin holds 
greater clinical promise than BNP. 
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5.5.1 Study Limitations 
Cardiovascular magnetic resonance was not available at the inception of the 
SALTIRE study.  Therefore, we needed to recruit another patient population 
to investigate the mechanism for troponin release in aortic stenosis.  
However, plasma cTnI concentrations in the Outcome Cohort also displayed 
a close association with left ventricular mass determined by 
echocardiography, and were unrelated to the burden of coronary 
atherosclerosis or the severity of valvular stenosis.  Similar mechanisms 
would therefore seem to govern cTnI release across both groups.  Another 
limitation is the lack of more sensitive markers of left ventricular systolic 
dysfunction in the Mechanism Cohort, for example cardiovascular magnetic 
resonance tagging techniques.  However, we elected not to perform these due 
to concerns about lengthening the scanning protocol in this elderly cohort of 
patients and compromising the detection of myocardial fibrosis. Finally, data 
on short-term biological variability (the change in concentration from one 
occasion to another) is very limited in disease states.  However, we do not 
anticipate significant short-term variability in chronic conditions such as 
aortic stenosis, although this will require further validation. 
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5.6 CONCLUSIONS 
In patients with aortic stenosis, plasma cTnI concentrations are a marker of 
left ventricular decompensation and myocardial fibrosis that are associated 
with cardiovascular deaths and aortic valve replacement.  High-sensitivity 
troponin assays hold major promise as a future clinical tool for patients with 
this condition.   
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6.1 SUMMARY 
AIMS: Electrocardiographic (ECG) left ventricular hypertrophy (LVH) with 
strain is associated with an adverse prognosis in aortic stenosis.  We 
investigated the mechanisms and outcomes associated with ECG-strain. 
  
METHODS: One hundred and two patients (70 [63,75] years, 66% males, 
aortic valve area 0.9 [0.7,1.2] cm2) underwent ECG, echocardiography and 
cardiovascular magnetic resonance: the Mechanism Cohort.  Myocardial 
fibrosis was determined using late gadolinium enhancement (LGE, 
replacement fibrosis) and T1 mapping (diffuse fibrosis). The relationship 
between ECG-strain and CMR was then assessed in an external Validation 
Cohort (n=64). The Outcome Cohort comprised of 140 patients from the 
Scottish Aortic Stenosis and Lipid Lowering Trial Impact on REgression 
(SALTIRE) study and followed up for 10.6 years (1,254 patient-years).  
 
RESULTS:  Compared to those without LVH (n=51) and LVH without ECG-
strain (n=30), patients with ECG-strain (n=21) had more severe aortic 
stenosis, increased left ventricular mass index, more myocardial injury (high-
sensitivity plasma cardiac troponin I concentration 4.3 [2.5,7.3] versus 7.3 
[3.2,20.8] versus 18.6 [9.0,45.2] ng/L respectively, P<0.001) and increased 
diffuse fibrosis (extracellular volume fraction 27.4±2.2 versus 27.2±2.9 versus 
30.9±1.9% respectively, P<0.001).  All patients with ECG-strain had mid-wall 
LGE (positive and negative predictive values of 100% and 86%, respectively).  
Indeed, LGE was independently associated with ECG-strain (OR 1.73, 95%CI 
1.08-2.77, P=0.02): a finding confirmed in the Validation Cohort.  In the 
Outcome Cohort, ECG-strain was an independent predictor of aortic valve 
replacement or cardiovascular death (HR 2.67, 95%CI 1.35-5.27, P<0.01). 
 
CONCLUSIONS: ECG-strain is a specific marker of mid-wall myocardial 
fibrosis and predicts adverse clinical outcomes in aortic stenosis.  
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6.2 INTRODUCTION 
Aortic stenosis is characterized by progressive valve narrowing and 
secondary changes in the myocardium (3). In response to increased afterload, 
left ventricular hypertrophy can develop in order to maintain wall stress and 
cardiac function.  Although this process appears to be compensatory in the 
early stages, pre-clinical studies have suggested cardiac performance can be 
preserved in the absence of hypertrophy (172,173). Moreover, the left 
ventricular hypertrophic response ultimately decompensates with 
progressive cell death and fibrosis driving the transition to symptoms, heart 
failure and adverse cardiovascular events (3,36,95).  There is therefore 
considerable interest in identifying early, objective markers of this 
decompensation that might identify asymptomatic patients who would 
benefit from early valve replacement.  
 
Electrocardiographic (ECG) strain is a well-recognized marker of left 
ventricular hypertrophy.  However, the exact mechanism underlying the 
characteristic ST and T wave abnormalities associated with this pattern is 
uncertain.  In this study, we hypothesized that ECG-strain is a marker of left 
ventricular decompensation, and investigated this association using 
cardiovascular magnetic resonance to assess the degree of left ventricular 
hypertrophy and myocardial fibrosis, and high-sensitivity plasma cardiac 
troponin I (cTnI) as a marker of myocardial injury. Moreover, we aimed to 
reassess the adverse prognosis previously associated with the ECG-strain 
pattern in patients with aortic stenosis (8).  
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6.3 METHODS 
Three cohorts were used for the study.  In the Mechanism Cohort, we 
determined the pathophysiology underlying the ECG-strain pattern using 
cardiovascular magnetic resonance and plasma cTnI concentration in 
patients recruited from the Edinburgh Heart Centre. This was then 
independently validated in an external Validation Cohort from the Royal 
Brompton Hospital, London.  Subsequently in the Outcome Cohort, we 
examined the prognostic role of ECG-strain in patients with aortic stenosis.  
The study was conducted in accordance with the Declaration of Helsinki, 
and approved by the local research ethics committee.  Written informed 
consent was obtained from all participants. 
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6.3.1 Patient Populations 
Mechanism Cohort: Patients with aortic stenosis (mild to severe) were 
recruited prospectively from the Edinburgh Heart Centre.  In addition to the 
exclusion criteria stated in Chapter 2, we also excluded patients with left or 
right bundle branch block, concurrent digoxin use, and impaired systolic 
function on cardiovascular magnetic resonance (ejection fraction <95th centile 
for age and sex) (129).  
 
Validation Cohort: Between 2011 and 2013, patients with moderate to severe 
aortic stenosis undergoing CMR were prospectively recruited from the Royal 
Brompton Hospital, London, using similar exclusion criteria. 
 
Outcome Cohort: Patients were initially recruited into the Scottish Aortic 
Stenosis and Lipid Lowering Trial, Impact on REgression (SALTIRE) study 
between March 2001 and April 2002, which comprised 155 patients with 
asymptomatic aortic stenosis who had been randomly assigned to either 
atorvastatin 80 mg or placebo once daily.  Patients were excluded if already 
on a statin, or if aortic valve replacement was planned (due to either 
symptoms or impaired systolic function) (127).  For the purposes of this 
analysis, patients on digoxin or with uninterpretable ECGs, or bundle branch 
block patterns were excluded. 
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6.3.2 Electrocardiography 
A standard 12-lead ECG was obtained in all participants and interpretation 
of the ECG was performed independently by two observers who were 
blinded to the clinical data and imaging findings.  Left ventricular 
hypertrophy on ECG was diagnosed based on the Romhilt-Estes point 
system (≥5 points) (125) and ECG-strain was defined as ≥1 mm concave 
downsloping ST depression with asymmetrical T wave inversion in the 
lateral leads (Figure 6.1A) (124). 
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FIGURE 6.1. ELECTROCARDIOGRAMS AND MYOCARDIAL BIOPSIES IN 
TWO PATIENTS WITH SEVERE AORTIC STENOSIS 
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6.3.3 Imaging Protocols 
Transthoracic echocardiography was performed in all participants in the 
Mechanism and Outcome Cohorts according to the protocol described in 
Chapter 2.  Cardiovascular magnetic resonance in the Mechanism Cohort 
was performed at 3T and the methodology has been described in detail in 
Chapter 2.  In addition, we also assessed left ventricular longitudinal 
shortening on cardiovascular magnetic resonance by measuring the 
difference in mitral annular displacement between end-systole and end-
diastole.  The mean value of the lateral and septal insertion sites (4-chamber 
view) and the anterior and inferior sites (2-chamber view) was used.  In the 
Validation Cohort, cardiovascular magnetic resonance was performed at 
1.5T, as previously described (58). 
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6.3.4 High-Sensitivity Plasma Cardiac Troponin I Assay  
Plasma cTnI concentrations were determined in patients in the Mechanism 
Cohort as a marker of myocyte injury using the ARCHITECT STAT high-
sensitive troponin I assay (Abbott Laboratories, Abbott Park, Illinois).  The 
method of detection and sensitivity of the assay have been described in 
Chapter 2.  Concentrations lower than the detection limit were assigned a 
value of 1.2 ng/L. 
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6.3.5 Calcium Scoring in the Outcome Cohort 
ECG-gated non-contrast computed tomography scans of the coronary 
arteries and aortic valve were performed in all patients in the Outcome 
Cohort using a double helix scanner (Twin II Flash, Philips Medical 
Systems).  Coronary artery and aortic valve calcium scores were determined 
by a single operator using the Picker Cardiac Scoring software (127). 
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6.3.6 Long-term Follow-up in the Outcome Cohort 
Clinical outcomes were obtained in the Outcome Cohort and adjudicated by 
two independent investigators blinded to the clinical and 
electrocardiographic data.  In-hospital and community deaths were captured 
from the General Register of Scotland.  Cardiovascular death was defined as 
death due to myocardial infarction, sudden cardiac death, heart failure, 
stroke, death related to cardiovascular procedures, and death due to other 
cardiovascular causes.  Each death was classified by the two independent 
investigators and any discrepancy was resolved by consensus.  Furthermore, 
all events, including surgical aortic valve replacements (no patients had 
transcatheter aortic valve implantation during follow-up), were confirmed 
by independent review of each patient’s healthcare record.  All patients in 
the Outcome Cohort were managed in our tertiary cardiac centre, and 
reviewed at a multi-disciplinary meeting prior to undergoing aortic valve 
replacement.  Only patients with established indications as per 
contemporary guidelines were referred for aortic valve replacement (5,169). 
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6.3.7 Statistical Analysis 
In the Mechanism Cohort, the association between ECG-strain and left 
ventricular mass and aortic stenosis severity was assessed using 
multivariable linear regression analysis to adjust for potential confounders.  
Furthermore, we assessed determinants associated with ECG-strain using 
univariate and multivariable logistic regression.  
 
In the Outcome Cohort, time-to-event curves in patients with and without 
ECG-strain were estimated using the Kaplan-Meier method and compared 
using the log-rank test.  To accommodate for competing risks, the association 
between time to aortic valve replacement or cardiovascular death and ECG-
strain was modeled as a composite outcome in Cox proportional hazards 
models.  The assumption for proportional hazards was assessed using the 
log (-log [survival]) versus log (survival time) plots and by examining the 
Schoenfeld residuals using R version 2.15.2 (Vienna, Austria).  Survival 
analyses and other standard statistical analyses were performed using 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA) and SPSS 
Version 19 (SPSS, Inc., Chicago, IL., USA), respectively. 
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6.4 RESULTS 
One hundred and two patients with aortic stenosis (70 [63, 75] years, 66% 
males, aortic valve area 0.9 [0.7, 1.2] cm2) were recruited into the Mechanism 
Cohort with a further 64 patients recruited into the Validation Cohort (79 [69, 
84] years, 69% males, aortic valve area 0.9 [0.7, 1.0] cm2) (Tables 6.1 and 6.2). 
After excluding patients with uninterpretable ECGs, bundle branch block or 
receiving digoxin therapy (n=15), 140 patients from the SALTIRE study were 
analyzed as part of the Outcome Cohort (69 [62, 75] years, 70% males, aortic 
valve area 1.0 [0.7, 1.3] cm2) (Table 6.3).  All patients in the Mechanism and 
Outcome Cohorts were Caucasians.  In the Validation Cohort, 92% were 
Caucasians and the remainder South Asians.  There were no observed racial 
differences with respect to the presence of left ventricular hypertrophy or 
strain on the ECG (P=0.95; Table 6.2).  
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TABLE 6.1. BASELINE CHARACTERISTICS OF PATIENTS IN THE 
MECHANISM COHORT 















 (n=102) (n=51) (n=30) (n=21)  
CLINICAL CHARACTERISTICS      
Age, years 
Sex, males, n (%) 
Diabetes mellitus, n (%) 
Hypertension, n % 
Coronary artery disease, n (%) 
Systolic blood pressure, mmHg 
Bicuspid aortic valve, n (%) 
NYHA Class, n (%)  















































ECHOCARDIOGRAPHY      
Aortic valve area, cm2  
Aortic jet velocity, m/s 






















Mid-wall fractional shortening, mm 
Mitral E/A ratio 
Deceleration time, ms 































CARDIOVASCULAR MAGNETIC RESONANCE   	  
Indexed left ventricular mass, g/m2 
Indexed end-diastolic volume (EDVi), ml/m2 
Indexed end-systolic volume, ml/m2 
Indexed stroke volume, ml 
LVMi/EDVi, g/mL 
Ejection fraction, % 
Longitudinal shortening, mm 
Patients with mid-wall late gadolinium 
enhancement, n (%)  
Amount of late gadolinium enhancement, % 



















































PLASMA CARDIAC TROPONIN I CONCENTRATION    









ANOVA post-hoc Bonferroni adjustment: aP<0.05 between no LVH and LVH without 
strain; bP<0.05 between LVH without strain and LVH with strain; cP<0.05 between no LVH 
and LVH with strain. 
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TABLE 6.2. BASELINE CHARACTERISTICS OF PATIENTS IN THE 
EXTERNAL VALIDATION COHORT 
 
‡The remaining patient had a large infarct 














 (n=64) (n=48) (n=5) (n=11)  
CLINICAL CHARACTERISTICS      
Age, years 
Sex, males, n (%) 
Diabetes mellitus, n (%) 
Hypertension, n % 
Coronary artery disease, n (%) 
Systolic blood pressure, mmHg 
 
Bicuspid aortic valve, n (%) 
NYHA Class, n (%)  
     III and IV 
Race 
     Caucasians 

































































CARDIOVASCULAR MAGNETIC RESONANCE    
Planimetered aortic valve area, cm2 
Indexed left ventricular mass (LVMi), g/m2 
Indexed end-diastolic volume (EDVi), mL/m2 
Indexed end-diastolic volume, mL/m2 
Indexed stroke volume, mL 
LVMi/EDVi, g/mL 
 
Ejection fraction, % 
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TABLE 6.3. CHARACTERISTICS OF PATIENTS IN THE OUTCOME 
COHORT 













 (n=140) (n=120) (n=20)  
CLINICAL CHARACTERISTICS     
Age, years 
Sex, males, n (%) 
Diabetes mellitus, n (%) 
Hypertension, n (%) 
Coronary artery disease, n (%) 
Systolic blood pressure, mmHg 
























ECHOCARDIOGRAPHY     
Aortic valve area, cm2  
Peak aortic jet velocity, m/s 
Mean pressure gradient, mmHg 
Ejection Fraction, % 





















COMPUTED TOMOGRAPHY     
Coronary calcium score, log AU 









PLASMA CARDIAC TROPONIN I CONCENTRATION   
Cardiac troponin I concentrations, ng/L 7.5 [5.7,13.4] 6.9 [5.3,11.4] 17.3 [10.5,29.6] <0.001 
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6.4.1 Mechanisms Underlying ECG-strain 
Fifty-one patients in the Mechanism Cohort fulfilled ECG criteria for left 
ventricular hypertrophy, demonstrating high predictive values for the 
presence of left ventricular hypertrophy on cardiovascular magnetic 
resonance (positive predictive value 96%, negative predictive value 89%).  Of 
these, 21 patients had the strain pattern on their ECGs. These patients with 
ECG-strain had the highest left ventricular mass index and most severe aortic 
stenosis compared to other patient groups (those without left ventricular 
hypertrophy on their ECG and those with left ventricular hypertrophy but 
no ECG-strain) (Table 6.1), even after the adjustment for age, sex and systolic 
blood pressure (P<0.001 for both).  Moreover, compared to other groups, 
these patients had increased end-diastolic volumes (P<0.01), worse diastolic 
function (P<0.001) and more severe symptoms (P<0.001; Table 6.1).  Despite 
similar left ventricular ejection fraction, patients with left ventricular 
hypertrophy and ECG-strain also had the worst longitudinal function, 
diastolic function (Figure 6.2) and mid-wall fractional shortening (Table 6.1). 
 
Interestingly, all patients with left ventricular hypertrophy and ECG-strain 
had focal mid-wall fibrosis (positive and negative predictive value of 100% 
and 86%, respectively; Figure 6.3B), strongly supporting ECG-strain as a 
specific marker of replacement myocardial fibrosis. Moreover these patients 
had more extensive diffuse myocardial fibrosis (Extracellular volume 
fraction: 30.9±1.9 versus 27.2±2.9 in patients with left ventricular hypertrophy 
and no ECG strain versus 27.4±2.2% in patients without left ventricular 
hypertrophy, P<0.001; Figure 6.3A) and myocardial injury as assessed by 
high-sensitivity plasma cTnI. Indeed, plasma cTnI concentrations were more 
than 4-fold higher in patients with strain than in the other patient groups 
(18.6 [9.0, 45.2] versus 7.3 [3.2, 20.8] ng/L in patients with left ventricular 
hypertrophy and no ECG-strain versus 4.3 [2.5, 7.3] ng/L in patients without 
left ventricular hypertrophy, P<0.001; Figure 6.2D). Three patients with 
ECG-strain had both an infarct and mid-wall pattern of fibrosis on late 
gadolinium enhancement, and our findings remained unchanged even after 
their exclusion.   
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On univariate analysis, ECG-strain was associated with an increased left 
ventricular mass index, more severe aortic stenosis, increased replacement 
and diffuse myocardial fibrosis, and diastolic dysfunction (all P<0.01; Table 
6.4) but was not associated with the presence of coronary artery disease (OR 
1.88; 95% confidence interval 0.68 to 5.18; P=0.22).  However, only increased 
myocardial fibrosis (either amount of late gadolinium enhancement or 
extracellular volume fraction) and the severity of aortic stenosis maintained 
an independent association on multivariate analysis with increased left 
ventricular mass index, increased myocardial injury and diastolic 
dysfunction all dropping out of the model (Models 3 and 4 in Table 6.4).  
 
Myocardial histology was available in two patients who underwent aortic 
valve replacement and biopsy, supporting increased myocardial fibrosis in 
patients with left ventricular hypertrophy and ECG-strain (Figure 6.1). 
However, not all patients with myocardial late gadolinium enhancement had 
a strain pattern on the ECG.  Indeed, of the 32 patients with myocardial late 
gadolinium enhancement, 11 patients (34%) did not have any evidence of 
ECG repolarization abnormalities.  Interestingly, these patients had ~40% 
less replacement fibrosis on late gadolinium enhancement compared to 
patients who had ECG-strain (5.6 [4.3, 7.5] versus 9.5 [7.5, 14.2] %, P=0.002) 
with no differences in the distribution of mid-wall late gadolinium 
enhancement between these groups (P=0.78).  
 
In the external Validation Cohort, similar findings were demonstrated (Table 
6.2; Figure 6.4).  There were 11 patients with ECG-strain, of whom 10 had 
isolated mid-wall fibrosis and one had extensive fibrosis from a large 
myocardial infarct to explain the ECG changes.  Conversely, 15 patients had 
mid-wall fibrosis but no ECG-strain.  In this cohort of patients with moderate 
to severe aortic stenosis, the positive and negative predictive values of left 
ventricular hypertrophy with ECG-strain for mid-wall fibrosis were 91% and 
72%, respectively. Patients with ECG-strain were again observed to have an 
advanced hypertrophic response associated with increased left ventricular 
mass index and reduced myocardial performance (Table 6.2).  
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FIGURE 6.2. MYOCARDIAL PERFORMANCE AND CARDIAC TROPONIN 
I CONCENTRATIONS IN PATIENTS WITH ELECTROCARDIOGRAPHIC 
STRAIN PATTERN 
  
Results were presented in box-and-whiskers plots (Tukey): the central box 
represents the interquartile range, with the median indicated by the line 
within the box.  The whiskers extend to the most extreme values within the 
1.5 interquartile ranges. 
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FIGURE 6.3. ASSOCIATION BETWEEN MYOCARDIAL FIBROSIS AND 
PATIENTS WITH ELECTROCARDIOGRAPHIC STRAIN PATTERN 
 
Patients with strain pattern on the electrocardiogram had increased 
extracellular volume fractions, suggestive of increased diffuse myocardial 
fibrosis (A).  Furthermore, all patients with electrocardiographic strain had a 
mid-wall pattern of late gadolinium enhancement (B).  Of note, about a third 
of patients with mid-wall late gadolinium enhancement did not have 
electrocardiographic strain.  The corresponding myocardial T1 map (A) and 
late gadolinium enhancement (B) of a patient with electrocardiographic strain 
demonstrated evidence of focal myocardial fibrosis in the mid-cavity lateral 
wall.  The extracellular volume fraction of the mid-cavity slice in this patient 
was 30.2%. 
Results in (A) presented in box-and-whiskers plots (Tukey): the central box 
represents the interquartile range, with the median indicated by the line 
within the box.  The whiskers extend to the most extreme values within the 
1.5 interquartile ranges. 
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Mid-wall fibrosis was predominantly found in the basal and mid-cavity (92% 
and 100% of all segments with late gadolinium enhancement in patients with 
and without ECG strain, respectively).  Whilst late gadolinium enhancement 
was observed more commonly in the septum, inferior and inferolateral than 
anterior segments, the distribution was not different between those with and 
without ECG strain (P=0.78). 
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6.4.2 Prognostic Value of ECG Strain  
In the Outcome Cohort, 20 patients (14%) had left ventricular with strain on 
ECG.  Consistent with the Mechanism Cohort, patients with ECG-strain had 
more severe aortic stenosis, increased left ventricular mass index and 
elevated plasma cTnI concentrations compared to those without strain 
(Table 6.3).  Of note, these elevated cTnI concentrations in patients with 
ECG-strain were similar to those observed in the Mechanism Cohort 
(P=0.85).   
 
Over 10.6 years of follow-up (1,254 patient-years), 63 patients had an aortic 
valve replacement and 22 patients died from a cardiovascular cause out of a 
total of 36 deaths.  ECG-strain was associated with a lower 10-year event-free 
survival rate for aortic valve replacement or cardiovascular death (log rank 
test <0.0001; Figure 6.5).  Indeed, this association persisted even after 
adjustment for traditional markers of an adverse outcome including the 
systolic ejection fraction, severity of aortic stenosis, left ventricular mass 
index and aortic valve calcium score (HR 2.67, 95% confidence interval 1.35 
to 5.27; P<0.01; Figure 6.6).   
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FIGURE 6.5. KAPLAN-MEIER ESTIMATE OF TIME TO EVENT BY 
STATUS OF ELECTROCARDIOGRAPHIC STRAIN PATTERN IN THE 
OUTCOME COHORT 
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FIGURE 6.6. COX MODELS IN PREDICTING TIME TO ADVERSE EVENTS 
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6.5 DISCUSSION 
This is the first cardiovascular magnetic resonance study to investigate the 
mechanisms underlying the ECG-strain pattern in patients with aortic 
stenosis, demonstrating that it is a highly specific marker of mid-wall 
myocardial fibrosis. Moreover ECG-strain was associated with increased 
myocardial injury, impaired left ventricular performance and was an 
independent predictor of cardiovascular death or aortic valve replacement.  
Our data therefore indicate that ECG-strain is a powerful biomarker of left 
ventricular decompensation in aortic stenosis with the ability to identify an 
at-risk population who may benefit from earlier valve replacement. 
 
Currently, aortic valve replacement is recommended in patients with severe 
aortic stenosis who have symptoms or evidence of left ventricular 
decompensation with an ejection fraction <50% (5).  However, symptoms are 
often subjective, particularly in the elderly, whilst a reduced ejection fraction 
is frequently a late manifestation and not necessarily reversible. There is 
therefore interest in exploring alternative, earlier and more objective markers 
of ventricular decompensation in aortic stenosis (95).      
 
Previous echocardiographic studies have demonstrated that ECG-strain is 
associated with an advanced hypertrophic response (174) and it has been 
hypothesized that the characteristic repolarization abnormalities relate to 
coronary perfusion abnormalities, even in the absence of coronary artery 
disease (75,175-177).  Our study adds to these data, demonstrating a close 
association between ECG-strain and myocardial injury and fibrosis. Indeed, 
across two independent cohorts, mid-wall myocardial fibrosis was present in 
31 of the 32 patients with strain on their ECGs, while the remaining subject 
had an extensive infarct to explain the ECG changes.  Moreover, patients 
with strain had evidence of higher plasma cTnI concentrations and worse 
myocardial function.  It has been established that myocardial ischemia, cell 
death and fibrosis are all key features that characterize the transition from 
hypertrophy to heart failure in aortic stenosis.  Our study would therefore 
support ECG-strain as a useful marker of left ventricular decompensation in 
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patients with this condition.  
 
In our Outcome Cohort, we have demonstrated that ECG-strain acts as a 
strong independent predictor of aortic valve replacement or cardiovascular 
death, over and above established prognostic markers such as systolic 
ejection fraction, severity of aortic stenosis, left ventricular mass index and 
aortic valve calcium score.  Indeed, patients with ECG-strain had more than a 
two-fold increase risk in adverse events compared to patients without. This 
concurs with previous studies that have demonstrated an adverse prognosis 
associated with ECG-strain (8,178,179).  However, our study provides much 
longer periods of follow up than have been described previously.  
 
There are clear potential advantages of using ECG-strain as a marker of left 
ventricular decompensation in aortic stenosis.  A 12-lead ECG is readily 
available, cheap and rapidly interpretable. However, whilst ECG-strain is an 
extremely specific marker for myocardial fibrosis, it is less sensitive.  Indeed, 
in our Mechanism Cohort, more than 30% of patients with replacement 
myocardial fibrosis did not have strain on the ECG. Importantly these 
patients had 40% less replacement fibrosis compared to those with strain, 
suggesting that strain is a relatively late manifestation and that 
cardiovascular magnetic resonance offers even more sensitive detection of 
myocardial fibrosis and left ventricular decompensation.  
 
Our data suggest that patients with ECG-strain who are asymptomatic 
would derive long-term benefit from early aortic valve replacement, due to 
the prevention of   progressive myocardial fibrosis and injury that would 
otherwise develop whilst waiting for the onset of symptoms.  The stage is 
now set for randomized controlled studies to investigate this strategy, 
examining the clinical utility of the ECG-strain pattern in guiding early aortic 
valve replacement alongside other novel and more sensitive markers of left 
ventricular decompensation including high-sensitivity cTnI concentrations 
and mid-wall late gadolinium enhancement (58,180).  
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6.5.1 Study Limitations 
In this study, separate cohorts were used to investigate the mechanism and 
prognosis of patients with ECG-strain because cardiovascular magnetic 
resonance was not available in the original SALTIRE study. We therefore 
cannot directly confirm that ECG-strain was similarly related to myocardial 
fibrosis in the Outcome study. However, ECG-strain in this population did 
demonstrate the same associations with increased left ventricular mass 
index, aortic stenosis severity and plasma cTnI concentrations, as observed in 
the Mechanism Cohort.  Moreover in our Validation Cohort, the same clear 
association between ECG-strain and mid-wall late gadolinium enhancement 
was also observed. We are therefore confident that ECG-strain acts as a 
specific marker of mid-wall myocardial fibrosis and left ventricular 
decompensation in the predominantly Caucasian patients investigated in this 
study, although further studies will be required for confirmation in different 
ethnic groups.   
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6.6 CONCLUSIONS 
In patients with aortic stenosis, ECG-strain is a specific marker of mid-wall 
myocardial fibrosis and an independent predictor of cardiovascular death or 
aortic valve replacement.  Future research should now examine whether the 
ECG-strain should be used as a marker of left ventricular decompensation to 
guide early aortic valve replacement in asymptomatic patients. 
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7.1 SUMMARY OF FINDINGS 
Aortic stenosis is a condition that affects both the aortic valve and the 
myocardium.  Advanced multi-parametric cardiovascular magnetic 
resonance has significantly increased the accuracy and precision of 
ventricular volumes and mass measurements, and has crucially improved 
tissue characterization of the myocardium.  In this thesis, I have highlighted 
the importance of looking beyond the valve, demonstrating the effects of 
stroke volume estimation on the classification of aortic stenosis severity  
(particularly those with discordant small aortic valve area and low mean 
pressure gradient aortic stenosis), and the adverse prognosis associated with 
markers of myocardial fibrosis.  Furthermore, I have optimized the novel 
application of myocardial T1 mapping in aortic stenosis. 
 
	   187	  
7.1.1 Stroke Volume Assessment and Discordant Small-area Low-
gradient Aortic Stenosis 
Discordant small aortic valve area low mean pressure gradient (small-area 
low-gradient) aortic stenosis is well described in patients with impaired 
systolic ejection fraction (7).  As a result of reduced cardiac output from the 
failing heart, the opening of the aortic valve is incomplete.  Therefore, the 
aortic valve area calculated from the continuity equation is smaller than 
expected and transvalvular gradient measured is low.  In recent years, 
discordant small-area low-gradient aortic stenosis is also increasingly 
recognized in patients with preserved systolic ejection fraction (paradoxical 
low-flow low-gradient aortic stenosis with preserved left ventricular 
ejection fraction) and this entity may have important prognostic significance 
(132-135).  Despite normal ejection fractions, stroke volumes are 
paradoxically reduced in these patients, thought to be the result of 
pronounced concentric remodeling and small cavity sizes (64,181).  Although 
the inherent limitations of echocardiography and inconsistent thresholds in 
current guidelines are recognised causes of discordant small-area low-
gradient, the significance of these effects on aortic stenosis classification has 
not been well demonstrated.  In my study consisting of 166 patients with 
aortic stenosis and healthy individuals, I have systematically demonstrated 
that the magnitude of stroke volume underestimation (and therefore, aortic 
valve area underestimation) by echocardiography is not trivial.  Indeed, the 
combination of this underestimation and inconsistent thresholds accounted 
for close to 50% of patients with discordant small-area low-gradient aortic 
stenosis.  After reclassification using stroke volume estimated from 
cardiovascular magnetic resonance and consistent thresholds, only 5 out of 
29 patients with discordant small-area low-gradient aortic stenosis had 
reduced stroke volumes due to either impaired systolic function or small left 
ventricles.  The remainder consisted of patients with moderate to severe 
disease, suggesting this represents an entity in transition from moderate to 
severe disease.  The findings also provide a possible explanation for the 
variable outcomes in different studies of such patients (132-135).  Further 
studies are now needed to investigate the long-term outcomes of patients 
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reclassified using this approach.  Interestingly, other echocardiographic 
approaches, such as indexed aortic valve area, dimensionless index or stroke 
volume estimation using the Teichholz formula, did not improve aortic 
stenosis classification. 
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7.1.2 Optimization of Myocardial T1 Mapping in Aortic Stenosis 
The limitations related to aortic stenosis classification highlighted earlier, 
alongside significant heterogeneity in the magnitude of hypertrophy in 
response to similar degrees of aortic valve narrowing, underscore the 
importance of assessing the myocardium in addition to the aortic valve.  
Myocyte death and myocardial fibrosis are key processes mediating the 
transition from compensatory left ventricular hypertrophy to 
decompensation (36).  Therefore, there is considerable interest in markers 
associated with this transition so as to identify high-risk individuals before 
heart failure ensues.   Indeed, emerging data have demonstrated the adverse 
prognosis associated with myocardial fibrosis (103-106,182,183).  Late 
gadolinium enhancement is a well-established cardiovascular magnetic 
resonance technique of assessing focal replacement fibrosis, but it is not well 
suited for assessing interstitial myocardial fibrosis, which has a more 
uniform pattern of distribution and predominates in conditions such as 
aortic stenosis (44).  Instead, novel myocardial T1 mapping techniques have 
been developed to overcome these inherent limitations in late gadolinium 
enhancement (107).  However, the optimal approach has not been established 
in aortic stenosis, particularly at 3T.   
 
In 40 patients with aortic stenosis and healthy volunteers, I have carefully 
characterized the temporal and regional profiles of four commonly used T1 
measures: pre-contrast T1, post-contrast T1, partition coefficient and 
extracellular volume fraction.  There was no variation in any of the T1 
measures across the 16 segments of the left ventricle in both healthy 
volunteers and patients with aortic stenosis.  Both partition coefficient and 
extracellular volume fraction did not vary with time, while post-contrast T1 
was relatively constant only after 15 min.  However, only partition coefficient 
and extracellular volume fraction demonstrated excellent reproducibility 
(including scan-rescan repeatability) and both measures were significantly 
higher in asymptomatic patients with aortic stenosis compared with control 
individuals.  This is particularly important because myocardial fibrosis is a 
slow and progressive process; therefore, a sensitive measure will be critical 
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to detect any small changes over time.  Extracellular volume fraction 
translates partition coefficient into a percentage of the myocardium affected 
by diffuse fibrosis and it has a theoretical advantage over partition coefficient 
because it also corrects for the effects of plasma volume, which can vary from 
day to day. 
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7.1.3 High-sensitivity Cardiac Troponin I as a Sensitive Marker of 
Myocardial Fibrosis 
Although cardiovascular magnetic resonance has great potential in risk 
stratifying patients, the clinical utility can be limited by cost, availability and 
patient suitability.  Therefore, my research has also explored suitable 
biomarkers for clinical use.   
 
Cardiac troponin is a structural protein present in the cardiac myocytes.  
Increased cardiac troponin concentrations have traditionally been considered 
to be a specific marker of myocardial necrosis in patients with acute coronary 
syndromes (115) and recent advances in assay technology have substantially 
improved sensitivity, allowing quantification of troponin concentrations at 
very low levels and with a high degree of precision.  This has allowed the 
detection of myocardial injury in a wide range of cardiac conditions, 
including aortic stenosis.  In more than 250 patients with aortic stenosis, I 
have demonstrated that high-sensitivity cardiac troponin I concentrations 
were independently associated with measures of left ventricular hypertrophy 
and myocardial fibrosis on cardiovascular magnetic resonance.  Importantly, 
increased cardiac troponin I concentrations were independently associated 
with adverse cardiovascular events over more than 10 years of follow-up.  
Because of the increased assay sensitivity, it was not surprising to find 
considerable overlap in cardiac troponin I concentrations between patients 
with aortic stenosis and control cohort.  A future strategy would therefore 
use high-sensitivity cardiac troponin I as a “gate keeper” for cardiovascular 
magnetic resonance to confirm myocardial fibrosis and ventricular 
decompensation in patients with aortic stenosis and elevated or increasing 
troponin I concentrations. 
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7.1.4 Electrocardiographic Left Ventricular Hypertrophy with Strain as 
a Specific Marker of Myocardial Fibrosis 
There are clear advantages of using electrocardiograms in clinical medicine.  
They are cheap and easily available.  Moreover, in a recent study, a particular 
electrocardiographic pattern of left ventricular hypertrophy with strain was 
shown to predict worse outcomes in patients with aortic stenosis (8).  In a 
study of more than 300 patients with aortic stenosis, I have confirmed left 
ventricular hypertrophy with strain pattern on the electrocardiogram is an 
independent predictor of aortic valve replacement or cardiovascular 
mortality over 10 years of follow-up; and across 2 cohorts of patients with 
aortic stenosis, I have demonstrated these characteristic repolarization 
abnormalities were highly specific for replacement myocardial fibrosis 
(specificity of 99% and sensitivity of 54%).  Furthermore, these patients had 
more extensive fibrosis, increased myocardial injury and worse cardiac 
function, suggesting this electrocardiographic pattern is a marker of 
advanced ventricular decompensation and that cardiovascular magnetic 
resonance may offer more sensitive detection of myocardial fibrosis and 
decompensation. 
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7.2 FUTURE DIRECTIONS 
Myocardial fibrosis is associated with adverse prognosis and this risk 
persists even after aortic valve replacement (51,58,103-106,184).  However, 
most of these studies were small and observational.  Furthermore, the 
association between aortic valve replacement and regression of myocardial 
fibrosis is conflicting (51,104) and more crucially, the benefits of early aortic 
valve replacement in asymptomatic high-risk patients with aortic stenosis 
remain untested.   
 
To date, we have one of the largest prospective cohorts of patients with aortic 
stenosis and cardiovascular magnetic resonance, designed to specifically 
address these critical gaps in knowledge.  In addition to comprehensive 
cardiovascular magnetic resonance at baseline, serial imaging will also be 
performed at 1- and 2-year follow-up regardless of aortic valve replacement.  
Using both conventional late gadolinium enhancement and novel myocardial 
T1 mapping techniques, the study will confirm the prognostic significance of 
myocardial fibrosis in aortic stenosis and whether this risk can be modified 
by aortic valve replacement.  Prospective follow-up and serial imaging will 
further our understanding in the natural history of the hypertrophic 
response in patients with and without aortic valve replacement.  This 
knowledge will be essential to set the stage for a randomised controlled trial 
to test the benefits of early intervention in asymptomatic patients with aortic 
stenosis and myocardial fibrosis.   
 
The relatively low prevalence of myocardial fibrosis in patients with aortic 
stenosis (approximately 30% and predominantly in patients with at least 
moderate severity), coupled with the limitations of cardiovascular magnetic 
resonance for wide spread clinical use, emphasizes the need for more cost 
effective markers to identify patients who may benefit from early valve 
replacement.  My future work will develop a clinical risk model based on 
markers of myocardial fibrosis (such as high-sensitivity cardiac troponin I 
and electrocardiographic strain pattern), clinical and echocardiographic 
parameters of aortic stenosis severity.  One potential approach could be that 
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low-risk patients are followed up conservatively with reassessment of risk in 
subsequent years, and early valve replacement be recommended for high-
risk patients.  Patients at intermediate risk could be further stratified with 
cardiovascular magnetic resonance. 
 
The assessment of disease severity and management of patients with aortic 
stenosis and impaired ejection fraction is extremely challenging and 
complex.  As highlighted earlier, recovery of myocardial function in patients 
with severe aortic stenosis and impaired systolic ejection fraction may be 
limited after aortic valve replacement because of irreversible myocardial 
damage.  Whilst evidence of contractile reserve with dobutamine stress 
echocardiography can predict myocardial function recovery and better 
outcome after aortic valve replacement, the converse is not always true 
(64,185).  In patients without contractile reserve, myocardial function 
recovery and prognosis were as good as those with contractile reserve if they 
survive replacement surgery (186,187).  These findings underscore the 
urgency of more accurate predictors of myocardial function recovery, 
particularly relevant in the recent years where transcatheter aortic valve 
implantation has emerged as an alternative to surgical valve replacement in 
patients deemed at high or prohibitive surgical risk (188,189).  In my future 
research, I will explore the role of cardiovascular magnetic resonance 
(particularly the presence and extent of myocardial fibrosis) and high-
sensitivity cardiac troponin I in predicting myocardial functional recovery 
after valve replacement in patients with aortic stenosis and impaired systolic 
ejection fraction.   
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7.3 CLINICAL PERSPECTIVES 
The indications for aortic valve replacement are clear in patients with severe 
aortic stenosis and symptoms (angina, syncope or dyspnoea) or impaired 
systolic function.  Without timely aortic valve replacement, the risk of death 
in these patients is about 2% per month (4,190).  Conversely, the 
management of asymptomatic patients is more controversial.  Many 
advocate conservative management because aortic valve replacement will 
not improve the overall quality of life since patients are asymptomatic.  
However, some recent evidence suggest improved outcomes with earlier 
surgery (10,11).  Therefore, the crucial question remains: who will benefit 
from early valve replacement?  
 
In recent years, there has been a greater appreciation that aortic stenosis is a 
condition that affects not only the valve but also the myocardium. Indeed the 
transition from left ventricular hypertrophy to heart failure appears to be a 
key factor in determining the development of symptoms and adverse events.  
Current assessments of this transition are limited and interest has 
surrounded the development of novel biomarkers of left ventricular 
decompensation.  
 
We have learnt that asymptomatic patients with aortic stenosis are a 
heterogeneous group, with some at higher risk of adverse cardiovascular 
events than others.  Indeed, the duration of the asymptomatic phase varies 
widely between individuals and despite the absence of symptoms, there is 
now substantial evidence to suggest ongoing myocardial damage during this 
subclinical phase.  Although the mechanism of sudden cardiac death in 
asymptomatic patients with aortic stenosis is not well understood, 
myocardial fibrosis and increased myocardial injury may be the substrates of 
lethal arrhythmias, above and beyond the severity of valvular obstruction.  
We now have in our armamentarium more sensitive measures of systolic 
dysfunction than the conventional ejection fraction. These include state-of-
the art imaging techniques to detect early myocardial fibrosis and high-
sensitivity assays to measure myocardial injury related to the increased 
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afterload and ventricular mass.  As the operative risks of aortic valve 
replacement improve and transcatheter aortic valve implantation techniques 
advance, there will be considerable interest in these novel markers to identify 
high-risk asymptomatic patients who may benefit from early aortic valvular 
replacement to prevent further myocardial damage and sudden cardiac 
death. 
 
Ultimately, randomized controlled trials will be required to evaluate fully 
these novel biomarkers of left ventricular decompensation, and whether this 
translates into improved outcomes in patients with aortic stenosis.  Instead of 
relying on a single marker, an integrative approach consisting of clinical 
characteristics, multi-modality imaging and blood biomarkers will best guide 
the need for aortic valve replacement. 
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Aortic	   stenosis	   is	   the	   most	   common	   adult	   heart	   valve	   condition	   seen	   in	   the	  
western	  world.	  It	  represents	  a	  significant	  health	  burden	  and	  is	  the	  most	  common	  
indication	   for	   aortic	   valve	   surgery.	   Yet	   the	  mechanisms	   causing	   this	   important	  
disease	   are	   poorly	   understood,	   and	   there	   are	   currently	   no	   effective	   medical	  
treatments	  capable	  of	  altering	   its	   course.	  The	  only	   treatment	  option	   is	   surgical	  
replacement	  of	  the	  valve	  when	  patients	  become	  symptomatic.	  However,	  patients	  
are	  usually	  elderly	  and	  not	  ideally	  suited	  to	  a	  major	  operation.	  Furthermore	  we	  
have	  very	   few	  markers	   that	  accurately	  predict	  prognosis	  or	  how	  quickly	  aortic	  
stenosis	  will	  progress	  and	  when	  surgery	  will	  be	  required.	  	  	  
	  
Given	   the	   lack	   of	   any	   form	   of	   effective	   medical	   therapy	   for	   aortic	   stenosis	  
combined	   with	   the	   absence	   of	   reliable	   markers	   of	   disease	   progression,	   we	  
believe	   that	   it	   is	   important	   to	  better	  understand	   the	  mechanisms	   that	  underlie	  
this	   condition	   in	   order	   to	   most	   effectively	   develop	   potential	   biomarkers	   and	  
therapy.	  	  
	  
Fibrosis	   plays	   an	   important	   role	   in	   the	   development	   of	   aortic	   stenosis	   and	   is	  
known	  to	  occur	  at	   two	  different	  sites:	   in	   the	  aortic	  valve	   itself	  and	   in	   the	  heart	  
muscle.	  Fibrosis	  causes	  the	  valve	  to	  become	  increasingly	  stiff	  which	  results	  in	  the	  
progressive	  narrowing	  of	  the	  valve	  orifice	  that	  is	  the	  hallmark	  of	  aortic	  stenosis.	  	  
	  
The	  muscle	  of	  the	  ventricle	  has	  to	  eject	  blood	  through	  this	  narrowed	  valve.	  This	  
puts	   an	   increased	   strain	   on	   the	   heart,	   which	   ultimately	   can	   also	   lead	   to	   the	  
development	  of	  fibrosis	  within	  the	  heart	  muscle.	  Fibrosis	  in	  the	  heart	  muscle	  is	  
associated	  with	  impaired	  performance	  and	  an	  adverse	  prognosis	  in	  other	  cardiac	  
conditions.	  	  	  
	  
	  
We	  propose	  to	  investigate	  the	  role	  of	  fibrosis	  both	  within	  the	  valve	  and	  the	  heart	  
muscle	   using	  magnetic	   resonance	   imaging	   (MRI).	   Fibrosis	   in	   the	   heart	   can	   be	  
examined	   by	   administration	   of	   a	   contrast	   agent	   called	   Gadolinium.	   Areas	   of	  
fibrosis	   can	   then	   be	   visualized	   by	   late	   gadolinium	   enhancement.	   In	   addition	  
physicists	  at	  the	  Royal	  Brompton	  Hopsital,	  London	  have	  developed	  a	  novel	  MRI	  
sequence,	  which	  should	  allow	  us	  to	  detect	  fibrosis	  with	  even	  greater	  sensitivity.	  	  	  
	  
AIM	  	  
To	  evaluate	  the	  role	  of	  myocardial	  and	  valvular	  fibrosis	  in	  Aortic	  stenosis	  using	  
cardiac	  MRI	  and	  both:	  
	  	  
A) Late	  gadolinium	  enhancement	  
B) A	  novel	  T1	  mapping	  sequence	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HYPOTHESES	  
We	  hypothesise	  that:	  
	  	  
1)	  The	  novel	  MRI	  sequence	  will	  be	  able	  to	  detect	  fibrosis	  of	  the	  valve	  and	  of	  the	  
heart	   muscle	   with	   equivalent	   or	   greater	   sensitivity	   than	   late	   gadolinium	  
enhancement.	  	  
	  
2)	  That	   increased	   fibrosis	  of	   the	  aortic	  valve	  will	   correlate	  with	   the	  severity	  of	  
aortic	  stenosis	  and	  predicts	  its	  rate	  of	  progression.	  	  
	  
3)	  That	  fibrosis	  in	  the	  heart	  muscle	  will	  predict	  prognosis	  and	  clinical	  outcome	  of	  
patients	  with	  Aortic	  stenosis	  
	  
	  
PATIENT	  POPULATION	  (total	  240)	  
We	  will	  recruit	  a	  total	  of	  240	  adults	  (192	  with	  aortic	  stenosis)	  who	  will	  be	  asked	  
to	   provide	   formal	   written	   consent	   after	   being	   provided	   with	   the	   information	  
sheets	  enclosed.	  	  	  
	  
This	  will	  comprise	  of:	  	  
1) 38	  age	  and	  sex	  matched	  control	  subjects	  
2) 10	  young	  healthy	  controls	  (35	  years	  and	  younger)	  
3) 48	  with	  mild	  aortic	  stenosis	  (peak	  velocity	  <3m/s)	  
4) 48	  with	  moderate	  aortic	  stenosis	  (Peak	  velocity	  3-­‐4m/s)	  
5) 48	  severe	  asymptomatic	  aortic	  stenosis	  
6) 48	   patients	   with	   severe	   symptomatic	   aortic	   stenosis	   due	   to	   undergo	  
aortic	  valve	  replacement	  (AVR)	  within	  1	  year.	  
	  
Patients	  in	  the	  control	  group	  will	  just	  have	  a	  baseline	  assessment	  to	  assess	  valve	  
and	  myocardial	   fibrosis	  and	  will	  not	  be	   followed	  up.	  Patients	   in	   the	  AVR	  group	  
will	  undergo	  a	  different	  protocol	  to	  the	  rest	  of	  the	  aortic	  stenosis	  patients.	  	  	  
	  
PATIENTS	  NOT	  UNDERGOING	  AVR	  WITHIN	  THE	  FIRST	  YEAR	  (n-­‐144)	  
As	  described	  below	  participants	  will	  be	  followed	  up	  for	  5	  years.	  This	  will	  include	  
3	  clinical	  assessments:	  as	  baseline,	  after	  1	  year	  and	  after	  2	  years.	  After	  	  3,	  4	  and	  5	  
years	  patients	  will	  be	  contacted	  by	  mail	  or	  phone	  to	  assess	  their	  progress.	  They	  
will	  not	  need	  to	  attend	  the	  hospital	  on	  those	  occasions.	  	  An	  optional	  repeat	  MRI	  
scan	  will	  be	  offered	  during	  1st	  and	  2nd	  year	  follow	  up.	  
	  
PATIENTS UNDERGOING AVR WITHIN THE FIRST YEAR (n=48) 
The protocol will differ for these 48 participants in terms of follow up as described 
below. Briefly they will have an additional CMR scan after 1 year to assess the role of 
surgery on the ventricle. In addition at the time of surgery we will retain their aortic 
valve, which is usually removed and discarded. We will also take small biopsy 
samples from the heart muscle using a small (3 mm diameter) needle called a tru-cut 
needle. Two or three passes of the needle will be required to acquire tiny 8 to 15 mg 
samples from the left ventricular wall. This simple technique safely acquires 
myocardial tissue as described in highly regarded, peer-reviewed literature (Heymans, 
Circulation 2005 and Elsasser JACC 2002). The sampling of this tiny amount of 
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tissue will not affect the function of the heart. Tissue from these biopsies will be 
analysed under a microscope to measure how much scar tissue (fibrosis) they contain. 
We can then compare these results to the results from late gadolinium enhancement 
and the novel MRI sequence. This will allow us to validate the new MRI sequence. 




1. Patients with coexistent moderate aortic regurgitation or mitral stenosis. 
2. Patients with acute valvular heart disease e.g. acute mitral regurgitation, active 
endocarditis. 
3. Patients with significant co-morbidities:  
a. severe renal impairment (GFR <30) 
b. liver impairment (INR > 2.0) 
4. Patients in acute pulmonary oedema or cardiogenic shock.  
5. Patients unsuitable for surgery for non-cardiac reasons e.g. patients with 
advanced malignancy 
6. Patients unable to give informed consent. 
7. Patients with significant vasculitis or hypertrophic obstructive 
cardiomyopathy. 
8. Pregnant patients or patients wishing to become pregnant during the 
timeframe of serial scanning. 
9. Patients with a contraindication to undergoing CMR. 




BASELINE	  ASSESSMENT	  (All	  patients	  including	  controls)	  
Patients	  will	  have	  a	  baseline	  clinical	  assessment.	  This	  will	  be	  conducted	  over	  the	  
period	   of	   a	   morning	   or	   an	   afternoon	   and	   will	   involve	   the	   following	   aspects.	  
Patients	   will	   be	   given	   a	   quality	   of	   life	   questionnaire	   (Kansas	   City	  
Cardiomyopathy	   Questionnaire:	   see	   attached)	   to	   assess	   their	   symptoms	   and	  
general	  well	   being.	   They	  will	   then	   be	   asked	   to	   perform	   a	   six	  minute	  walk	   test	  
where	   they	  are	  asked	   to	  walk	  as	   far	  as	  possible,	   in	  six	  minutes,	  back	  and	   forth	  
between	  two	  points	  30metres	  apart.	  Cardiac	  MRI	  will	  then	  be	  performed	  (using	  
the	   protocol	   outlined	   in	   detail	   below)	   followed	   by	   an	   echocardiogram	   during	  
which	   severity	   of	   aortic	   stenosis	   will	   be	   assessed	   (peak	   velocity	   through	   the	  
valve,	  peak	  gradient,	  aortic	  valve	  area).	  A	  plastic	  tube	  will	  need	  to	  be	  inserted	  in	  
to	  the	  subject’s	  vein	  in	  order	  to	  allow	  administration	  of	  the	  contrast	  agent	  during	  
the	  MRI	  scan.	  At	  this	  time	  30mls	  of	  blood	  will	  be	  taken	  (FBC,	  U+E,	  LFT,	  CRP,	  BNP,	  
Galectin	  3	   and	  other	  markers	   of	   fibrosis:	   including	  PIIINP,	  TIMP-­‐1,	  TGF-­‐β,	   PIP,	  
Angiotensin	   2,	   Hyaluronic	   acid).	   	   Finally	   subjects	   will	   be	   fitted	   with	   a	   Holter	  
monitor,	  which	  will	  monitor	  their	  cardiac	  rhythm	  for	  the	  next	  72	  hours.	  	  
	  
12	  MONTH	  FOLLOW	  UP	  (All	  patients	  excluding	  controls)	  
All	  patients	  included	  in	  the	  study	  will	  be	  followed	  up	  at	  one	  year.	  It	  will	  comprise	  
the	   same	   format	   as	   the	   baseline	   assessment.	   	   An	   MRI	   will	   be	   performed	   in	  
patients	  in	  the	  AVR	  group.	  	  	  In	  all	  other	  patients	  (excluding	  controls),	  an	  optional	  
MRI	  scan	  will	  be	  offered	  to	  patients	  if	  they	  are	  keen.	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2	  year	  follow	  up	  (All	  patients	  excluding	  controls)	  
All	   patients	   included	   in	   the	   study	   will	   be	   followed	   up	   at	   two	   years.	   It	   will	  
comprise	   the	   same	   format	   as	   the	   baseline	   assessment.	   Cardiac	   MRI	   will	   be	  
offered	  to	  all	  patients	  during	  2nd	  year	  of	  follow-­‐up.	  
	  
ANNUAL	  FOLLOW	  UP	  FOR	  5	  YEARS	  
At	  3,	  4	  and	  5	  years	  following	  the	  baseline	  scans	  participants	  will	  be	  contacted	  by	  
phone	   and	   mail	   to	   assess	   progress	   (hospital	   admission,	   major	   cardiovascular	  
events).	  Mortality	  data	  will	   be	  updated	   from	   the	  office	   of	   national	   statistics,	   in	  
addition	  we	  will	  check	  the	  hospital	  computer	  patient	  records	  system	  “TRAK”	  to	  
ensure	   that	   the	   relatives	   of	   patients	   who	   have	   dies	   are	   not	   contacted	  
unnecessarily.	  	  
	  
CARDIAC	  MRI	  PROTOCOL	  
Patients	   will	   be	   asked	   to	   fill	   in	   a	   safety	   questionnaire	   to	   assess	   for	   any	  
contraindication	   to	   cardiac	   MRI	   scanning.	   An	   iv	   cannula	   will	   be	   inserted	   and	  
blood	   samples	   taken.	   Patients	   will	   be	   changed	   in	   to	   a	   gown	   and	   ECG	   stickers	  
placed	  on	  their	  chest.	  They	  will	  then	  be	  taken	  in	  to	  the	  MRI	  scanner.	  Patients	  will	  
be	  attached	  to	  an	   infusion	  pump	  to	  allow	  for	   the	   injection	  of	  contrast	  and	  then	  
put	  inside	  the	  scanner.	  	  
	  
Basic	   cardiac	   MR	   protocols	   (axial	   view	   –	   2	   chamber	   view	   –	   4	   chamber	   view)	  
using	  black	  blood	  imaging	  will	  be	  performed	  to	   localize	  the	   long	  and	  short	  axis	  
views	  of	   the	   left	  ventricle	  (LV).	   	  A	   long	  axis	  cine	  view	  of	  LV	  and	  short	  axis	  cine	  
stack	  of	  multiple	  slices	  (LV	  base	  to	  apex)	  will	  be	  acquired	  to	  allow	  calculation	  of	  
ventricular	   volumes	   and	   mass	   and	   ejection	   fractions.	   Cine	   views	   of	   the	   aortic	  
valve	   (2	   long	   axis	   views	   and	   then	   short	   axis	   stack	   through	   the	   valve	   with	   no	  
gaps)	  will	   also	   be	   taken	   to	   allow	   for	   planimetry	   of	   aortic	   valve	   area,	   and	   flow	  
velocity	  images	  will	  be	  taken	  to	  allow	  for	  measurement	  of	  peak	  velocity	  through	  
the	  valve.	  	  
	  
The	  patient	  will	   then	   receive	   contrast.	   0.1mmol/kg	  Gadolinium	   (Gadovist)	  will	  
be	   injected	   using	   a	   Medrad	   Spectris	   MR–compatible	   pump	   injector	   at	  
3mls/second,	   followed	  by	  a	  20ml	   flush	  of	   saline	  at	   the	  same	   injection	  rate.	  We	  
will	   then	   perform	   T1	   mapping	   of	   the	   left	   ventricle	   using	   the	   novel	   sequence	  
developed	  by	   our	   collaborators	   at	   the	  Brompton,	   10	  minutes	   after	  Gadolinium	  
injection	   we	   will	   acquire	   inversion	   recovery	   prepared	   spoiled	   gradient	   echo	  
images	  in	  standard	  long	  and	  short	  axis	  views	  to	  detect	  areas	  of	  late	  gadolinium	  
enhancement.	  
	  
Subjects	   will	   be	   in	   the	   scanner	   for	   approximately	   45	   minutes.	   Patients	   who	  
tolerate	  the	  scan	  well	  will	  be	  asked	  if	  they	  mind	  returning	  48	  hours	  later	  after	  for	  
a	  further	  Cardiac	  MRI	  scan	  after	  administration	  of	  another	  contrast	  agent	  called	  
Feraheme.	  Feraheme	  is	  well	  tolerated	  and	  licensed	  for	  clinical	  human	  use	  in	  the	  
treatment	  of	  iron	  deficiency	  in	  chronic	  kidney	  disease.	  However	  it	  also	  allows	  for	  
the	  detection	  of	  inflammation	  on	  MRI	  scanning.	  It	  is	  given	  as	  an	  infusion,	  which	  
will	  be	  medically	  supervised.	  We	  hope	  to	  use	  it	  to	  detect	  areas	  of	   inflammation	  
within	  the	  valve	  alongside	  the	  fibrosis.	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INCIDENTAL	  FINDINGS	  
All	   CMR	   scans	   will	   be	   reviewed	   by	   a	   consultant	   radiologist.	   Any	   indicental	  
findings	  made	  during	   these	  scans	  will	  be	   reported	   to	   the	  patient’s	  GP	  and	  /	  or	  
consultant	  cardiologist	  as	  appropriate.	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Volunteer	  Information	  Sheet	  
(Aortic	  stenosis:	  not	  undergoing	  surgery)	  
	  
	  
ROLE	  OF	  FIBROSIS	  IN	  THE	  PROGRESSION	  OF	  AORTIC	  STENOSIS	  
	   	   	  
	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  to	  
participate,	  it	  is	  important	  that	  you	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  
will	   involve.	  Please	  read	  the	  following	   information	  and	  discuss	   it	  with	  others	   if	  you	  wish.	   If	  
there	  is	  anything	  that	  you	  are	  still	  unclear	  about	  or	  any	  questions	  that	  you	  would	  like	  to	  ask	  
you	  can	  contact	  us	   for	   further	   information.	  You	  can	  also	  contact	  Dr	  Bloomfield	  who	   is	  not	  
directly	  involved	  with	  this	  study	  but	  can	  give	  you	  independent	  advice.	  He	  can	  be	  contacted	  
through	  the	  Royal	  Infirmary	  switchboard	  	  (0131	  242	  1000)	  by	  asking	  for	  his	  secretary.	  
	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  information	  sheet.	  
	  
Why	  are	  we	  doing	  this	  study?	  	  
	  
Aortic	  stenosis	  is	  a	  condition	  caused	  by	  narrowing	  of	  one	  the	  major	  valves	  within	  the	  heart.	  
The	  reasons	  why	  this	  narrowing	  develops	  are	  poorly	  understood.	  Using	  magnetic	  resonance	  
imaging	   (MRI)	  we	  want	   to	   study	   the	   role	  of	   scarring	  or	   “fibrosis”	   in	   aortic	   stenosis,	  which	  
occurs	  both	   in	   the	   valve	   and	   in	   the	  heart	  muscle.	   Scarring	  of	   the	   valve	   contributes	   to	   the	  
valve	  narrowing.	  	  
	  
If	  we	   understand	   how	   the	   scarring	   occurs	  we	  may	   be	   able	   to	   develop	   new	   treatments	   to	  
slow	  or	  prevent	  this	  disease.	  	  
	  
Why	  have	  I	  been	  chosen	  to	  take	  part?	  
We	  are	  looking	  for	  patients	  with	  aortic	  stenosis	  to	  study	  using	  these	  scans.	  Using	  MRI	  we	  will	  
assess	  how	  much	  scarring	   is	  occurring	   in	  your	  valve	  and	  heart	  muscle.	  After	  one	  year	  and	  
two	  years	  we	  will	  ask	  you	  to	  come	  back	  for	  a	  clinical	  assessment,	  after	  that	  we	  will	  keep	  in	  
contact	  yearly	  by	  post	  and	  phone	  for	  3	  years	  to	  keep	  an	  eye	  on	  how	  you	  are	  getting	  on.	  By	  
doing	   the	   same	   thing	   in	   many	   patients	   we	   will	   develop	   a	   good	   understanding	   of	   how	  
important	  scarring	  is	  in	  the	  progression	  of	  your	  disease.	  	  
	  
It	   is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  decide	  to	  take	  part	  you	  will	  be	  
given	  this	  information	  sheet	  to	  keep	  and	  you	  will	  be	  asked	  to	  sign	  a	  consent	  form.	  Even	  once	  
you	  have	  signed	  the	  form	  you	  can	  still	  withdraw	  at	  any	  time	  and	  you	  do	  not	  have	  to	  give	  a	  
reason.	  	  
	  
You	  will	  not	  benefit	  directly	  from	  this	  study.	  However,	  the	  information	  we	  get	  could	  help	  us	  
to	  improve	  the	  way	  we	  treat	  patients	  with	  aortic	  stenosis	  in	  the	  future.	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What	  will	  happen	  to	  me	  if	  I	  decide	  to	  take	  part?	  
	  
We	   will	   need	   to	   perform	   two	   different	   assessments	   of	   you	   and	   your	   valve.	   The	   first	   will	  
happen	  when	  you	  first	  agree	  to	  participate,	  the	  second	  a	  year	  later.	  	  
	  
Assessment	  when	  you	  register	  in	  the	  trial	  
You	  will	  be	   invited	  to	   the	  clinic	  and	  the	   following	  will	  happen.	  We	  will	   talk	  about	  whether	  
you	   have	   any	   symptoms;	   ask	   you	   to	   fill	   in	   a	   quality	   of	   life	   questionnaire;	   perform	   a	   full	  
examination	  of	  your	  heart;	  and	  organise	  an	  echo	  (ultrasound)	  scan	  of	  your	  heart.	  The	  echo	  
test	  is	  not	  painful	  and	  involves	  no	  harmful	  affects	  to	  you.	  You	  will	  already	  have	  had	  one	  of	  
these	  scans	  in	  the	  clinic.	  We	  will	  then	  ask	  you	  to	  walk	  between	  two	  points	  30	  metres	  apart.	  
The	  idea	  is	  that	  you	  walk	  as	  far	  as	  possible	  back	  and	  forth	  for	  6	  minutes.	  	  
	  
You	  will	  then	  have	  an	  MRI	  scan	  of	  your	  heart.	  We	  will	  put	  a	  plastic	  tube	  (cannula)	  in	  to	  your	  
arm	  so	  that	  we	  can	  give	  you	  the	  contrast	  agent,	  Gadolinium.	  At	  the	  same	  time	  we	  will	  take	  
some	  blood	   from	  the	  cannula.	   If	  you	   like	  you	  can	  go	   in	   to	  a	  model	  of	   the	  MRI	  machine	  to	  
check	  you	  will	  be	  happy	  lying	  in	  it:	  occasionally	  people	  can	  feel	  a	  bit	  claustrophobic.	  We	  will	  
then	  perform	  the	  MRI	  scan:	  you	  will	  lie	  on	  a	  bed	  that	  moves	  into	  the	  scanner.	  You	  will	  lie	  in	  
the	   scanner	   for	   about	   45minutes.	   You	   will	   need	   to	   follow	   some	   very	   simple	   breathing	  
instructions	  from	  time	  to	  time.	  It	  is	  not	  painful.	  
	  
Finally	  when	  the	  MRI	  scan	  is	  finished	  we	  will	  ask	  you	  to	  wear	  an	  ECG	  recorder	  for	  72	  hours	  to	  
check	  for	  any	  underlying	  problems	  with	  the	  rhythm	  of	  the	  heart.	  If	  you	  tolerate	  the	  MRI	  scan	  
well	  then	  we	  may	  ask	  you	  to	  come	  back	  after	  2	  days	  for	  another	  MRI	  scan.	  This	  time	  we	  will	  
give	   you	   another	   contrast	   agent	   via	   a	   cannula,	   which	   looks	   at	   inflammation	   rather	   than	  
fibrosis.	  This	  contrast	  agent	  is	  safe	  and	  used	  in	  everyday	  clinical	  practice	  as	  a	  treatment	  for	  
iron	  deficiency.	  If	  you	  would	  rather	  have	  just	  the	  one	  MRI	  scan	  then	  that	  is	  fine.	  
	  
Assessment	  after	  1	  year	  
This	  will	  involve	  exactly	  the	  same	  assessment	  as	  during	  your	  first	  visit.	  	  You	  may	  be	  asked	  to	  
undergo	  a	  repeat	  cardiac	  MRI.	  	  However,	  this	  is	  an	  optional	  investigation.	  
	  
Assessment	  after	  2	  yeara	  
This	  will	  involve	  exactly	  the	  same	  assessment	  as	  during	  your	  first	  visit.	  You	  may	  be	  asked	  to	  
undergo	  a	  repeat	  cardiac	  MRI.	  	  However,	  this	  is	  an	  optional	  investigation.	  
	  
Yearly	  assessment	  at	  3,	  4	  and	  5	  years	  
We	  will	   contact	  you	  by	  post	  or	  mail	  each	  year	   to	   see	  how	  you	  are	  getting	  on.	  You	  will	  no	  
need	  to	  come	  back	  up	  to	  the	  hospital	  other	  than	  for	  your	  routine	  clinical	  appointments.	  
	  
Heart	  Failure	  Questionnaire	  
We	  will	  ask	  you	  to	  complete	  a	  simple	  questionnaire	  that	  usually	  applies	  to	  patients	  who	  have	  
heart	  failure.	  Some	  patients	  with	  aortic	  stenosis	  may	  develop	  symptoms	  of	  heart	  failure	   in	  
the	  end	  stages.	  We	  understand	  that	  you	  may	  not	  have	  any	  of	  these	  symptoms	  but	  would	  be	  
grateful	  if	  you	  could	  complete	  the	  questionnaire	  so	  that	  we	  can	  compare	  the	  answers	  to	  the	  
other	  patients	  in	  the	  study.	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What	  happens	  to	  the	  blood	  samples	  that	  are	  taken?	  
A	  proportion	  will	  be	  tested	  right	  away	  for	  various	  tests.	  A	  portion	  of	  the	  blood	  samples	  taken	  
will	  be	  frozen,	  and	  stored	  in	  an	  anonymised	  manner	  so	  that	  further	  tests	  may	  be	  performed	  
on	  it	  in	  the	  future.	  Any	  further	  tests	  would	  require	  future	  ethical	  approval.	  	  
	  
Is	  there	  anything	  else	  that	  I	  have	  to	  do?	  
There	  are	  no	  restrictions	  on	  your	  lifestyle	  through	  participating	  in	  this	  study.	  
	  
Will	  taking	  part	  in	  this	  study	  affect	  my	  treatment?	  
No	  –	  you	  will	  still	  be	  followed	  up	  by	  your	  cardiologist	  as	  if	  you	  were	  not	  participating	  in	  the	  
trial.	  	  
	  
What	  are	  the	  side	  effects	  of	  taking	  part?	  
The	  MRI	  and	  echo	  scans	  are	  very	  safe.	  All	  contrast	  agents	  are	  safe.	  You	  cannot	  have	  them	  if	  
you	  have	   kidney	  problems	  or	   any	  metal	   in	   your	  body	  but	  we	  will	   check	   that	   you	  have	  no	  
contraindications	  very	  carefully	  before	  allowing	  you	  to	  take	  part	  in	  the	  study.	  	  
	  	  
What	  are	  the	  possible	  disadvantages	  of	  taking	  part?	  
Involvement	   in	   the	   trial	   will	   mean	   you	   attending	   for	   various	   appointments	   and	   scans.	  
Whenever	  possible	  we	  will	  ensure	  that	  these	  occur	  during	  the	  same	  visit.	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  will	  not	  be	  any	  direct	  benefit	  to	  you	  of	  taking	  part	   in	  the	  study,	  however	   it	   is	  hoped	  
that	  the	  findings	  of	  this	  study	  will	  benefit	  other	  patients	  with	  aortic	  stenosis	   in	  the	  future.	  
The	  information	  from	  the	  MRI	  scans	  can	  occasionally	  provide	  extra	  information	  that	  may	  be	  
useful	  to	  your	  cardiologist	  or	  your	  general	  practitioner.	  We	  will	  make	  certain	  that	  if	  any	  such	  
information	  arises	  that	  your	  cardiologist/	  general	  practitioner	  will	  be	  informed.	  
	  
Will	  my	  GP	  be	  informed?	  
As	  long	  as	  you	  agree	  we	  would	  like	  to	  inform	  your	  General	  Practitioner	  of	  your	  participation	  
in	  this	  study.	  
	  
What	  if	  something	  goes	  wrong?	  
If	  you	  are	  harmed	  by	  taking	  part	  in	  this	  research	  project,	  there	  are	  no	  special	  compensation	  
arrangements,	   although	   in	   the	   case	   of	   negligent	   harm,	   subjects	   will	   be	   covered	   by	   the	  
University	  of	  Edinburgh	  insurance	  policy.	  If	  you	  are	  harmed	  as	  a	  result	  of	  the	  study	  you	  may	  
have	  grounds	  for	  legal	  action	  but	  you	  may	  have	  to	  pay	  for	  this.	  If	  you	  are	  not	  satisfied	  with	  
any	   aspect	   of	   the	  way	   you	  were	   approached	   or	   your	   treatment	   during	   this	   study,	   please	  
contact	  the	  Faculty	  of	  Medicine	  at	  the	  University	  of	  Edinburgh.	  	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
All	  the	  information	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  
confidential.	  Any	  information	  about	  you	  which	  leaves	  the	  hospital	  will	  have	  your	  name	  and	  
address	  removed	  so	  that	  you	  cannot	  be	  recognised	  from	  it.	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
Once	  we	  have	  completed	  the	  study	  and	  analysed	  the	  results,	  we	  will	  write	  a	  paper	  which	  will	  
be	   submitted	   for	   publication	   in	   one	   of	   the	  medical	   journals.	  We	   do	   not	   routinely	   contact	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participants	  to	  inform	  them	  of	  the	  outcome	  of	  the	  research	  but	  would	  be	  happy	  to	  do	  so	  if	  
requested.	   If	   you	  would	   like	   a	   copy	  of	   the	   results	   please	   contact	  Dr	   Calvin	   Chin	   using	   the	  
contact	  details	  listed	  below.	  You	  will	  not	  be	  personally	  identified	  in	  any	  report/publication.	  
	  
Who	  is	  organising	  the	  research?	  
The	  study	   is	  being	  organised	  through	  the	  University	  of	  Edinburgh.	  Your	  doctors	  will	  not	  be	  
paid	  for	  including	  you	  in	  this	  study.	  
	  
Who	  has	  reviewed	  the	  study?	  
The	  study	  has	  been	  reviewed	  by	  the	  South	  East	  Scotland	  Research	  Ethics	  Committee	  2.	  
	  
Where	  can	  I	  obtain	  further	  information	  about	  the	  study?	  
You	  can	  get	  further	  information	  from	  Dr	  Calvin	  Chin	  or	  Prof	  Newby	  who	  will	  arrange	  to	  meet	  
you.	  	  You	  could	  also	  discuss	  the	  study	  with	  Dr	  Bloomfield	  who	  is	  another	  doctor	  working	  in	  
this	   hospital	   who	   is	   not	   involved	   in	   the	   study	   and	   can	   therefore	   act	   as	   an	   independent	  
advisor.	  
	  
Dr	   Chin	   can	   be	   reached	   by	   contacting	   his	   mobile	   on	   07535001086;	   his	   email	  
cchin03m@gmail.com:	   or	   by	   letter	   addressed	   to	   the	   Cardiovascular	   Research	   Unit,	  
Chancellor’s	   Building,	   49	   Little	   France	   Crescent,	   Edinburgh	   EH16	   SU4.	   Prof	   Newby	   can	   be	  
contacted	  via	  the	  hospital	  switchboard	  (0131	  536	  1000).	  
	  




Thank	  you	  once	  again	  for	  reading	  this	  information	  sheet.	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Volunteer	  Information	  Sheet	  
(Aortic	  stenosis:	  undergoing	  AVR)	  
	  
	  
ROLE	  OF	  FIBROSIS	  IN	  THE	  PROGRESSION	  OF	  AORTIC	  STENOSIS	  
	   	   	  
	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  to	  
participate,	  it	  is	  important	  that	  you	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  
will	   involve.	  Please	  read	  the	  following	   information	  and	  discuss	   it	  with	  others	   if	  you	  wish.	   If	  
there	  is	  anything	  that	  you	  are	  still	  unclear	  about	  or	  any	  questions	  that	  you	  would	  like	  to	  ask	  
you	  can	  contact	  us	   for	   further	   information.	  You	  can	  also	  contact	  Dr	  Bloomfield	  who	   is	  not	  
directly	  involved	  with	  this	  study	  but	  can	  give	  you	  independent	  advice.	  He	  can	  be	  contacted	  
through	  the	  Royal	  Infirmary	  switchboard	  	  (0131	  242	  1000)	  by	  asking	  for	  his	  secretary.	  
	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  information	  sheet.	  
	  
Why	  are	  we	  doing	  this	  study?	  	  
	  
Aortic	  stenosis	  is	  a	  condition	  caused	  by	  narrowing	  of	  one	  the	  major	  valves	  within	  the	  heart.	  
The	  reasons	  why	  this	  narrowing	  develops	  are	  poorly	  understood.	  Using	  magnetic	  resonance	  
imaging	   (MRI)	  we	  want	   to	   study	   the	   role	  of	   scarring	  or	   “fibrosis”	   in	   aortic	   stenosis,	  which	  
occurs	  both	   in	   the	   valve	   and	   in	   the	  heart	  muscle.	   Scarring	  of	   the	   valve	   contributes	   to	   the	  
valve	  narrowing.	  	  
	  
If	  we	   understand	   how	   the	   scarring	   occurs	  we	  may	   be	   able	   to	   develop	   new	   treatments	   to	  
slow	  or	  prevent	  this	  disease.	  	  
	  
Why	  have	  I	  been	  chosen	  to	  take	  part?	  
We	   are	   looking	   for	   patients	   with	   aortic	   stenosis	   who	   are	   about	   to	   have	   an	   aortic	   valve	  
replacement.	  Using	  MRI	  we	  will	  assess	  how	  much	  scarring	  or	  “fibrosis”	   is	  occurring	   in	  your	  
valve	  and	  heart	  muscle.	  At	  the	  time	  of	  surgery	  we	  will	  then	  take	  your	  original	  valve	  (which	  is	  
usually	   just	   discarded)	   and	   a	   small	   bit	   of	   heart	  muscle,	   and	   see	   how	  much	   scarring	   there	  
really	  is	  in	  these	  bit	  of	  tissue.	  This	  will	  allow	  us	  to	  know	  how	  good	  our	  scans	  are	  at	  detecting	  
scarring.	  	  
	  
After	  1	  year	  we	  will	  perform	  a	  clinical	  assessment	  and	  further	  MRI	  scan	  to	  see	  if	  the	  amount	  
of	   scarring	  has	  changed.	  After	  2	  years	  we	  will	   repeat	   the	  clinical	  assessment	  only.	  We	  will	  
then	  keep	  in	  contact	  yearly	  by	  post	  and	  phone	  over	  the	  next	  3	  years	  to	  keep	  an	  eye	  on	  how	  
you	   are	   getting	   on.	   By	   doing	   the	   same	   thing	   in	   lots	   of	   patients	   we	   will	   develop	   a	   good	  
understanding	   of	   how	   good	   our	   scans	   are	   at	   detecting	   fibrosis.	   We	   will	   also	   know	   how	  
important	  scarring	   is	   in	  how	  well	  patients	  do	  after	  surgery	  and	  whether	   it	   is	  reversible.	   	   In	  
total	  the	  trial	  will	  run	  for	  five	  years.	  	  
	  
It	   is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  decide	  to	  take	  part	  you	  will	  be	  
given	  this	  information	  sheet	  to	  keep	  and	  you	  will	  be	  asked	  to	  sign	  a	  consent	  form.	  Even	  once	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you	  have	  signed	  the	  form	  you	  can	  still	  withdraw	  at	  any	  time	  and	  you	  do	  not	  have	  to	  give	  a	  
reason.	  	  
	  
You	  will	  not	  benefit	  directly	  from	  this	  study.	  However,	  the	  information	  we	  get	  could	  help	  us	  
to	  improve	  the	  way	  we	  treat	  patients	  with	  aortic	  stenosis	  in	  the	  future.	  
	  
	  
What	  will	  happen	  to	  me	  if	  I	  decide	  to	  take	  part?	  
	  
We	   will	   need	   to	   perform	   two	   different	   assessments	   of	   you	   and	   your	   valve.	   The	   first	   will	  
happen	  when	  you	  first	  agree	  to	  participate,	  the	  second	  a	  year	  later.	  	  
	  
Assessment	  when	  you	  register	  in	  the	  trial	  
You	  will	  be	  invited	  to	  the	  clinic	  for	  a	  clinical	  assessment.	  The	  following	  will	  happen.	  We	  will	  
talk	  about	  whether	  you	  have	  any	  symptoms;	  ask	  you	  to	  fill	  in	  a	  quality	  of	  life	  questionnaire;	  
perform	  a	   full	   examination	  of	   your	   heart;	   and	  organise	   an	   echo	   (ultrasound)	   scan	  of	   your	  
heart.	  The	  echo	  test	   is	  not	  painful	  and	   involves	  no	  harmful	  affects	  to	  you.	  You	  will	  already	  
have	  had	  one	  of	  these	  scans	  in	  the	  clinic.	  We	  will	  then	  ask	  you	  to	  walk	  between	  two	  points	  
30	  metres	  apart.	  The	  idea	  is	  that	  you	  walk	  as	  far	  as	  possible	  back	  and	  forth	  between	  these	  
two	  points	  for	  6	  minutes.	  	  
	  
You	  will	  then	  have	  an	  MRI	  scan	  of	  your	  heart.	  We	  will	  put	  a	  plastic	  tube	  (cannula)	  in	  to	  your	  
arm	  so	  that	  we	  can	  give	  you	  the	  contrast	  agent.	  At	  the	  same	  time	  we	  will	  take	  some	  blood	  
from	  the	  cannula.	  If	  you	  like	  you	  can	  go	  in	  to	  a	  model	  of	  the	  MRI	  machine	  to	  check	  you	  will	  
be	  happy	  lying	  in	  it.	  We	  will	  then	  perform	  the	  MRI	  scan:	  you	  will	  lie	  on	  a	  bed	  that	  moves	  into	  
the	  scanner.	  You	  will	   lie	   in	  the	  scanner	  for	  about	  45minutes.	  You	  will	  need	  to	  follow	  some	  
very	  simple	  breathing	  instructions	  from	  time	  to	  time.	  It	  is	  not	  painful.	  
	  
Finally	  when	  the	  MRI	  scan	  is	  finished	  we	  will	  ask	  you	  to	  wear	  an	  ECG	  recorder	  for	  72	  hours	  to	  
check	  for	  any	  underlying	  problems	  with	  the	  rhythm	  of	  the	  heart.	  If	  you	  tolerate	  the	  MRI	  scan	  
well	  then	  we	  may	  ask	  you	  to	  come	  back	  after	  2	  days	  for	  another	  MRI	  scan.	  This	  time	  we	  will	  
give	   you	   another	   contrast	   agent	   via	   a	   cannula,	   which	   looks	   at	   inflammation	   rather	   than	  
fibrosis.	  This	  contrast	  agent	  is	  safe	  and	  used	  in	  everyday	  clinical	  practice	  as	  a	  treatment	  for	  
iron	  deficiency.	  If	  you	  would	  rather	  have	  just	  the	  one	  MRI	  scan	  then	  that	  is	  fine.	  
	  
	  
Aortic	  valve	  replacement	  
You	  will	  have	  your	  aortic	  valve	  replacement	  as	  planned.	  Your	  original,	  narrowed	  aortic	  valve	  
will	  be	  removed.	  Usually	  it	  is	  discarded,	  however,	  we	  will	  collect	  it	  so	  that	  we	  can	  look	  at	  it	  
under	  the	  microscope	  and	  see	  how	  much	  scarring	   is	  there.	  Also	  during	  the	  surgery	  we	  will	  
take	  a	  tiny	  amount	  of	  your	  heart	  muscle.	  We	  will	  do	  this	  using	  a	  small	  biopsy	  needle	  (3mm	  in	  
diameter)	   called	   a	   tru-­‐cut	   needle.	   Two	   or	   three	   passes	   of	   the	   needle	   will	   be	   required	   to	  
acquire	  tiny	  8	  to	  15	  mg	  samples	  from	  the	  left	  ventricular	  wall.	  This	  simple	  technique	  safely	  
acquires	  myocardial	   tissue	  and	  has	  been	  used	  many	   times	  before	   in	  previous	   studies.	   The	  
sampling	  of	  this	  tiny	  amount	  of	  tissue	  will	  not	  affect	  the	  function	  of	  the	  heart.	  We	  can	  then	  
study	  this	  also	  under	  the	  microscope	  to	  see	  how	  much	  fibrosis	  is	  present.	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Assessment	  after	  1	  year	  
This	  will	  involve	  exactly	  the	  same	  assessment	  as	  during	  your	  first	  visit	  
	  
Assessment	  after	  2	  years	  
This	  will	  involve	  exactly	  the	  same	  assessment	  as	  during	  your	  first	  visit.	  You	  may	  be	  asked	  to	  
undergo	  a	  repeat	  cardiac	  MRI.	  	  However,	  this	  is	  an	  optional	  investigation.	  
	  
Yearly	  assessment	  at	  3,	  4	  and	  5	  years	  
We	  will	   contact	  you	  by	  post	  or	  mail	  each	  year	   to	   see	  how	  you	  are	  getting	  on.	  You	  will	  no	  
need	  to	  come	  back	  up	  to	  the	  hospital	  other	  than	  for	  your	  routine	  clinical	  appointments.	  
	  
Heart	  Failure	  Questionnaire	  
We	  will	  ask	  you	  to	  complete	  a	  simple	  questionnaire	  that	  usually	  applies	  to	  patients	  who	  have	  
heart	  failure.	  Some	  patients	  with	  aortic	  stenosis	  may	  also	  	  develop	  symptoms	  of	  heart	  failure	  
in	  the	  end	  stages.	  We	  understand	  that	  you	  may	  not	  suffer	  	  from	  any	  of	  these	  symptoms	  but	  
would	   be	   grateful	   if	   you	   could	   complete	   the	   questionnaire	   so	   that	   we	   can	   compare	   the	  
answers	  to	  the	  other	  patients	  in	  the	  study.	  	  
	  
What	  happens	  to	  the	  blood	  samples	  that	  are	  taken?	  
A	  proportion	  will	  be	  tested	  right	  away	  for	  various	  tests.	  A	  portion	  of	  the	  blood	  samples	  taken	  
will	  be	  frozen,	  and	  stored	  in	  an	  anonymised	  manner	  so	  that	  further	  tests	  may	  be	  performed	  
on	  them	  in	  the	  future.	  Any	  further	  tests	  would	  require	  future	  ethical	  approval.	  	  
	  
What	  will	  happen	  to	  my	  aortic	  valve?	  
We	  will	  take	  the	  valve	  to	  the	  laboratory	  and	  initially	  slice	  it	  in	  to	  segments.	  We	  will	  then	  look	  
at	   these	  segments	  under	   the	  microscopy	   to	  see	  how	  much	  scarring	   is	  present.	  The	   rest	  of	  
your	   valve	  will	   then	  by	   frozen,	   and	   stored	   in	   an	   anonymised	  manner	   so	   that	   further	   tests	  
may	  be	  performed	  in	  the	  future.	  Any	  further	  tests	  would	  require	  future	  ethical	  approval.	  	  
	  
What	  will	  happen	  to	  the	  biopsy	  of	  my	  heart	  tissue?	  
We	  will	  take	  the	  heart	  muscle	  to	  the	  laboratory	  and	  initially	  slice	  it	  in	  to	  segments.	  We	  will	  
then	  look	  at	  these	  slices	  under	  the	  microscopy	  to	  see	  how	  much	  scarring	  is	  present.	  The	  rest	  
of	  your	  valve	  will	  then	  by	  frozen,	  and	  stored	  in	  an	  anonymised	  manner	  so	  that	  further	  tests	  
may	  be	  performed	  in	  the	  future.	  Any	  further	  tests	  would	  require	  future	  ethical	  approval.	  	  
	  
Is	  there	  anything	  else	  that	  I	  have	  to	  do?	  
There	  are	  no	  restrictions	  on	  your	  lifestyle	  through	  participating	  in	  this	  study.	  
	  
Will	  taking	  part	  in	  this	  study	  affect	  my	  treatment?	  
No	  –	  you	  will	  still	  be	  followed	  up	  by	  your	  cardiologist	  as	  if	  you	  were	  not	  participating	  in	  the	  
trial.	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What	  are	  the	  side	  effects	  of	  taking	  part?	  
The	  MRI	  and	  echo	  scans	  are	  very	  safe.	  All	  contrast	  agents	  are	  safe.	  You	  cannot	  have	  them	  if	  
you	   have	   kidney	   failure	   or	   any	   metal	   in	   your	   body	   but	   we	   will	   check	   that	   you	   have	   no	  
contraindications	  very	  carefully	  before	  allowing	  you	  to	  take	  part	  in	  the	  study.	  	  
Your	  aortic	  valve	  is	  usually	  discarded	  at	  the	  time	  of	  surgery	  so	  us	  using	  it	  will	  in	  no	  way	  affect	  
your	  treatment.	  The	  biopsy	  of	  your	  heart	  muscle	  is	  only	  tiny	  and	  will	  not	  effect	  how	  your	  
heart	  pumps.	  	  
	  
What	  are	  the	  possible	  disadvantages	  of	  taking	  part?	  
Involvement	   in	   the	   trial	   will	   mean	   you	   attending	   for	   various	   appointments	   and	   scans.	  
Whenever	  possible	  we	  will	  ensure	  that	  these	  occur	  during	  the	  same	  visit.	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  will	  not	  be	  any	  direct	  benefit	  to	  you	  of	  taking	  part	   in	  the	  study,	  however	   it	   is	  hoped	  
that	  the	  findings	  of	  this	  study	  will	  benefit	  other	  patients	  with	  aortic	  stenosis	   in	  the	  future.	  
The	  information	  from	  the	  MRI	  scans	  can	  occasionally	  provide	  extra	  information	  that	  may	  be	  
useful	  to	  your	  cardiologist	  or	  your	  general	  practitioner.	  We	  will	  make	  certain	  that	  if	  any	  such	  
information	  arises	  that	  your	  cardiologist/	  general	  practitioner	  will	  be	  informed	  
	  
Will	  my	  GP	  be	  informed?	  
As	  long	  as	  you	  agree	  we	  would	  like	  to	  inform	  your	  General	  Practitioner	  of	  your	  participation	  
in	  this	  study.	  
	  
What	  if	  something	  goes	  wrong?	  
If	  you	  are	  harmed	  by	  taking	  part	  in	  this	  research	  project,	  there	  are	  no	  special	  compensation	  
arrangements,	   although	   in	   the	   case	   of	   negligent	   harm,	   subjects	   will	   be	   covered	   by	   the	  
University	  of	  Edinburgh	  insurance	  policy.	  If	  you	  are	  harmed	  as	  a	  result	  of	  the	  study	  you	  may	  
have	  grounds	  for	  legal	  action	  but	  you	  may	  have	  to	  pay	  for	  this.	  If	  you	  are	  not	  satisfied	  with	  
any	   aspect	   of	   the	  way	   you	  were	   approached	   or	   your	   treatment	   during	   this	   study,	   please	  
contact	  the	  Faculty	  of	  Medicine	  at	  the	  University	  of	  Edinburgh.	  	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
All	  the	  information	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  
confidential.	  Any	  information	  about	  you	  which	  leaves	  the	  hospital	  will	  have	  your	  name	  and	  
address	  removed	  so	  that	  you	  cannot	  be	  recognised	  from	  it.	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
Once	  we	  have	  completed	  the	  study	  and	  analysed	  the	  results,	  we	  will	  write	  a	  paper	  which	  will	  
be	   submitted	   for	   publication	   in	   one	   of	   the	  medical	   journals.	  We	   do	   not	   routinely	   contact	  
participants	  to	  inform	  them	  of	  the	  outcome	  of	  the	  research	  but	  would	  be	  happy	  to	  do	  so	  if	  
requested.	   If	   you	  would	   like	   a	   copy	  of	   the	   results	   please	   contact	  Dr	   Calvin	   Chin	   using	   the	  
contact	  details	  listed	  below.	  You	  will	  not	  be	  personally	  identified	  in	  any	  report/publication.	  
	  
Who	  is	  organising	  the	  research?	  
The	  study	   is	  being	  organised	  through	  the	  University	  of	  Edinburgh.	  Your	  doctors	  will	  not	  be	  
paid	  for	  including	  you	  in	  this	  study.	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Who	  has	  reviewed	  the	  study?	  
The	  study	  has	  been	  reviewed	  by	  the	  South	  East	  Scotland	  Research	  Ethics	  Committee	  2.	  
	  
Where	  can	  I	  obtain	  further	  information	  about	  the	  study?	  
You	  can	  get	  further	  information	  from	  Dr	  Calvin	  Chin	  or	  Prof	  Newby	  who	  will	  arrange	  to	  meet	  
you.	  	  You	  could	  also	  discuss	  the	  study	  with	  Dr	  Bloomfield	  who	  is	  another	  doctor	  working	  in	  
this	   hospital	   who	   is	   not	   involved	   in	   the	   study	   and	   can	   therefore	   act	   as	   an	   independent	  
advisor.	  
	  
Dr	   Chin	   can	   be	   reached	   by	   contacting	   his	   mobile	   on	   07535	   001	   086;	   his	   email	  
cchin03m@gmail.com	   or	   by	   letter	   addressed	   to	   the	   Cardiovascular	   Research	   Unit,	  
Chancellor’s	   Building,	   49	   Little	   France	   Crescent,	   Edinburgh	   EH16	   SU4.	   Prof	   Newby	   can	   be	  
contacted	  via	  the	  hospital	  switchboard	  (0131	  536	  1000).	  
	  




Thank	  you	  once	  again	  for	  reading	  this	  information	  sheet.	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ROLE	  OF	  FIBROSIS	  IN	  THE	  PROGRESSION	  OF	  AORTIC	  STENOSIS	  
	   	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  whether	  or	  not	  to	  
participate,	  it	  is	  important	  that	  you	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  
will	   involve.	  Please	  read	  the	  following	   information	  and	  discuss	   it	  with	  others	   if	  you	  wish.	   If	  
there	  is	  anything	  that	  you	  are	  still	  unclear	  about	  or	  any	  questions	  that	  you	  would	  like	  to	  ask	  
you	  can	  contact	  us	   for	   further	   information.	  You	  can	  also	  contact	  Dr	  Bloomfield	  who	   is	  not	  
directly	  involved	  with	  this	  study	  but	  can	  give	  you	  independent	  advice.	  He	  can	  be	  contacted	  
through	  the	  Royal	  Infirmary	  switchboard	  	  (0131	  242	  1000)	  by	  asking	  for	  his	  secretary.	  
	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  information	  sheet.	  
	  
Why	  are	  we	  doing	  this	  study?	  	  
Aortic	  stenosis	  is	  a	  condition	  caused	  by	  narrowing	  of	  one	  the	  major	  valves	  within	  the	  heart.	  
The	  reasons	  why	  this	  narrowing	  develops	  are	  poorly	  understood.	  Using	  magnetic	  resonance	  
imaging	   (MRI)	  we	  want	   to	   study	   the	   role	  of	   scarring	  or	   “fibrosis”	   in	   aortic	   stenosis,	  which	  
occurs	  both	   in	   the	   valve	   and	   in	   the	  heart	  muscle.	   Scarring	  of	   the	   valve	   contributes	   to	   the	  
valve	  narrowing.	  	  
	  
If	  we	   understand	   how	   the	   scarring	   occurs	  we	  may	   be	   able	   to	   develop	   new	   treatments	   to	  
slow	  or	  prevent	  this	  disease.	  	  
	  
Why	  have	  I	  been	  chosen	  to	  take	  part?	  
We	  are	  looking	  for	  patients	  with	  normal	  valves	  to	  act	  as	  “controls”	  in	  this	  study.	  Using	  MRI	  
we	  will	   assess	  how	  much	   scarring	   is	   occurring	   in	   your	   valve	  and	  heart	  muscle.	  We	  do	  not	  
anticipate	  to	  find	  any	  scarring	  in	  your	  heart.	  We	  can	  then	  compare	  these	  results	  to	  those	  of	  
scans	  taken	  in	  patients	  with	  aortic	  stenosis	  and	  see	  if	  there	  is	  a	  difference.	  	  
	  
It	   is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  decide	  to	  take	  part	  you	  will	  be	  
given	  this	  information	  sheet	  to	  keep	  and	  you	  will	  be	  asked	  to	  sign	  a	  consent	  form.	  Even	  once	  
you	  have	  signed	  the	  form	  you	  can	  still	  withdraw	  at	  any	  time	  and	  you	  do	  not	  have	  to	  give	  a	  
reason.	  	  
	  
You	  will	  not	  benefit	  directly	  from	  this	  study.	  However,	  the	  information	  we	  get	  could	  help	  us	  
to	  improve	  the	  way	  we	  treat	  patients	  with	  aortic	  stenosis	  in	  the	  future.	  
	  
What	  will	  happen	  to	  me	  if	  I	  decide	  to	  take	  part?	  
You	  will	  need	  to	  attend	  the	  hospital	  for	  one	  day.	  We	  will	  firstly	  see	  you	  in	  the	  clinic	  and	  talk	  
about	   whether	   you	   have	   any	   symptoms;	   ask	   you	   to	   fill	   in	   a	   quality	   of	   life	   questionnaire;	  
perform	  a	   full	   examination	  of	   your	   heart;	   and	  organise	   an	   echo	   (ultrasound)	   scan	  of	   your	  
heart.	  The	  echo	  test	   is	  not	  painful	  and	   involves	  no	  harmful	  affects	  to	  you.	  You	  will	  already	  
 
Version 5 18/03/2014  
have	  had	  one	  of	  these	  scans	  in	  the	  clinic.	  We	  will	  then	  ask	  you	  to	  walk	  between	  two	  points	  
30	  metres	  apart.	  The	  idea	  is	  that	  you	  walk	  as	  far	  as	  possible	  back	  and	  forth	  for	  6	  minutes.	  	  
	  
You	  will	  then	  have	  an	  MRI	  scan	  of	  your	  heart.	  We	  will	  put	  a	  plastic	  tube	  (cannula)	  in	  to	  your	  
arm	  so	  that	  we	  can	  give	  you	  the	  contrast	  agent,	  Gadolinium.	  At	  the	  same	  time	  we	  will	  take	  
some	  blood	   from	  the	  cannula.	   If	  you	   like	  you	  can	  go	   in	   to	  a	  model	  of	   the	  MRI	  machine	  to	  
check	  you	  will	  be	  happy	  lying	  in	  it:	  occasionally	  people	  can	  feel	  a	  bit	  claustrophobic.	  We	  will	  
then	  perform	  the	  MRI	  scan:	  you	  will	  lie	  on	  a	  bed	  that	  moves	  into	  the	  scanner.	  You	  will	  lie	  in	  
the	   scanner	   for	   about	   45minutes.	   You	   will	   need	   to	   follow	   some	   very	   simple	   breathing	  
instructions	  from	  time	  to	  time.	  It	  is	  not	  painful.	  Finally	  when	  the	  MRI	  scan	  is	  finished	  we	  will	  
ask	  you	  to	  wear	  an	  ECG	  recorder	  for	  72	  hours	  to	  check	  for	  any	  underlying	  problems	  with	  the	  
rhythm	  of	  the	  heart.	  
	  
Heart	  Failure	  Questionnaire	  
We	  will	  ask	  you	  to	  complete	  a	  simple	  questionnaire	  that	  usually	  applies	  to	  patients	  who	  have	  
heart	  failure.	  We	  understand	  that	  you	  do	  not	  have	  heart	  failure	  but	  would	  be	  grateful	  if	  you	  
could	  complete	  the	  questionnaire	  so	  that	  we	  can	  compare	  the	  answers	  to	  the	  other	  patients	  
in	  the	  study.	  	  
	  
What	  happens	  to	  the	  blood	  samples	  that	  are	  taken?	  
A	  proportion	  will	  be	  tested	  right	  away	  for	  various	  tests.	  A	  portion	  of	  the	  blood	  samples	  taken	  
will	  be	  frozen,	  and	  stored	  in	  an	  anonymised	  manner	  so	  that	  further	  tests	  may	  be	  performed	  
on	  it	  in	  the	  future.	  Any	  further	  tests	  would	  require	  future	  ethical	  approval.	  	  
	  
Is	  there	  anything	  else	  that	  I	  have	  to	  do?	  
There	  are	  no	  restrictions	  on	  your	  lifestyle	  through	  participating	  in	  this	  study.	  
	  
Will	  taking	  part	  in	  this	  study	  affect	  my	  treatment?	  
No	  –	  you	  will	  still	  be	  followed	  up	  by	  your	  cardiologist	  as	  if	  you	  were	  not	  participating	  in	  the	  
trial.	  	  
	  
What	  are	  the	  side	  effects	  of	  taking	  part?	  
The	  MRI	  and	  echo	  scans	  are	  very	  safe.	  You	  cannot	  have	  them	  if	  you	  have	  kidney	  problems	  or	  
any	  metal	  in	  your	  body	  but	  we	  will	  check	  that	  you	  have	  no	  contraindications	  very	  carefully	  
before	  allowing	  you	  to	  take	  part	  in	  the	  study.	  	  
	  	  
What	  are	  the	  possible	  disadvantages	  of	  taking	  part?	  
Involvement	   in	   the	   trial	   will	   mean	   you	   attending	   for	   various	   appointments	   and	   scans.	  
Whenever	  possible	  we	  will	  ensure	  that	  these	  occur	  during	  the	  same	  visit.	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  will	  not	  be	  any	  direct	  benefit	  to	  you	  of	  taking	  part	   in	  the	  study,	  however	   it	   is	  hoped	  
that	  the	  findings	  of	  this	  study	  will	  benefit	  other	  patients	  with	  aortic	  stenosis	   in	  the	  future.	  
The	  information	  from	  the	  MRI	  scans	  can	  occasionally	  provide	  extra	  information	  that	  may	  be	  
useful	  to	  your	  cardiologist	  or	  your	  general	  practitioner.	  We	  will	  make	  certain	  that	  if	  any	  such	  
information	  arises	  that	  your	  cardiologist/	  general	  practitioner	  will	  be	  informed	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Will	  my	  GP	  be	  informed?	  
As	  long	  as	  you	  agree	  we	  would	  like	  to	  inform	  your	  General	  Practitioner	  of	  your	  participation	  
in	  this	  study.	  
	  
What	  if	  something	  goes	  wrong?	  
If	  you	  are	  harmed	  by	  taking	  part	  in	  this	  research	  project,	  there	  are	  no	  special	  compensation	  
arrangements,	   although	   in	   the	   case	   of	   negligent	   harm,	   subjects	   will	   be	   covered	   by	   the	  
University	  of	  Edinburgh	  insurance	  policy.	  If	  you	  are	  harmed	  as	  a	  result	  of	  the	  study	  you	  may	  
have	  grounds	  for	  legal	  action	  but	  you	  may	  have	  to	  pay	  for	  this.	  If	  you	  are	  not	  satisfied	  with	  
any	   aspect	   of	   the	  way	   you	  were	   approached	   or	   your	   treatment	   during	   this	   study,	   please	  
contact	  the	  Faculty	  of	  Medicine	  at	  the	  University	  of	  Edinburgh.	  	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
All	  the	  information	  collected	  about	  you	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  
confidential.	  Any	  information	  about	  you	  which	  leaves	  the	  hospital	  will	  have	  your	  name	  and	  
address	  removed	  so	  that	  you	  cannot	  be	  recognised	  from	  it.	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
Once	  we	  have	  completed	  the	  study	  and	  analysed	  the	  results,	  we	  will	  write	  a	  paper	  which	  will	  
be	   submitted	   for	   publication	   in	   one	   of	   the	  medical	   journals.	  We	   do	   not	   routinely	   contact	  
participants	  to	  inform	  them	  of	  the	  outcome	  of	  the	  research	  but	  would	  be	  happy	  to	  do	  so	  if	  
requested.	   If	   you	  would	   like	   a	   copy	  of	   the	   results	   please	   contact	  Dr	   Calvin	   Chin	   using	   the	  
contact	  details	  listed	  below.	  You	  will	  not	  be	  personally	  identified	  in	  any	  report/publication.	  
	  
Who	  is	  organising	  the	  research?	  
The	  study	   is	  being	  organised	  through	  the	  University	  of	  Edinburgh.	  Your	  doctors	  will	  not	  be	  
paid	  for	  including	  you	  in	  this	  study.	  
	  
Who	  has	  reviewed	  the	  study?	  
The	  study	  has	  been	  reviewed	  by	  the	  South	  East	  Scotland	  Research	  Ethics	  Committee	  2.	  
	  
Where	  can	  I	  obtain	  further	  information	  about	  the	  study?	  
You	  can	  get	  further	  information	  from	  Dr	  Calvin	  Chin	  or	  Prof	  Newby	  who	  will	  arrange	  to	  meet	  
you.	  You	  could	  also	  discuss	  the	  study	  with	  Dr	  Bloomfield	  who	  is	  another	  doctor	  working	  in	  
this	   hospital	   who	   is	   not	   involved	   in	   the	   study	   and	   can	   therefore	   act	   as	   an	   independent	  
advisor.	  
	  
Dr	   Chin	   can	   be	   reached	   by	   contacting	   his	   mobile	   on	   07535001086;	   his	   email	  
cchin03m@gmail.com	   or	   by	   letter	   addressed	   to	   the	   Cardiovascular	   Research	   Unit,	  
Chancellor’s	   Building,	   49	   Little	   France	   Crescent,	   Edinburgh	   EH16	   SU4.	   Prof	   Newby	   can	   be	  
contacted	  via	  the	  hospital	  switchboard	  (0131	  536	  1000).	  




Thank	  you	  once	  again	  for	  reading	  this	  information	  sheet	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Volunteer	  Consent	  Form	  	  




ROLE	  OF	  FIRBOSIS	  IN	  THE	  PROGRESSION	  OF	  AORTIC	  STENOSIS	  
	  
Participant	  Name	   	  
Participant	  DOB	   	  
Participant	  identification	  No	  for	  this	  trial	   	  
	  
☐	  	  	  I	  confirm	  that	  I	  have	  read	  and	  understood	  the	  accompanying	  information	  sheet.	  
☐	  	  	  I	  agree	  to	  take	  part	  in	  the	  above	  research	  project	  as	  described	  in	  the	  information	  
sheet.	  
☐	  	  	  I	  understand	  that	  this	  will	  not	  influence	  the	  medical	  treatment	  that	  is	  planned	  for	  me	  
in	  any	  way.	  	  
☐	  	  	  I	  understand	  that	  I	  am	  under	  no	  obligation	  to	  participate	  in	  this	  research,	  that	  I	  may	  
withdraw	  from	  the	  study	  at	  any	  stage	  and	  that	  doing	  so	  will	  not	  influence	  my	  treatment	  in	  
any	  way.	  
☐	  	  	  	  	  	  I	  understand	  that	  any	  information	  related	  to	  my	  case	  will	  be	  stored	  in	  an	  anonymised	  
manner	  
☐	  	  	  I	  consent	  to	  my	  GP	  being	  informed	  as	  to	  my	  participation	  in	  the	  trial.	  
☐	  	  I	  understand	  that	  blood	  samples	  will	  be	  stored	  for	  future	  use.	  I	  agree	  to	  them	  being	  




Signed………………………………………………………………………..……………	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Calcified aortic stenosis is a condition that affects the valve and the myocardium. As the valve
narrows, left ventricular hypertrophy occurs initially as an adaptive mechanism to maintain
cardiac output. Ultimately, the ventricle decompensates and patients transition towards heart
failure and adverse events. Current guidelines recommend aortic valve replacement in patients
with severe aortic stenosis and evidence of decompensation based on either symptoms or an
impaired ejection fraction <50%. However, symptoms can be subjective and correlate only
modestly with the severity of aortic stenosis whilst impaired ejection fraction is an advanced
manifestation and often irreversible. In this review, the authors will discuss the pathophysiology
of left ventricular hypertrophy and the transition to heart failure. Subsequently, the authors will
examine novel biomarkers that may better identify the transition from hypertrophy to heart
failure and therefore guide the optimal timing for aortic valve replacement.
KEYWORDS: aortic stenosis • cardiac MRI • echocardiography • left ventricular decompensation • left ventricular
hypertrophy • myocardial fibrosis • myocardial T1 mapping • myocyte death • tissue Doppler imaging
Calcific aortic stenosis is the most common valvu-
lar heart condition in developed countries, dis-
playing an increasing prevalence with age [1,2].
Aortic stenosis is characterized by progressive nar-
rowing of the aortic valve that is driven by a com-
plex, active and highly regulated process of
inflammation, fibrosis and calcification that leads
to leaflet thickening and immobility [3,4]. While
the pathophysiology is in many respects similar to
atherosclerosis, the factors driving symptom
development and clinical events are different [2,5].
For example, aortic stenosis is characterized by
the hypertrophic response of the left ventricle that
occurs in response to the progressive valve nar-
rowing. This is initially adaptive, restoring wall
stress and cardiac performance, but ultimately
this process decompensates and patients progress
toward heart failure, symptoms and adverse clini-
cal outcomes [6].
Current guidelines advocate aortic valve
replacement in patients with severe valvular
stenosis and evidence of left ventricular (LV)
decompensation: the latter defined by either
the presence of symptoms or an impaired ejec-
tion fraction <50% [7,8]. Unfortunately, aortic
stenosis commonly occurs in elderly patients
with comorbidities (such as coronary artery
disease, hypertension and chronic lung dis-
eases) that may confound symptom presenta-
tion and contribute to adverse cardiovascular
outcomes. Furthermore, an impaired ejection
fraction occurs late in the disease process when
myocardial damage may not be reversible.
While the risk of sudden cardiac death during
the asymptomatic phase is relative low (~1%
per year in large prospective series [9,10]), it is
not negligible. Indeed, recent studies have sug-
gested improved outcomes with early aortic
valve replacement in asymptomatic patients
with preserved systolic function [11,12].
There is considerable interest in defining
more objective and sensitive biomarkers of LV
decompensation, so that those at particularly
high risk can be identified and offered early
surgery. In this review, we will first discuss the
pathophysiology of LV hypertrophy in aortic
stenosis and how this ultimately progresses to
heart failure. We will then review some novel
biomarkers of this transition that might have
an increasing role in future clinical practice.
Pathophysiology of LV hypertrophy
In LV pressure overload conditions such as
aortic stenosis and hypertension, myocyte size








































































and myocardial wall thickness increase to restore wall stress (s)
according to the LaPlace’s Law: s = [P  r]/2 h, where P is LV
pressure, r is LV radius and h is the myocardial wall thickness.
The changes in ventricular pressure, radius and wall thickness are
therefore initially adaptive, maintaining cardiac output and sys-
tolic function (FIGURE 1) [13].
Interestingly, there is significant heterogeneity in the magni-
tude of hypertrophy that patients develop in response to similar
degrees of aortic valve narrowing. Indeed, multiple studies have
shown only a weak correlation between the severity of aortic valve
narrowing and LV mass [14–17]. Moreover, approximately
10–20% of patients with severe aortic stenosis have no evidence
of LV hypertrophy [17,18]. Sex-related differences partially explain
this variation, with women having smaller ventricles and lower
myocardial mass compared with men [19–23], potentially as a con-
sequence of differences in sex-related hormones and overall body
mass [20,23]. However, other clinical factors are also known to
influence the magnitude of the hypertrophic response. These
include age, the metabolic syndrome, obesity, angiotensin-
converting enzyme insertion/deletion polymorphisms and impor-
tantly concomitant hypertension, which imposes an additional
load on the left ventricle [16,24–28]. In order to account for both
the arterial and valvular load on the left ventricle, a measure of
the global LV hemodynamic load (valvulo-arterial impedance,
ZVA) has been proposed, with ZVA values >3.5–4.5 mmHg/ml/
m2 providing incremental prognostic value in patients with mod-
erate-to-severe aortic stenosis [29,30]. A more complex ventricular–
valvular–arterial coupling model has also been developed to more
accurately reflect the dynamic interaction between the left ventri-
cle, the narrowed aortic valve and the arterial system [31].
However, the clinical and prognostic value of this theoretical
model remains to be established.
Different patterns of ventricular remodeling and hypertrophy
are also well described among patients with aortic stenosis. These
are traditionally classified into four groups based upon the myo-
cardial wall thickness, the LV volume and the mass: normal
geometry, concentric remodeling, concentric hypertrophy and
eccentric hypertrophy [32]. More recently, cardiovascular mag-
netic resonance (CMR) studies have suggested that asymmetric
patterns of remodeling and hypertrophy can also be observed in
more than a quarter of patients alongside the traditional patterns
described above [15]. However, it remains unclear how patients
transition between these different patterns, how they relate to the
progression to heart failure and what the clinical consequences of
these patterns might be. One interesting related aspect is the so-
called paradoxical low-flow low-gradient severe aortic stenosis
with preserved ejection fraction. This commonly occurs in
patients with concentric remodeling who have increased myocar-
dial wall thickness and small LV volumes. As a consequence,
stroke volumes are reduced despite a preserved ejection fraction,
resulting in a lower than expected mean pressure gradient in the
presence of severe aortic stenosis [33].
The transition from hypertrophy to heart failure
As LV hypertrophy increases, it will ultimately decompensate.
This is characterized by progressive impairment in LV perfor-
mance and the development of symptoms (FIGURE 1) [14,17,34]. The
pathologic change from ventricular adaptation to decompensa-
tion is driven primarily by two processes: myocyte death and
myocardial fibrosis [35]. Myocyte death is predominantly in the
form of proteosomal-mediated autophagy and oncosis (cellular
and organelle swelling associated with increased membrane per-
meability), which occurs alongside more conventional forms of
apoptosis [35]. This cell death is believed to be activated by neuro-
humoral mediators such as angiotensin II and norepinephrine
[36–39], and by progressive myocardial ischemia. The latter relates
to increased myocardial oxygen demand (due to the increased
myocardial mass and afterload) and reduced coronary flow
reserve (due to impaired microcirculatory perfusion and inade-
quate expansion of coronary capillary density despite the absence
of coronary artery disease) [40,41].
Myocardial fibrosis is one of the histological hallmarks of end-
stage heart failure [42]. The pathogenesis of myocardial fibrosis is
complex and the distribution varies, depending on the underly-
ing pathology, although it generally exists in two predominant
forms (FIGURE 2) [43]. Replacement fibrosis commonly occurs late in
the disease process, is not believed to be reversible and is charac-
terized by a more localized distribution corresponding to areas of
myocyte loss [43,44]. By contrast, interstitial fibrosis is more dif-
fusely distributed, reflecting the more uniform and progressive
accumulation of collagen in the interstitium, and is thought to be
potentially reversible with targeted therapy. Both types of fibrosis
are present in aortic stenosis, occupying up to 30% of the myo-
cardium [13,45,46] and leading to progressive impairment of myo-
















Figure 1. The pathophysiology of left ventricular
hyeprtrophy and the transition to heart failure in aortic
stenosis. In response to the narrowed aortic valve, left
ventricular hypertrophy occurs initially to maintain cardiac output
and wall stress. Ultimately, it decompensates and heart failure
and other symptoms ensue. The transition from adaptation to
heart failure is driven by myocyte death and myocardial fibrosis,
mediated by angiotensin II and norepinephrine activation as well
as myocardial ischemia from increased afterload and left
ventricular mass.
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Markers of LV hypertrophy
LV hypertrophy is commonly assessed using echocardiography
and the 12-lead electrocardiogram. These are non-invasive,
inexpensive and well-tolerated tests, although the latter is
relatively insensitive in detecting hypertrophy [47]. By both
methods, the presence of LV hypertrophy in patients with aor-
tic stenosis is associated with worse symptoms, impaired systolic
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Figure 2. Types of myocardial fibrosis in aortic stenosis.While there are three predominant patterns of myocardial fibrosis, depending
on the underlying pathology inflicted on the myocardium, in aortic stenosis two forms predominate: replacement and interstitial myocardial
fibrosis. Replacement fibrosis occurs late in the disease process and is characterized by a more localized distribution corresponding to areas
of myocyte loss. By contrast, interstitial fibrosis has a more diffuse distribution and appears to be reversible with targeted therapy.
Reproduced with permission from [43].








































































In a recent study of 218 asymptomatic patients with aortic
stenosis, excessive ventricular mass on echocardiography
(defined as measured LV mass exceeding >10% of the pre-
dicted value) was associated with a 4.5-fold increase in adverse
events, independent of aortic stenosis severity [49]. Although
assessments of LV mass by echocardiography are widely used
and well studied, they rely heavily upon suitable echocardiogra-
phy windows and a series of geometrical and mathematical
assumptions [32]. This may limit accurate measurements, partic-
ularly in subjects with distorted left ventricles or asymmetrical
ventricular hypertrophy.
Electrocardiographic evidence of advanced ventricular hyper-
trophy is similarly associated with an adverse prognosis. Data
from the recent Simvastatin and Ezetimibe in Aortic Stenosis
substudy demonstrated an independent association between
electrocardiographic LV hypertrophy with strain and cardiovas-
cular events in more than 1500 patients and 4 years of follow-
up [9]. The exact mechanisms underlying electrocardiographic
strain remain unclear, but are related to more severe aortic ste-
nosis, increased LV mass and depressed systolic function, indi-
cating that this inexpensive and widely available test is a
marker of an advanced hypertrophic response [50].
CMR imaging is well recognized as the non-invasive
reference standard for measuring LV mass, volumes and
ejection fraction [51,52]. It is being increasingly used to inves-
tigate the hypertrophic response in aortic stenosis and, con-
sistent with the electrocardiographic and echocardiographic
data, a recent study observed a trend to the CMR-derived
indexed LV mass predicting all-cause mortality on univari-
ate analysis (hazard ratio: 1.01; 95% CI: 1.00–1.02;
p = 0.06) [53]. Further studies are required to confirm this
finding in larger patient populations.
Markers of LV decompensation
LV performance
Systolic function
The LV ejection fraction is the conventional marker of global
systolic dysfunction. Current guidelines recommend aortic valve
replacement in patients with severe aortic stenosis and a
reduced ejection fraction <50% [7,8]. However, the evidence for
using ejection fraction as an indication for aortic valve replace-
ment is weak. Indeed, this recommendation is largely based
upon limited retrospective studies that demonstrated an
improvement in LV function following aortic valve replacement
in patients with severe aortic stenosis and impaired ejection
fraction [54,55].
One of the key limitations in using the ejection fraction in
aortic stenosis is its tendency to overestimate myocardial sys-
tolic function in the presence of advanced concentric hyper-
trophy. This is because the associated increases in myocardial
wall thickness and filling pressures, alongside reductions in
ventricular volumes can result in a normal or even supra-
normal ejection fraction, despite significant impairment in
intrinsic myocardial contractility [56–58]. By contrast, echocar-
diographic assessment of mid-wall fractional shortening and
longitudinal function better reflect such contractility. They
have been associated with the presence of symptoms and the
magnitude of the LV afterload in aortic stenosis, although
their prognostic significance remains to be established [59–63].
In addition, novel myocardial deformation imaging (strain
and strain rate) using 2D speckle tracking echocardiography
has been proposed as an alternative and highly sensitive tech-
nique for the assessment of intrinsic myocardial contractil-
ity [64,65]. This approach measures the magnitude of myofibril
contraction in the left ventricle, which varies in direction
according to the different myocardial layers. Indeed, multidi-
rectional strain imaging has demonstrated that myocardial
dysfunction is present despite preserved ejection fraction and
that it progresses in a step-wise fashion from subendocardial
dysfunction in mild aortic stenosis (abnormal longitudinal
deformation) to mid-wall dysfunction in moderate aortic ste-
nosis (abnormal circumferential deformation), and eventually
transmural dysfunction in severe disease (abnormal radial
deformation) [66–68]. This technique also appears to provide prog-
nostic information, with impaired longitudinal myocardial strain
and strain rate predicting an adverse outcome in asymptomatic
patients with aortic stenosis [69].
Diastolic function
Diastolic dysfunction and impaired LV relaxation occur in aortic
stenosis as the left ventricle hypertrophies and becomes
fibrosed [13,70–72], frequently preceding reductions in ejection
fraction. Current studies examining diastolic dysfunction in aor-
tic stenosis have largely relied on Doppler mitral inflow and
myocardial tissue velocities [48,73–75], with limited data using
myocardial strain and strain rate imaging. These echocardio-
graphic measures of diastolic dysfunction are associated with
worse symptomatic status [48,75], and predict adverse cardiovascu-
lar events [30,73,76]. Therefore, they hold potential as early markers
of LV decompensation, although their relationship with the
more sensitive markers of systolic dysfunction is not well under-
stood and there is some inconsistency with respect to their prog-
nostic value [74].
Measurement of the left atrial size is an alternative method
for assessing diastolic function that has been the subject of sev-
eral small-scale studies [30,76]. It is also closely linked with the
development of atrial fibrillation, which in the context of aortic
stenosis is associated with advanced hypertrophy, an impaired
ejection fraction and an increased risk of heart failure and cere-
brovascular events [77].
Role of exercise stress testing
The prompt identification of symptoms is crucial in the effec-
tive management of patients with aortic stenosis, given the
poor prognosis associated with their development [6]. However,
it should be noted that the cardinal symptoms established by
Ross and Braunwald (angina, exertional dyspnea, pre-syncope,
syncope) were based on young patients with bicuspid or rheu-
matic disease (average age of 63 years old at time of death)
compared with the older patients who present today with
Review Chin, Vassiliou, Jenkins, Prasad, Newby & Dweck







































































calcific aortic stenosis and comorbidities. The assessment of
symptoms in contemporary clinical practice is therefore fre-
quently challenging. Underreporting is common, and patients
may unconsciously limit their activities to minimize symptoms.
In these situations, exercise stress testing performed under close
supervision and with careful monitoring of blood pressure and
electrocardiographic changes may be helpful in unmasking oth-
erwise latent symptoms. However, in a meta-analysis of 7 stud-
ies and 491 patients with asymptomatic severe aortic stenosis,
the sensitivity, specificity, positive and negative predictive values
for an adverse cardiac event after an abnormal exercise stress
test were only modest at 75, 71, 66 and 79%, respectively [78].
Nevertheless, both the American Heart Association/American
College of Cardiology and European Society of Cardiology
guidelines recommend that aortic valve replacement be consid-
ered in patients who develop exercise-limiting symptoms or an
abnormal blood pressure response (defined as an increase in
systolic blood pressure of <20 mmHg) on exercise stress
testing [7,8,79].
Blood biomarkers of ventricular decompensation
Brain natriuretic peptide & N-terminal proBNP
Interest has surrounded the use of the blood biomarkers
brain natriuretic peptide (BNP) and the related N-terminal
fragment of proBNP (NT-proBNP) in aortic stenosis. These
are endogenous cardiac hormones released in response to
increased LV wall stress and are therefore elevated in patients
with decompensated LV function. Several studies have dem-
onstrated that their levels increase as patients transition from
hypertrophy to heart failure and that they hold promise in
assessing patients with equivocal symptoms and severe disease
[80–84]. However, the value of measuring BNP and NT-
proBNP in patients who are asymptomatic is less certain. In
early studies, BNP and NT-proBNP demonstrated a better
correlation with clinical outcomes than traditional measures
of aortic stenosis severity [83,85,86]. However, two recent stud-
ies have questioned their prognostic value, failing to demon-
strate an incremental prognostic value when other clinical
and echocardiographic measures of aortic stenosis were also
considered [82,87]. Of note, patients in the latter two studies
were older (79–83 years old vs 68–72 years old in the other
studies), hinting at an important limitation of these bio-
markers as both BNP and NT-proBNP increase substantially
with advancing age independent of the presence of aortic
valve disease [88,89]. This lack of specificity in the elderly (the
population most commonly affected by aortic stenosis)
makes the selection of appropriate thresholds difficult.
Moreover, BNP and NT-proBNP lack sensitivity and levels
only increase in the later stages of LV decompensation when
symptoms and other markers of LV dysfunction are already
apparent [90].
High-sensitivity cardiac troponin concentrations
An alternative blood biomarker that appears to be released
earlier during the transition from hypertrophy to heart failure
is cardiac troponin. Increased cardiac troponin concentrations
have traditionally been considered to be a specific marker of
myocardial necrosis in patients with acute coronary syn-
dromes [91]. However, recent advances in assay sensitivity
allow quantification of plasma cardiac troponin with a high
degree of precision at extremely low plasma concentra-
tions [92]. This allows the detection of myocardial injury in a
wide range of cardiac conditions aside from acute coronary
syndromes, including aortic stenosis. As previously discussed,
myocyte death is believed to be one of the key factors driving
LV decompensation in aortic stenosis, and this provides a
clear rationale for troponin as a cheap and potentially widely
available biomarker of this process.
In a recent study, high-sensitivity cardiac troponin T concen-
trations were detectable in all 57 patients with moderate and
severe aortic stenosis. Moreover, these levels correlated positively
with LV wall thickness, ventricular mass and the severity of
aortic stenosis but interestingly did not appear related to the
presence of co-existent coronary artery disease. Furthermore,
the highest quartile of high-sensitivity troponin T concentra-
tions was associated with worst 2-year survival rates [93]. We
have recently demonstrated similar findings using a high-
sensitivity troponin I assay in more than 250 patients and
10 years of follow-up, again showing that high-sensitivity
troponin I concentrations were most closely associated with
the increased LV mass and myocardial fibrosis on CMR, and
that they predicted an adverse outcome [94]. Although these
early data are encouraging, further studies involving larger
populations are now needed to confirm these findings and to
investigate the potential clinical role for high-sensitivity car-
diac troponin in aortic stenosis.
Myocardial fibrosis
A second key mediator in the transition from hypertrophy
to heart failure is myocardial fibrosis [95]. Recently, non-
invasive techniques have been developed using CMR that
are capable of directly visualizing and quantifying such
fibrosis. These involve the administration of gadolinium
contrast, which accumulates in regions of fibrosis and
increases signal in these regions. This technique can there-
fore identify areas of replacement fibrosis in the myocar-
dium, which appear bright in the mid-wall of the left
ventricle, in contrast to the surrounding black-appearing
normal myocardium (FIGURE 3) [43,96,97]. Importantly, this pat-
tern of fibrosis can be differentiated from that observed
with prior myocardial infarction, which is also frequently
observed in patients with aortic stenosis.
Several CMR studies have investigated the role of late gad-
olinium enhancement in this condition. In a recent study
consisting of 143 patients with moderate-to-severe aortic ste-
nosis, we demonstrated that the presence of replacement
fibrosis was an independent predictor of mortality providing
incremental prognostic value over and above that of the ejec-
tion fraction. Indeed, patients with myocardial fibrosis had
an eightfold increase in all-cause mortality compared with








































































those without fibrosis despite similar aortic stenosis severity
and coronary artery disease burden [53]. Similar findings
have been observed in patients following aortic valve
replacement, with the presence of replacement late gadolin-
ium enhancement being associated with adverse ventricular
remodeling and worse perioperative and long-term out-
comes following aortic valve replacement [98–101]. Interest-
ingly, replacement myocardial fibrosis as detected by late
gadolinium enhancement does not appear to be reversible
following valve replacement [98], suggesting that once
observed in the ventricle, surgery should be considered early
before further irreversible fibrosis develops. This hypothesis
requires further investigation, but in our opinion late gado-
linium enhancement is likely to prove a useful clinical
marker of early LV decompensation and indicator for
prompt valve replacement.
The predominant form of myocardial fibrosis in aortic ste-
nosis is actually interstitial not replacement fibrosis. This is uni-
formly distributed through the myocardium and unlike
replacement fibrosis, it is thought to be reversible with targeted
therapies [102–104]. As a consequence of its diffuse distribution,
this form fibrosis is not detected by the late gadolinium
enhancement technique, which relies on a difference in signal
intensity between normal and fibrotic
regions [43]. Instead, novel myocardial
T1 mapping approaches have been devel-
oped to quantify this form of fibrosis
(FIGURE 3). To date, four major T1
approaches have been assessed and vali-
dated against histology with promising
results (TABLE 1). In a recent study, we have
compared these different techniques using
a standardized and systematic approach,
demonstrating that in aortic stenosis the
extracellular volume fraction holds the
most promise based on its superior repro-
ducibility (±3%) and ability to differenti-
ate patients with this condition from
healthy controls [105]. Prospective out-
come data with respect to myocardial
T1 mapping are lacking in aortic steno-
sis, although they have been established
in other cardiovascular patient popula-
tions [106,107].
Two additional novel biomarkers of
myocardial fibrosis also deserve mention,
although data with respect to aortic ste-
nosis are lacking. Galectin-3 is a member
of the lectin family and an important
mediator of myocardial fibrosis as dem-
onstrated by a number of experimental
studies [108–110]. It has emerged as a
potentially useful prognostic marker in
patients with heart failure, having
recently been associated with all-cause
mortality in a community-based study [111–114]. We believe this
simple blood test will hold similar promise in aortic stenosis.
18F-Fluciclatide is a PET tracer that has a high affinity for
extracellular integrin receptors, thereby acting as a marker of
fibrosis activity [115]. Indeed, these integrin receptors are
upregulated in states of fibrosis [116,117] and our preliminary
data in patients with myocardial infarction indicate that
18F-Fluciclatide activity does indeed map to regions of infarc-
tion. A technique capable of measuring fibrosis activity in the
myocardium would have potential clinical application in aor-
tic stenosis and further research using 18F-fluciclatide PET is
warranted in this condition.
Conclusion
The transition from hypertrophy to heart failure plays a key
role in the development of symptoms and adverse events in
patients with aortic stenosis. Currently, the identification of
this transition and the need for surgery is based on symptoms
or a reduced ejection fraction. However, both of these parame-
ters have their limitations and therefore, there is considerable
interest in novel biomarkers that can provide earlier and more
objective evidence of ventricular decompensation. Further work





Figure 3. Late gadolinium enhancement imaging and myocardial T1 mapping in
a patient with planned aortic valve replacement for severe aortic stenosis. (A)
Late gadolinium enhancement imaging demonstrates areas of replacement fibrosis in the
basal antero- and infero-septal segments. (B) 20 min post-contrast myocardial T1 map
of the same basal slice reveals areas of replacement fibrosis, corresponding to the late
gadolinium enhanced image. In addition, the extracellular volume fraction calculated in
this patient was elevated at 32.7% (the normal extracellular volume in healthy volun-
teers was 26.0 ± 1.6%). Myocardial biopsy sampled during aortic valve replacement
confirms the presence of myocardial fibrosis. (C) Collagen fibers stain pink with picro-
sirius red and (D) blue with Masson’s trichrome.
Data taken from [105].
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of biomarkers that might better guide the timing of aortic valve
replacement.
Expert commentary & five-year view
The indications for aortic valve replacement are clear in
patients with severe aortic stenosis and symptoms (angina, syn-
cope or dyspnea) or impaired systolic function. Without timely
aortic valve replacement, the risk of death in these patients is
about 2% per month [6,118]. Conversely, the management of
asymptomatic patients is more controversial. Many advocate
conservative management because aortic valve replacement will
not improve the overall quality of life since patients are asymp-
tomatic. However, some recent evidence suggest improved out-
comes with earlier surgery [11,12]. Therefore, the crucial question
remains: who will benefit from early valve replacement?
In recent years, there has been a greater appreciation that
aortic stenosis is a condition that affects not only the valve,
but also the myocardium. Indeed, the transition from LV
hypertrophy to heart failure appears to be a key factor in
determining the development of symptoms and adverse
events. Current assessments of this transition are limited and
interest has surrounded the development of novel biomarkers
of LV decompensation.
We have also learnt that asymptomatic patients with aortic
stenosis are a heterogeneous group, with some at higher risk of
adverse cardiovascular events than others. Indeed, the duration
of the asymptomatic phase varies widely between individuals
and despite the absence of symptoms, there is now substantial
evidence to suggest ongoing myocardial damage during this
subclinical phase. Although the mechanism of sudden cardiac
death in asymptomatic patients with aortic stenosis is not well
understood, myocardial fibrosis and increased myocardial injury
may be the substrates of lethal arrhythmias, above and beyond
the severity of valvular obstruction. We now have in our arma-
mentarium more sensitive measures of systolic dysfunction than
the conventional ejection fraction, state-of-the art imaging tech-
niques to detect early myocardial fibrosis and high-sensitivity
assays to measure myocardial injury related to the increased
afterload and ventricular mass (FIGURE 4). As the operative risks of
aortic valve replacement improve and transcatheter aortic valve
implantation techniques advance, there will be considerable
interest in these novel markers to identify high-risk asymptom-
atic patients who may benefit from early aortic valvular replace-
ment to prevent further myocardial damage and sudden cardiac
death.
Ultimately, randomized controlled trials will be required
to fully evaluate these novel biomarkers of LV decompensa-
tion, and whether this translates into improved outcomes in
patients with aortic stenosis. Instead of relying on a single
marker, we believe an integrative approach consisting of
clinical characteristics, novel imaging and blood biomarkers
will best guide the need for aortic valve replacement. In par-
ticular, high-sensitivity cardiac troponin assays could be
used as a screening tool, with patients demonstrating ele-
vated concentrations proceeding to CMR imaging to con-
firm the presence of mid-wall replacement fibrosis and LV
decompensation.
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Gadolinium accumulates in areas of
fibrosis because of an expanded
extracellular volume
Post-contrast T1 values are reduced in
areas of fibrosis
Contrast improves sensitivity in
identifying myocardial fibrosis
Can be incorporated in clinical
scan easily
Confounded by individual variation in





Estimates contrast volume of distribution
in the interstitial space
Expressed as a ratio of T1 signal change in
the myocardium and blood pool
l = DRmyocardium/DRblood pool, where
DR = 1/post-contrast T1 – 1/native T1
Excellent scan-rescan
reproducibility
Does not account for contrast volume




Similar to partition coefficient, corrects for
contrast volume of distribution in the
plasma
ECV = l  [1 – hematocrit]
Excellent scan-rescan
reproducibility
Hematocrit sampling required in
patients
Comparison of values across centers
may be limited by variabilities in
scanners and protocols
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Easy to measure. Patients with an advanced response are







Appears to be a sensitive marker of LV decompensation in
aortic stenosis but not specific. Further studies are required
to investigate its role in aortic stenosis 
Late gadolinium enhancement
and myocardial T1 mapping
Replacement fibrosis assessed using late gadolinium
enhancement imaging offers prognostic information in initial
studies. It does not appear to reverse after aortic valve
replacement.
T1 mapping technique detects a different form of fibrosis




Cheap and widely available. It occurs late in the disease
process and is associated with an advanced hypertrophic
response and markers of LV decompensation. Offers




and tissue Doppler velocities
Easy to measure.  However, there are conflicting results with
respect to their ability to predict adverse events
Systolic
dysfunction
Speckle imaging (strain and
strain rate)
Holds potential in detecting early systolic dysfunction before
changes in the ejection fraction are apparent
Brain natriuretic peptide 
and N-terminal pro-BNP
Increased levels are not manifest until late in the disease
process 
Helpful in patients with equivocal symptoms, but the
prognostic value in asymptomatic patients is conflicting
Ejection fraction Underestimates intrinsic myocardial systolic dysfunction
especially in presence of concentric hypertrophy
Figure 4. A summary of markers of ventricular decompensation associated with aortic stenosis.
BNP: Brain natriuretic peptide; ECV: Extracellular volume; EF: Ejection fraction; LGE: Late gadolinium enhancement; TDI: Tissue
Doppler imaging.
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• Aortic stenosis is a disease of the valve and the myocardium. In the myocardium, the transition from hypertrophy to heart failure is a
key determinant of the development of symptoms and adverse events. This decompensation is mediated by progressive myocyte death
and myocardial fibrosis.
• Currently, aortic valve replacement is recommended in patients with severe aortic stenosis and evidence of decompensation, based on
either symptoms or impaired ejection fraction <50%.
• Recent studies suggest that early aortic valve replacement improves clinical outcomes in asymptomatic patients with severe disease and
preserved systolic function.
• There is emerging interest in novel markers of left ventricular (LV) decompensation to identify patients who may benefit from early
aortic valve replacement. These biomarkers include the following:
– Advanced LV hypertrophy. This can be assessed with different degrees of sensitivity using the electrocardiogram, echocardiography and
cardiovascular magnetic resonance imaging and is associated with a worse prognosis.
– Speckle tracking echocardiography. This is more sensitive than the systolic ejection fraction in detecting intrinsic myocardial dysfunction.
Impaired longitudinal strain and strain rate predict an adverse outcome in asymptomatic patients with aortic stenosis.
– Diastolic dysfunction. This precedes an impaired ejection fraction and is associated with the onset and progression of symptoms.
However, there is some inconsistency in the literature with respect to its prognostic role.
– Brain natriuretic peptide and N-terminal pro-brain natriuretic peptide concentrations. These appear useful in evaluating patients with
equivocal symptoms. However, their prognostic value in asymptomatic patients is conflicting.
– High-sensitivity cardiac troponin concentrations hold potential in detecting the myocyte death that drives the transition from
hypertrophy to heart failure. More studies are needed to confirm their prognostic value.
– Myocardial fibrosis assessment using cardiovascular magnetic resonance. This technique can now be used to identify and quantify the
fibrosis driving LV decompensation with initial data suggesting this approach can provide important prognostic data.
• Future research is needed to investigate these novel biomarkers and assess whether they can better identify asymptomatic patients who
would benefit from early aortic valve replacement.
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36. González A, López B, Ravassa S, et al.
Stimulation of cardiac apoptosis in essential
hypertension: potential role of angiotensin
II. Hypertension 2002;39(1):75-80
37. Tokuda K, Kai H, Kuwahara F, et al.
Pressure-independent effects of angiotensin
II on hypertensive myocardial fibrosis.
Hypertension 2004;43(2):499-503
38. Communal C, Singh K, Pimentel DR, et al.
Norepinephrine stimulates apoptosis in
adult rat ventricular myocytes by activation
of the beta-adrenergic pathway. Circulation
1998;98(13):1329-34
39. Weber KT, Brilla CG. Pathological
hypertrophy and cardiac interstitium.
Fibrosis and renin-angiotensin-aldosterone
system. Circulation 1991;83(6):1849-65
40. Marcus ML, Koyanagi S, Harrison DG,
et al. Abnormalities in the coronary
circulation that occur as a consequence of
cardiac hypertrophy. Am J Med 1983;
75(3A):62-6
41. Galiuto L, Lotrionte M, Crea F, et al.
Impaired coronary and myocardial flow in
severe aortic stenosis is associated with
increased apoptosis: a transthoracic Doppler
and myocardial contrast echocardiography
study. Heart 2006;92(2):208-12
42. Schaper J, Speiser B. The extracellular
matrix in the failing human heart. Basic Res
Cardiol 1992;87(Suppl 1):303-9
43. Mewton N, Liu CY, Croisille P, et al.
Assessment of myocardial fibrosis with
cardiovascular magnetic resonance. J Am
Coll Cardiol 2011;57(8):891-903
44. Bing OH, Ngo HQ, Humphries DE, et al.
Localization of alpha1(I) collagen mRNA in
myocardium from the spontaneously
hypertensive rat during the transition from
compensated hypertrophy to failure. J Mol
Cell Cardiol 1997;29(9):2335-44
45. Villari B, Campbell SE, Hess OM, et al.
Influence of collagen network on left
ventricular systolic and diastolic function in
aortic valve disease. J am Coll Cardiol
1993;22(5):1477-84
46. Weidemann F, Herrmann S, Störk S, et al.
Impact of myocardial fibrosis in patients
with symptomatic severe aortic stenosis.
Circulation 2009;120(7):577-84
47. Murphy ML, Thenabadu PN, de Soyza N,
et al. Sensitivity of electrocardiographic
criteria for left ventricular hypertrophy
according to type of cardiac disease. Am J
Cardiol 1985;55(5):545-9
48. Dahl JS, Christensen NL, Videbaek L, et al.
Left ventricular diastolic function is
associated with symptom status in severe
aortic valve stenosis. Circ Cardiovasc
Imaging 2014;7(1):142-8
49. Cioffi G, Faggiano P, Vizzardi E, et al.
Prognostic effect of inappropriately high left
ventricular mass in asymptomatic severe
aortic stenosis. Heart 2011;97(4):301-7
50. Greve AM, Gerdts E, Boman K, et al.
Differences in cardiovascular risk profile
between electrocardiographic hypertrophy
versus strain in asymptomatic patients with
aortic stenosis (from SEAS Data). Am J
Cardiol 2011;108(4):541-7
Review Chin, Vassiliou, Jenkins, Prasad, Newby & Dweck







































































51. Myerson SG, Bellenger NG, Pennell DJ.
Assessment of left ventricular mass by
cardiovascular magnetic resonance.
Hypertension 2002;39(3):750-5
52. Grothues F, Smith GC, Moon JCC, et al.
Comparison of interstudy reproducibility of
cardiovascular magnetic resonance with
two-dimensional echocardiography in
normal subjects and in patients with heart
failure or left ventricular hypertrophy. Am J
Cardiol 2002;90(1):29-34
53. Dweck MR, Joshi S, Murigu T, et al.
Midwall fibrosis is an independent predictor
of mortality in patients with aortic stenosis.
J am Coll Cardiol 2011;58(12):1271-9
54. Smith N, McAnulty JH, Rahimtoola SH.
Severe aortic stenosis with impaired left
ventricular function and clinical heart
failure: results of valve replacement.
Circulation 1978;58(2):255-64
55. Connolly HM, Oh JK, Orszulak TA, et al.
Aortic valve replacement for aortic stenosis
with severe left ventricular dysfunction.
Prognostic indicators. Circulation 1997;
95(10):2395-400
56. Dumesnil JG, Shoucri RM. Effect of the
geometry of the left ventricle on the
calculation of ejection fraction. Circulation
1982;65(1):91-8
57. Pibarot P, Dumesnil JG. Improving
assessment of aortic stenosis. JAm Coll
Cardiol 2012;60(3):169-80
58. Lancellotti PP, Donal EE, Magne JJ, et al.
Impact of global left ventricular afterload on
left ventricular function in asymptomatic
severe aortic stenosis: a two-dimensional
speckle-tracking study. Eur J Echocardiogr
2010;11(6):537-43
59. Aurigemma GP, Silver KH, Priest MA,
Gaasch WH. Geometric changes allow
normal ejection fraction despite depressed
myocardial shortening in hypertensive left
ventricular hypertrophy. JAm Coll Cardiol
1995;26(1):195-202
60. Ballo P, Mondillo S, Motto A, Faraguti SA.
Left ventricular midwall mechanics in
subjects with aortic stenosis and normal
systolic chamber function. J Heart Valve
Dis 2006;15(5):639-50
61. Cramariuc D, Cioffi G, Rieck E, et al.
Low-flow aortic stenosis in asymptomatic
patients: valvular-arterial impedance and
systolic function from the SEAS Substudy.
JACC Cardiovasc Imaging 2009;2(4):390-9
62. Lam CSP, Roger VL, Rodeheffer RJ, et al.
Cardiac structure and ventricular-vascular
function in persons with heart failure and
preserved ejection fraction from Olmsted
county, Minnesota. Circulation 2007;
115(15):1982-90
63. Takeda S, Rimington H, Smeeton N, et al.
Long axis excursion in aortic stenosis. Heart
2001;86(1):52-6
64. Manovel A, Dawson D, Smith B, et al.
Assessment of left ventricular function by
different speckle-tracking software. Eur J
Echocardiogr 2010;11(5):417-21
65. Blessberger H, Binder T. Two dimensional
speckle tracking echocardiography: basic
principles. Heart 2010;96(9):716-22
66. Cramariuc D, Gerdts E, Davidsen ES, et al.
Myocardial deformation in aortic valve
stenosis: relation to left ventricular
geometry. Heart 2010;96(2):106-12
67. Ng ACT, Delgado V, Bertini M, et al.
Alterations in multidirectional myocardial
functions in patients with aortic stenosis and
preserved ejection fraction:
a two-dimensional speckle tracking analysis.
Eur Heart J 2011;32(12):1542-50
68. Delgado V, Tops LF, van Bommel RJ,
et al. Strain analysis in patients with severe
aortic stenosis and preserved left ventricular
ejection fraction undergoing surgical valve
replacement. Eur Heart J 2009;30(24):
3037-47
69. Lancellotti P, Donal E, Magne J, et al. Risk
stratification in asymptomatic moderate to
severe aortic stenosis: the importance of the
valvular, arterial and ventricular interplay.
Heart 2010;96(17):1364-71
70. Hess OM, Villari B, Krayenbuehl HP.
Diastolic dysfunction in aortic stenosis.
Circulation 1993;87(5 Suppl):IV73-6
71. Bruch C, Stypmann J, Grude M, et al.
Tissue Doppler imaging in patients with
moderate to severe aortic valve stenosis:
clinical usefulness and diagnostic accuracy.
Am Heart J 2004;148(4):696-702
72. Villari B, Hess OM, Kaufmann P, et al.
Effect of aortic valve stenosis (pressure
overload) and regurgitation (volume
overload) on left ventricular systolic and
diastolic function. Am J Cardiol 1992;
69(9):927-34
73. Biner S, Rafique AM, Goykhman P, et al.
Prognostic value of E/E´ ratio in patients
with unoperated severe aortic stenosis.
JACC Cardiovasc Imaging 2010;3(9):
899-907
74. Stewart RAH, Kerr AJ, Whalley GA, et al.
Left ventricular systolic and diastolic
function assessed by tissue Doppler imaging
and outcome in asymptomatic aortic
stenosis. Eur Heart J 2010;31(18):2216-22
75. Park SJ, Enriquez-Sarano M, Chang SA,
et al. 1-s2.0-S1936878X12009539-main.
JACC Cardiovasc Imaging 2013;6(2):
137-46
76. Casaclang-Verzosa G, Malouf JF, Scott CG,
et al. Does left atrial size predict mortality
in asymptomatic patients with severe aortic
stenosis? Echocardiography 2010;27(2):
105-9
77. Greve AM, Gerdts E, Boman K, et al.
Prognostic importance of atrial fibrillation
in asymptomatic aortic stenosis: the
simvastatin and ezetimibe in aortic stenosis
study. Int J Cardiol 2013;166(1):72-6
78. Rafique AM, Biner S, Ray I, et al.
Meta-analysis of prognostic value of stress
testing in patients with asymptomatic severe
aortic stenosis. Am J Cardiol 2009;104(7):
972-7
79. Amato MC, Moffa PJ, Werner KE, et al.
Treatment decision in asymptomatic aortic
valve stenosis: role of exercise testing. Heart
2001;86(4):381-6
80. Gerber IL, Stewart RAH, Legget ME, et al.
Increased plasma natriuretic peptide levels
reflect symptom onset in aortic stenosis.
Circulation 2003;107(14):1884-90
81. Nessmith MG, Fukuta H, Brucks S, et al.
Usefulness of an elevated B-type natriuretic
peptide in predicting survival in patients
with aortic stenosis treated without surgery.
Am J Cardiol 2005;96(10):1445-8
82. Ben-Dor I, Minha S, Barbash IM, et al.
Correlation of brain natriuretic peptide
levels in patients with severe aortic stenosis
undergoing operative valve replacement or
percutaneous transcatheter intervention with
clinical, echocardiographic, and
hemodynamic factors and prognosis. Am J
Cardiol 2013;112(4):574-91
83. Bergler-Klein J, Klaar U, Heger M, et al.
Natriuretic peptides predict symptom-free
survival and postoperative outcome in severe
aortic stenosis. Circulation 2004;109(19):
2302-8
84. Weber M, Arnold R, Rau M, et al. Relation
of N-terminal pro-B-type natriuretic peptide
to severity of valvular aortic stenosis. Am J
Cardiol 2004;94(6):740-5
85. Monin J-L, Lancellotti P, Monchi M, et al.
Risk score for predicting outcome in
patients with asymptomatic aortic stenosis.
Circulation 2009;120(1):69-75
86. Lancellotti P, Moonen M, Magne J, et al.
Prognostic effect of long-axis left ventricular
dysfunction and B-type natriuretic peptide
levels in asymptomatic aortic stenosis. Am J
Cardiol 2010;105(3):383-8








































































87. Cimadevilla C, Cueff C, Hekimian G, et al.
Prognostic value of B-type natriuretic
peptide in elderly patients with aortic valve
stenosis: the COFRASA-GENERAC study.
Heart 2013;99(7):461-7
88. Raymond I, Groenning BA,
Hildebrandt PR, et al. The influence of age,
sex and other variables on the plasma level
of N-terminal pro brain natriuretic peptide
in a large sample of the general population.
Heart 2003;89(7):745-51
89. Costello-Boerrigter LC, Boerrigter G,
Redfield MM, et al. Amino-terminal
pro-B-type natriuretic peptide and B-type
natriuretic peptide in the general
community: determinants and detection of
left ventricular dysfunction. J Am Coll
Cardiol 2006;47(2):345-53
90. Ikeda T, Matsuda K, Itoh H, et al. Plasma
levels of brain and atrial natriuretic peptides
elevate in proportion to left ventricular
end-systolic wall stress in patients with
aortic stenosis. Am Heart J 1997;133(3):
307-14
91. Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal definition of myocardial
infarction. Nat Rev Cardiol 2012;9(11):
620-33
92. Apple FS, Ler R, Murakami MM.
Determination of 19 cardiac troponin I and
T assay 99th percentile values from a
common presumably healthy population.
Clin Chem 2012;58(11):1574-81
93. Røsjø H, Andreassen J, Edvardsen T, et al.
Prognostic usefulness of circulating
high-sensitivity troponin T in aortic stenosis
and relation to echocardiographic indexes of
cardiac function and anatomy. Am J
Cardiol 2011;108(1):88-91
94. Chin CWL, Shah AS, McAllistair D, et al.
High sensitivity troponin I concentrations
are a marker of an advanced hypertrophic
response and adverse outcomes in patients
with aortic stenosis. Eur Heart J 2014
doi:10.1093/eurheartj/ehu189 [Epub ahead
of print]
95. Villari B, Vassalli G, Monrad ES, et al.
Normalization of diastolic dysfunction in
aortic stenosis late after valve replacement.
Circulation 1995;91(9):2353-8
96. McCrohon JA, Moon JCC, Prasad SK,
et al. Differentiation of heart failure related
to dilated cardiomyopathy and coronary
artery disease using gadolinium-enhanced
cardiovascular magnetic resonance.
Circulation 2003;108(1):54-9
97. Mahrholdt H, Wagner A, Judd RM, et al.
Delayed enhancement cardiovascular
magnetic resonance assessment of
non-ischaemic cardiomyopathies. Eur Heart
J 2005;26(15):1461-74
98. Weidemann F, Niemann M, Herrmann S,
et al. A new echocardiographic approach for
the detection of non-ischaemic fibrosis in
hypertrophic myocardium. Eur Heart J
2007;28(24):3020-6
99. Quarto C, Dweck MR, Murigu T, et al.
Late gadolinium enhancement as a potential
marker of increased perioperative risk in
aortic valve replacement. Interact Cardiovasc
Thorac Surg 2012;15(1):45-50
100. Azevedo CF, Nigri M, Higuchi ML, et al.
Prognostic Significance of Myocardial
Fibrosis Quantification by Histopathology
and Magnetic Resonance Imaging in
Patients With Severe Aortic Valve Disease.
J Am Coll Cardiol 2010;56(4):278-87
101. Milano AD, Faggian G, Dodonov M, et al.
Prognostic value of myocardial fibrosis in
patients with severe aortic valve stenosis.
J Thorac Cardiovasc Surg 2012;144(4):
830-7
102. Dı́ez J, Querejeta R, López B, et al.
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ABSTRACT
Background: Discordance between small aortic valve area (AVA; < 1.0
cm2) and lowmean pressure gradient (MPG;< 40mmHg) affects a third
of patientswithmoderate or severe aortic stenosis (AS).Wehypothesized
that this is largely due to inaccurate echocardiographicmeasurements of
the left ventricular outflow tract area (LVOTarea) and stroke volume
alongside inconsistencies in recommended thresholds.
Methods: One hundred thirty-three patients with mild to severe AS and
33 control individuals underwent comprehensive echocardiography
and cardiovascular magnetic resonance imaging (MRI). Stroke volume
and LVOTarea were calculated using echocardiography and MRI, and
the effects on AVA estimation were assessed. The relationship
between AVA and MPG measurements was then modelled with
nonlinear regression and consistent thresholds for these parameters
calculated. Finally the effect of these modified AVA measurements
and novel thresholds on the number of patients with small-area low-
gradient AS was investigated.
RESUME
Introduction : La discordance entre une surface valvulaire aortique
retrecie (SVA; < 1,0 cm2) et un faible gradient de pression moyen
(GPM; < 40 mm Hg) touche un tiers des patients souffrant d’une
stenose aortique (SA) moderee ou grave. Nous avons pose l’hypothèse
que ceci est grandement dû aux mesures echocardiographiques
inexactes de la surface de la chambre de chasse du ventricule gauche
(surface de la CCVG) et au volume systolique de même qu’à l’in-
coherence des seuils recommandes.
Methodes : Cent trente-trois (133) patients souffrant de SA legère à
grave et 33 temoins ont subi une echocardiographie complète et une
imagerie cardiovasculaire par resonance magnetique (ICRM). Le volume
systolique et la surface de la CCVG ont ete calcules à l’aide de
l’echocardiographie et de l’ICRM, et les effets sur l’estimation de la SVA
et les mesures du GPM ont alors ete modeles à l’aide de la regression
non lineaire et les seuils coherents de ces paramètres ont ete calcules.
Finalement, l’effet de ces mesures modifiees de la SVG et des nouveaux
Discordant small aortic valve area (AVA; < 1.0 cm2), low
mean pressure gradient (MPG; < 40 mm Hg) aortic stenosis
occurs in approximately 30% of patients with aortic stenosis
evaluated using echocardiography.1,2 This has classically been
attributed to patients with low flow states, such as those with
reduced left ventricular (LV) ejection fractions.3 However, in
recent years, it has been recognized that small-area low-
gradient aortic stenosis can also be observed in the presence of
a preserved ejection fraction: so-called “paradoxical low-flow,
low-gradient severe aortic stenosis.” The outcomes associated
with such patients have been variable in different studies,4-7
presumably reflecting a heterogeneous population and high-
lighting the uncertainty with regard to the actual severity of
aortic stenosis in this subgroup.
Using the continuity equation, the AVA is calculated
based on the ratio between the Doppler stroke volume and
the post-aortic valve flow. Doppler stroke volume relies
crucially on accurate estimation of the LV outflow tract
(LVOT) area (LVOTarea) according to the formula:
Doppler stroke volume ¼ LVOTarea  LVOT flow. On
2-dimensional echocardiography, the LVOTarea is derived
from LVOT diameter measurements made on the parasternal
long-axis view and the assumption that the LVOT is circular.
However, recent experience from transcatheter aortic valve
replacement sizing has demonstrated that the LVOT is
frequently elliptical and not circular, and as a consequence,
measurements made using echocardiography underestimate
the true LVOTarea.
8,9 The implication is therefore that
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echocardiography might also underestimate the true LV
stroke volume and AVA.
In addition, it is widely acknowledged that the severity
thresholds for AVA and MPG recommended in current
guidelines are inherently inconsistent,1,10 with theoretical
models suggesting an AVA of 1.0 cm2 corresponds more
closely to a MPG of 30-35 mm Hg than the recommended
threshold of 40 mm Hg.10,11
We hypothesized that the combination of LVOTarea un-
derestimation and inconsistent thresholds might influence the
classification of aortic stenosis severity, and contribute to the
number of patients with discordant small-area low-gradient
aortic stenosis. The aims of the study were first to compare
stroke volume estimation using echocardiography with the
gold standard noninvasive cardiovascular magnetic resonance
imaging (MRI) assessment and to establish the optimal
thresholds for severe aortic stenosis. Subsequently we then
sought to investigate whether correcting for these 2 factors




Patients with mild to severe aortic stenosis were prospec-
tively recruited from the Edinburgh Heart Centre, and control
individuals without aortic stenosis were recruited from the
local community. We excluded patients with other significant
valvular heart disease (moderate to severe), contraindications
to MRI, and cardiomyopathies (inherited or acquired).
The study was conducted in accordance with the Decla-
ration of Helsinki, and approved by the local ethics com-
mittee. Written informed consent was obtained from all
subjects.
Echocardiography
Transthoracic echocardiography was performed in all
patients (iE33, PhilipsMedical Systems, Best, The Netherlands)
by a research ultrasonographer (A.C.W.), and a cardiologist
trained in echocardiography (C.W.L.C.). The severity of aortic
stenosis was assessed according to the American College of
Cardiology/American Heart Association guidelines. Specifically,
severe aortic stenosis was defined as an AVA of < 1 cm2 and
MPG > 40 mm Hg.12 In the parasternal long-axis view, the
LVOT diameter was measured at the insertion of the aortic
cusps, from the inner edge of the septal endocardium to the
inner edge of the anterior mitral leaflet in midsystole (Fig. 1A),
because the cross-sectional shape is believed to be more circular
at this level.3 LVOT velocity-time integral was measured in the
apical 5-chamber view using pulsed-wave Doppler just proximal
to the aortic valve. We were careful to obtain a laminar spectral
tracing, avoiding contamination from flow across the aortic
valve.
The peak aortic jet velocity and MPG were derived from
the aortic valve velocity-time integral, using continuous-wave
Doppler. The highest aortic jet velocity and MPG was
determined in multiple acoustic windows using standard S51
and D2cwc probes (Philips Medical Systems), and corrobo-
rated by the 2 operators. The mean of 3 readings (5 if the
patient had atrial fibrillation) was recorded. Doppler stroke
volume was estimated (LVOTarea  LVOT velocity-time
integral) and used to calculate the AVA with the continuity
equation (stroke volume/aortic valve velocity-time integral).
Normal stroke volume using echocardiography was defined as
 35 mL/m2.13 In a further analysis, we had also estimated
stroke volume according to the Teichholz method14 and the
effects on aortic stenosis classification.
The severity of aortic valve calcification was assessed in the
short-axis view of the aortic valve using a score of 1-4,15 and
corroborated between the 2 operators. Valvuloarterial
impedance, a measure of global afterload, was calculated as
(systolic blood pressure þ MPG)/MRI stroke volume.
MRI
All participants underwent MRI at 3T (Magnetom Verio,
Siemens AG, Healthcare Sector, Erlangen, Germany). Cine
images were acquired using a balanced steady-state free
Results: Compared with MRI, echocardiography underestimated
LVOTarea (n¼ 40;0.7 cm2; 95% confidence interval [CI],2.6 to 1.3),
stroke volumes (6.5 mL/m2; 95% CI, 28.9 to 16.0) and conse-
quently, AVA (0.23 cm2; 95% CI, 1.01 to 0.59). Moreover, an AVA
of 1.0 cm2 corresponded to MPG of 24 mm Hg based on echocar-
diographic measurements and 37 mm Hg after correction with MRI-
derived stroke volumes. Based on conventional measures, 56
patients had discordant small-area low-gradient AS. Using MRI-derived
stroke volumes and the revised thresholds, a 48% reduction in
discordance was observed (n ¼ 29).
Conclusions: Echocardiography underestimated LVOTarea, stroke vol-
ume, and therefore AVA, compared with MRI. The thresholds based
on current guidelines were also inconsistent. In combination, these
factors explain > 40% of patients with discordant small-area low-
gradient AS.
seuils sur le nombre de patients ayant une SA à surface retrecie et à
faible gradient a ete examine.
Resultats : Comparativement à l’ICRM, l’echocardiographie a sous-
estime la surface de la CCVG (n ¼ 40; 0,7 cm2; intervalle de con-
fiance [IC] à 95 %, 2,6 à 1,3), les volumes systoliques (6,5 ml/m2;
IC à 95 %, 28,9 à 16,0) et, consequemment, la SVA (0,23 cm2; IC à
95 %, 1,01 à 0,59). De plus, une SVA de 1,0 cm2 correspondait à un
GPM de 24 mm Hg selon les mesures echocardiographiques et de 37
mm Hg après la correction des volumes systoliques issus de l’ICRM.
Selon les mesures traditionnelles, 56 patients avaient une SA à sur-
face retrecie et à faible gradient. À partir des volumes systoliques issus
de l’ICRM et des seuils revises, une reduction de la discordance de
48 % a ete observee (n ¼ 29).
Conclusions : L’echocardiographie a sous-estime la surface de la
CCVG, le volume systolique et, par consequent, la SVA comparative-
ment à l’ICRM. Les seuils des lignes directrices actuelles etaient
egalement incoherents. Combines, ces facteurs expliquent la raison
pour laquelle > 40 % des patients souffrent d’une SA dont la surface
retrecie et le faible gradient sont discordants.
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precision sequence in the short-axis of the left ventricle
extending from the atrioventricular ring to the apex (8-mm
parallel slices with 2-mm spacing). The endocardial borders
were planimetered in end-diastole and end-systole to quantify
ventricular volumes and function (Argus, Siemens AG,
Healthcare Sector). Papillary muscles and minor trabecula-
tions were included in the volume measurements during
both phases of the cardiac cycle as previously described
(Fig. 1B).16,17 Stroke volume was measured as the difference
between the end-diastolic and end-systolic LV volumes (in the
absence of significant mitral regurgitation), and indexed
to body surface area. Normal indexed LV volumes, stroke
volumes, and ejection function were defined using sex- and
age-specific ranges.18 LV mass was calculated from the total
end-diastolic myocardial volume multiplied by the specific
gravity of the myocardium (1.05 g/mL).
Figure 1. Estimation of left ventricular outflow tract (LVOT) area using echocardiography and magnetic resonance imaging. (A) The LVOT diameter
was measured at the aortic cusp insertion points (red arrows) in the parasternal long axis view. The LVOT area was estimated from the diameter
measured. (B) The stroke volume was calculated as the difference between end-diastolic and end-systolic volumes. Planimetry of the endocardial
borders (red contours in end-diastolic and end-systolic frames) was performed including the papillary muscles and minor trabeculations in volume
measurements during both phases of the cardiac cycle. Left ventricular mass was calculated by multiplying the total end-diastolic myocardial
volume (green and red contours in the end-diastolic frame) by the specific gravity of the myocardium (1.05 g/mL). Papillary muscles and minor
trabeculations were excluded in mass measurements, with care taken to avoid right ventricular trabeculations. (C) Planimetry of the LVOT area in
the coaxial short axis view on cardiovascular magnetic resonance imaging at mid-systole.
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In 40 patients, additional coaxial short-axis cine slices were
acquired from the level of the aortic valve. The LVOTarea was
planimetered at the base of the aortic valve (the slice at which
all 3 cusps were first observed to disappear) in midsystole and
comparisons were made with the LVOTarea estimated from
the LVOT diameter on 2-dimensional echocardiography
(Fig. 1C).
Curve-fitting and statistical analysis
In patients with normal stroke volumes, the relationship
between AVA and MPG was modelled according to the Gorlin
equation: AVA ¼ c/OMPG (GraphPad Prism 5, GraphPad
Software Inc, San Diego, CA). No rules were set for the initial
value for the modelling parameter, c. We generated 2 curve-
fitting models with AVA derived using Doppler stroke vol-
ume and MRI stroke volume.
The distribution of all continuous variables was assessed for
normality using the Shapiro-Wilk test, and presented as either
mean  SD or median (interquartile range). Comparison was
performed using the Student t test or analysis of variance with
post hoc Bonferroni adjustment. The Mann-Whitney U and
Kruskal-Wallis with post hoc Dunn tests were used for
nonparametric data. Categorical variables were expressed in
percentages and compared using the c2 test. The correlation
between continuous data was assessed with the Pearson cor-
relation and presented as r2 values. Comparison between
echocardiographic and MRI indices of stroke volume, LVO-
Tarea, and AVA was assessed using the Bland-Altman analysis.
Fixed and proportional biases with 95% limits of agreement
were reported. A 2-sided P < 0.05 was considered statistically
significant.
Results
A total of 133 patients with mild to severe aortic stenosis
(AVA, 0.98  0.40 cm2; MPG, 33  20 mm Hg; peak aortic
velocity, 3.8  0.9 m/s) and 33 control individuals were
recruited. The median interval between echocardiography
and MRI was 9 (interquartile range, 5-29) days. Compared
Table 1. Baseline characteristics of patients with aortic stenosis and control individuals*
Control individuals (n ¼ 33) Aortic stenosis (n ¼ 133) P
Clinical characteristics
Age, mean years  SD 54  23 68  12 < 0.01
Male sex, n (%) 18 (55) 89 (67) 0.40
Hypertension, n (%) 9 (27) 85 (64) < 0.01
Diabetes mellitus, n (%) 0 18 (14) d
Coronary artery disease, n (%) 3 (9) 44 (33) 0.01
Atrial fibrillation, n (%) 0 3 (2) d
Echocardiography
LVOT diameter, cm 2.05  0.17 2.07  0.24 0.66
LVOT cross-sectional area, cm2 3.30  0.55 3.39  0.85 0.60
LVOT velocity time integral, cm 20.9  3.7 23.5  4.4 0.01
Doppler stroke volume, mL 70  19 79  19 < 0.01
Doppler stroke volume (indexed), mL/m2 38  8 42  10 < 0.01
Aortic valve area, cm2 2.36  0.59 0.98  0.40 < 0.01
Aortic valve area (indexed), cm2/m2 1.26  0.26 0.52  0.21 < 0.01
Mean pressure gradient, mm Hg 4  1 33  20 < 0.01
Peak aortic velocity, m/s 1.4  0.2 3.8  0.9 < 0.01
Dimensionless index 0.72  0.10 0.28  0.09 < 0.01
Aortic valve calcium score, median (IQR) 1 (1, 1) 3 (3, 4) < 0.01
Valvuloarterial impedance, mm Hg/mL/m2 3.2  0.7 4.0  1.0 0.34
End-diastolic volume, mLy 93  25 87  26 0.17
End-diastolic volume (indexed), mL/m2y 50  13 46  13 0.12
End-systolic volume, mLy 41  14 38  14 0.29
End-systolic volume (indexed), mL/m2y 22  7 20  7 0.16
Stroke volume, mLy 51  16 49  14 0.48
Stroke volume (indexed), mL/m2y 28  8 26  7 0.16
Ejection fraction, %y 56  9 57  7 0.49
Mild mitral regurgitation, n (%) 2 (6) 19 (14) 0.37
Mild aortic regurgitation, n (%) 2 (6) 57 (43) < 0.01
Cardiovascular Magnetic Resonance Imaging
End-diastolic volume, mL 140  32 135  35 0.47
End-diastolic volume (indexed) (EDVi), mL/m2 75  13 72  16 0.34
End-systolic volume, mL 51  15 46  18 0.14
End-systolic volume (indexed), mL/m2 27  7 24  9 0.08
Stroke volume, mL 89  19 90  22 0.81
Stroke volume (indexed), mL/m2 47  8 48  10 0.59
Ejection fraction, % 64  4 67  7 0.02
Left ventricular mass (indexed) (LVMi), g/m2 67  15 89  22 < 0.01
LVMi/EDVi, g/mL 0.90  0.13 1.25  0.26 < 0.01
EDVi, indexed end diastolic volume; IQR, interquartile range; LVMi, indexed left ventricular mass; LVOT, left ventricular outflow tract.
* Characteristics of patients with aortic stenosis were classified based on aortic valve area estimated using Doppler-derived stroke volume presented in
Supplemental Table S1.
yEstimated using the Teichholz formula.
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with control individuals, patients with aortic stenosis had
greater ejection fraction rates (64  4% and 67  7%,
respectively; P ¼ 0.02) despite similar LV end-diastolic vol-
umes (75  13 mL/m2 and 72  16 mL/m2, respectively;
P ¼ 0.34) and stroke volumes (47  8 mL/m2 and 48  10
mL/m2, respectively; P ¼ 0.59) (Table 1 and Supplemental
Table S1).
Doppler and cardiac MRI stroke volume
Doppler stroke volume correlated only weakly with
MRI stroke volume measurements (r2 ¼ 0.12; P < 0.001;
Fig. 2A) and underestimated the stroke volume by > 6
mL/m2 compared with MRI (6.5 mL/m2; 95% confi-
dence interval [CI], 28.9 to 16.0 mL/m2; Fig. 2B).
Similar results were observed after excluding the 19 pa-
tients in the cohort with mild mitral regurgitation (r2 ¼
0.14; P < 0.001; mean difference, 6.1 mL/m2; 95%
CI, 28.2 to 16.0 mL/m2). This in part appears to
be due to underestimation of the LVOTarea using echo-
cardiography compared with planimetered LVOTarea
measurements (0.7 cm2; 95% CI, 2.6 to 1.3 cm2;
Fig. 3). Indeed, when we subsequently recalculated stroke
volume using the planimetered LVOTarea, an excellent
correlation with MRI stroke volumes was observed (r2 ¼
0.87; P < 0.001; Fig. 2C) without significant fixed or
proportional biases (1.3 mL/m2; 95% CI, 9.9 to 7.3
mL/m2; Fig. 2D). Moreover, this effect translated into an
underestimation of the AVA calculated using
echocardiography-derived stroke volumes compared with
MRI-measured stroke volumes (0.23 cm2; 95%
CI, 1.01 to 0.59 cm2; Fig. 4). As previously described,
the explanation for echocardiographic underestimation of
the LVOTarea appears related to its elliptic shape. Indeed,
the mean ellipticity ratio (ratio of the maximum to min-
imum LVOT diameter) was 1.2  0.1, with only 28% of
these patients having a circular LVOT (defined as ellip-
ticity ratio of 1.0). Of note, we achieved excellent intra-
observer (r2 ¼ 1.00; P < 0.001; mean difference 0.5 
2.7%) and interobserver (r2 ¼ 0.98; P < 0.001; mean
difference 1.1  5.4%) agreement in the planimetered
LVOT measurements using MRI.
Figure 2. Stroke volume correlation and Bland-Altman analysis. Doppler stroke volume correlated weakly with magnetic resonance imaging (MRI)
stroke volume (A), with a fixed bias and wide limits of agreement (B). In 40 patients, stroke volume was calculated using planimetered left ven-
tricular outflow tract area on MRI and Doppler left ventricular outflow tract flow (MRI-Doppler). This approach demonstrated excellent correlation with
MRI stroke volume (C), without significant bias (D).
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Consistent AVA and MPG cutoffs
Based on measurements derived from Doppler stroke vol-
ume, an MPG of 40 mm Hg corresponded to an AVA of 0.77
cm2, and an AVA of 1.0 cm2 corresponded to an MPG of only
24 mm Hg (AVA ¼ 4.85/OMPG; r2 ¼ 0.73; Fig. 5A). When
MRI stroke volume measurements were used to calculate the
AVA, an MPG of 40 mm Hg corresponded to an AVA of
0.97 cm2 and an AVA of 1.0 cm2 corresponded to an MPG of
37 mm Hg (AVA ¼ 6.13/OMPG; r2 ¼ 0.81; Fig. 5B).
Discordant small-area low-gradient aortic stenosis
Using the conventional echocardiographic estimation of
MPG and AVA, and the thresholds for severe disease based on
current guidelines (AVA, 1.0 cm2 and MPG, 40 mm Hg),12,19
56 patients with aortic stenosis (42%) had discordant small-
area low-gradient aortic stenosis (Fig. 6A).
Using a stepwise approach, we first assessed the effect of
using AVA measurements derived from MRI stroke volumes
on this proportion of patients with discordant small-area low-
gradient aortic stenosis. This resulted in 20 patients being
reclassified as having nonsevere aortic stenosis (median aortic
valve calcium score of 3; valvuloarterial impedance, 3.7  0.7
mm Hg/mL/m2), leaving 36 with small-area low-gradient
aortic stenosis (Fig. 6B). Subsequently, when we used the
revised thresholds already described herein (AVA of 1.0 cm2
and MPG of 37 mm Hg), a further 7 patients were reclassified
with severe disease (all had aortic valve calcium score of 4 and
valvuloarterial impedance of 4.5  1.2 mm Hg/mL/m2). This
left only 29 patients with discordant small-area low-gradient
aortic stenosis, a reduction of 48% compared with the original
classification (Fig. 6C). Of these, 3 patients had impaired
systolic function and 2 had a low stroke volume due to small
LV cavity volumes. The remainder appeared to consist of
patients with moderate to severe disease with values for a wide
Figure 3. Left ventricular outflow tract (LVOT) area correlation and Bland-Altman analysis. Although LVOT area estimated using echocardiography
demonstrated a moderate correlation with planimetered LVOT area on magnetic resonance imaging (A), the echocardiographic LVOT area under-
estimated the planimetered area with wide limits of agreement (B).
Figure 4. Aortic valve area corrleation and Bland-Altman analysis. Aortic valve area estimated using Doppler stroke volume and magnetic resonance
imaging-derived stroke volume demonstrated poor agreement and significant underestimation (A), despite excellent correlation (B).
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range of parameters that were intermediate between concor-
dant moderate and severe disease (Supplemental Table S2).
This included the aortic valve calcium score, which was 3 in
48% and 4 in 52% of patients.
Stroke volume estimation and aortic stenosis
classification using the Teichholz formula
In a further analysis, we assessed an alternate echocardio-
graphic method for estimating stroke volumes using the
Teichholz formula.14 Results were similar, with the correla-
tion between echocardiography-estimated and MRI-derived
stroke volumes remaining weak (r2 ¼ 0.16; P < 0.001),
and 51% of patients classified as having discordant small-area
low-gradient aortic stenosis.
Discussion
In this study, we have systematically demonstrated that
echocardiography underestimates the LVOTarea, the LV
Figure 5. Relationship between aortic valve area and mean pressure gradient. The aortic valve area was calculated from the continuity equation
using Doppler stroke volume. An aortic valve area of 1.0 cm2 corresponded to a mean pressure gradient of 24 mm Hg (A). Correcting these values
using the magnetic resonance imaging stroke volume, an aortic valve area of 1.0 cm2 corresponded to a mean pressure gradient of 37 mm Hg (B).
Figure 6. Reclassification of aortic stenosis severity. Using traditional echocardiographic measurements and the recommended severity cutoffs
established in current guidelines (A), 56 patients had discordant small-area low-gradient aortic stenosis. Twenty patients were reclassified to
concordant nonsevere aortic stenosis when cardiovascular magnetic resonance imaging stroke volume was used to estimate aortic valve area (B).
A further 7 patients were reclassified as having concordant severe disease using the revised thresholds of 1.0 cm2 and 37 mm Hg (C). The
corresponding pie charts show the flow states in patients with discordant small-area low-gradient aortic stenosis (stroke volume estimated using
cardiovascular magnetic resonance imaging).
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stroke volume, and as a consequence, the AVA. Moreover we
have demonstrated that there are inconsistencies in the
guideline thresholds of severity with an AVA of 1.0 cm2
corresponding to an MPG of 24 mm Hg based on standard
echocardiographic measures and 37 mm Hg when MRI-
derived stroke volumes are used. Finally we have shown that
if we correct for these 2 factors using the more accurate MRI
estimation of the stroke volume to calculate AVA and revised
thresholds, more than 40% of the patients with small-area
low-gradient aortic stenosis were reclassified as having
concordant measurements.
Two-dimensional and Doppler echocardiography assess-
ments are the predominant methods used worldwide to assess
the severity of aortic stenosis. However, the echocardiographic
estimation of the AVA relies on accurate measurement of
stroke volume. Unfortunately as demonstrated in this study,
echocardiography frequently underestimated the stroke vol-
ume compared with the noninvasive gold-standard measure-
ments made using MRI. As a consequence, echocardiography
would also appear to underestimate the AVA. Our data pro-
vide explanations for these observations. A subgroup of 40
patients had coaxial short-axis cine images of their LVOT.
This allowed accurate and reproducible planimetered mea-
surements of the LVOTarea to be compared with the derived
measurements made using 2-dimensional echocardiographic
diameter measurements. Similar to previous studies,8,9 we
have demonstrated that such echocardiographic measures
underestimate the true LVOTarea in part because of the fact
that the LVOT is frequently elliptical not circular. Indeed,
when Doppler stroke volumes were corrected using the more
accurate planimetered measurements of the LVOTarea, a good
correlation withMRI-derived stroke volumes was subsequently
observed. Further to our analyses, we have also explored using
other echocardiographic indices such as indexed AVA and the
dimensionless index. Unfortunately, these techniques were also
associated with inherent limitations related to the LVOTarea
measurements (see the Evaluation of Aortic Stenosis Classifica-
tion Using Indexed Aortic Valve Area and the Dimensionless Index
section of the Supplementary Material).
Inconsistencies in the MPG and AVA thresholds recom-
mended in the current guidelines are well described.1,10,20
Consistent with previous reports,1,10 our echocardiography
data confirmed an AVA of 1.0 cm2 corresponded to a MPG of
only 24 mm Hg, significantly lower than the threshold of 40
mm Hg stated in current guidelines. Interestingly, this
improved to 37 mm Hg when MRI stroke volume measure-
ments were used to calculate AVA, much closer to the rec-
ommended threshold although still discrepant.
Multiple previous studies have shown that a third of
patients with moderate and severe aortic stenosis have
discordant disease severity according to their AVA and MPG
values. Interest has surrounded this group because of its
ubiquity and the uncertainty in the outcome associated with
these patients. Although some studies have suggested that
patients with small-area low-gradient aortic stenosis have a
prognosis similar to those with moderate disease, others have
indicated the exact opposite and that their outcomes are more
akin to those with severe disease.4,6,7,21
In the final part of the study, we investigated whether the
underestimation of the AVA using echocardiography and
inconsistencies in the guideline thresholds might explain the
ubiquity of patients with small-area low-gradient aortic
stenosis and help resolve the true severity of their disease. We
demonstrated that correcting for these 2 factors reduced the
number of patients with a small-area low-gradient by > 40%.
Of the remaining 29 subjects, 3 had low flow due to an
impaired ejection fraction and 2 had low flow due to small LV
cavity size. The remainder appeared to genuinely sit on the
borderline between moderate and severe disease with param-
eters that were intermediate between those observed in
concordant severe and nonsevere groups. Our data would
therefore indicate that discordance in the assessment of aortic
stenosis severity can be reduced by correcting for AVA
underestimation and inconsistent thresholds, but further
studies are now needed to investigate the long-term outcomes
of patients reclassified using this approach.
Limitations
In this study, assessment of the planimetered LVOTarea
using MRI was only available in 40 patients. However, this
was believed to be a large enough sample size to assess the
inaccuracies associated with LVOT diameter measurements
and the data are consistent with the large and expanding
literature investigating LVOTarea measurements for the sizing
of transcatheter aortic valve bioprostheses.9 Moreover, the
baseline characteristics were similar between these 40 patients
and the entire cohort of patients with aortic stenosis (see the
Baseline Characteristics of the 40 Patients With Planimetered
Left Ventricular Outflow Tract Area on Cardiovascular
Magnetic Resonance section of the Supplementary Material).
We also used echocardiography to assess aortic valve calcifi-
cation. Although this provides important prognostic infor-
mation,15 computed tomography provides a more sensitive
quantification of aortic valve calcification and has recently
been shown to provide differentiation as to the true severity of
patients with small-area low-gradient aortic stenosis.2,22 Phase
contrast MRI is an alternate method to estimate stroke vol-
ume, but this technique is associated with its own problems,
particularly in patients with aortic stenosis in whom complex
aortic flow in the ascending aorta can result in measurement
inaccuracy. This is a particular problem at 3T. However, in an
exploratory analysis, we demonstrated excellent correlation
and agreement between phase contrast and volumetric stroke
volume on MRI (see the Comparison of Doppler, MRI Volu-
metric, and Phase Contrast Stroke Volume Estimation section of
the Supplementary Material). Finally, we were not able to
perform echocardiography and MRI on the same day because
many of our elderly patients could not tolerate both pro-
cedures at the same visit. However, no patient experienced
any cardiac events or changes in medications between the 2
scans and after correcting for inaccuracies in the LVOTarea, an
excellent agreement was observed between MRI and
echocardiography-derived stroke volumes. This would argue
against any significant variability in stroke volumes between
the scans.
Conclusions
Echocardiography underestimated the AVA because of
an underestimation of the LVOTarea and stroke volume,
compared with MRI. These factors, along with inconsistent
AVA and MPG cutoffs in the current guidelines, account
Chin et al. 1071
Aortic Stenosis Classification With MRI
for > 40% of patients with discordant small-area low-gradient
aortic stenosis.
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TABLE S1. CHARACTERISTICS OF PATIENTS WITH AORTIC STENOSIS 
CLASSIFIED BASED ON AORTIC VALVE AREA ESTIMATED USING 





 (n=44) (n=56) (n=28) 
 
P value 
Clinical Characteristics     
Age, years 65±13 72±10 68±11 0.02a 
Males, n (%) 32 (72) 34 (61) 19 (68) 0.44 
Height, cm 169±9 163±8 168±8 <0.01a,b 
Body mass index, kg/m2 29±5 29±5 27±4 0.13 
Body surface area, m2 1.9±0.2 1.8±0.2 1.9±0.2 0.07 
Hypertension, n (%) 27 (61) 40 (71) 16 (57) 0.36 
Diabetes Mellitus, n (%) 9 (20) 6 (11) 3 (11) 0.32 
Coronary artery disease, n (%) 14 (32) 15 (27) 12 (43) 0.33 
Atrial fibrillation, n (%) 0 3 (5) 0 - 
     
Systolic blood pressure, mmHg 147±20 154±20 147±22 0.19 
Echocardiography     
Left ventricular outflow tract (LVOT) 
diameter, cm 
2.19±0.21 1.96±0.19 2.08±0.24 <0.01a,b 
LVOT cross-sectional area, cm2 3.79±0.75 3.05±0.57 3.43±0.78 <0.01a 
LVOT velocity time integral, cm 24.5±4.2 23.0±4.5 22.7±4.3 0.15 
Doppler stroke volume, mL 92±18 70±13 78±19 <0.01a,c 
Doppler stroke volume (indexed), mL/m2 48±10 38±7 42±10 <0.01a,c 
     
Aortic valve area, cm2 1.38±0.38 0.79±0.15 0.69±0.17 <0.01a,c 
Aortic valve area (indexed), cm2/m2 0.72±0.20 0.43±0.08 0.37±0.09 <0.01a,c 
Mean pressure gradient, mmHg 20±8 29±9 54±17 <0.01a,b,c 
Peak aortic velocity, m/s 3.0±0.5 3.7±0.5 4.8±0.6 <0.01 a,b,c 
Dimensionless index 0.36±0.09 0.26±0.05 0.20±0.04 <0.01 a,b,c 
Aortic valve calcium score 3 [2,3] 3 [3,4] 4 [4,4] <0.01 a,b,c 
Valvuloarterial impedance, mmHg•ml-1•m-2 3.6±0.8 4.9±1.1 5.0±1.2 <0.01a,c 
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End-diastolic volume, mL¶ 94±21 82±26 83±23 0.03a 
End-diastolic volume (indexed), mL/m2 ¶ 49±10 45±13 44±12 0.15 
End-systolic volume, mL¶ 42±12 36±14 35±14 0.04 
End-systolic volume (indexed), mL/m2 ¶ 22±6 19±7 19±7 0.11 
Stroke volume, mL¶ 53±12 46±13 48±13 0.04a 
Stroke volume (indexed), mL/m2 ¶ 28±6 25±7 26±7 0.25 
Ejection fraction, %¶ 56±7 57±7 59±8 0.40 
     
Mild mitral regurgitation, n (%) 3 (7) 9 (16) 7 (25) 0.10 
Mild aortic regurgitation, n (%) 18 (41) 27 (48) 12 (43) 0.24 
Cardiovascular Magnetic Resonance     









     
End-diastolic volume, mL 142±30 126±25 139±40 0.03a 
End-diastolic volume (indexed) (EDVi), 
mL/m2 
74±13 69±13 74±19 0.17 
End-systolic volume, mL 47±17 43±15 47±20 0.38 
End-systolic volume (indexed), mL/m2 25±8 23±8 25±10 0.75 
Stroke volume, mL 95±19 83±16 92±26 <0.01a 
Stroke volume (indexed), mL/m2 49±8 45±8 49±12 0.08 
Ejection fraction, % 67±7 66±7 67±7 0.84 
Left ventricular mass (indexed) (LVMi), 
g/m2 
85±18 85±21 99±25 <0.01b,c 
LVMi/EDVi, g/mL 1.17±0.23 1.24±0.24 1.38±0.28 <0.01b,c 
 
¶ Estimated using the Teichholz formula 
‡ Planimetered left ventricular outflow tract area was performed in 40 patients.  One 
patient was classified with large-area high-gradient aortic stenosis 
a P<0.05 between non-severe and small-area low-gradient aortic stenosis  
b P<0.05 between small-area low-gradient and severe aortic stenosis 
c P<0.05 between non-severe and severe aortic stenosis 
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TABLE S2.  CHARACTERISTICS OF PATIENTS WITH DISCORDANT 
SMALL-AREA LOW-GRADIENT AORTIC STENOSIS AFTER CORRECTION 
FOR STROKE VOLUME UNDERESTIMATION AND INCONSISTENT 
THRESHOLDS 
 
  Non-severe Small-area low-gradient Severe 
  (n=61) (n=29) (n=33) 
P value 
Clinical Characteristics         
Age, years 66±13 73±9 72±9 <0.01a,c 
Male, n (%) 44 (72) 15 (52) 20 (61) 0.15 
Height, cm 168±9 161±9 165±8 <0.01a 
Body mass index, kg/m2 29±5 30±5 27±3 0.09 
Body surface area, m2 1.9±0.2 1.8±0.2 1.8±0.2 0.02 
Hypertension, n (%) 38 (62) 21 (72) 22 (67) 0.64 
Diabetes mellitus, n (%) 11 (18) 3 (10) 4 (12) 0.56 
Coronary artery disease, n (%) 18 (30) 7 (24) 17 (52) 0.04 
Atrial fibrillation, n (%) - 3 (10) - - 
       
Systolic blood pressure, mmHg 149±21 151±22 151±23 0.91 
Echocardiography         
Left ventricular outflow tract (LVOT) 
diameter, cm 
2.14±0.21 1.94±0.21 2.02±0.25 <0.01a,c 
LVOT cross-sectional area, cm2 3.64±0.73 3.01±0.63 3.28±0.82 <0.01a 
LVOT velocity time integral, cm 23.6±4.2 23.3±5.1 23.7±4.4 0.93 
Doppler stroke volume, mL 86±19 69±14 77±20 <0.01a 
Doppler stroke volume (indexed), mL/m2 45±10 38±8 42±10 <0.01a 
     
Aortic valve area, cm2 1.24±0.41 0.76±0.16 0.71±0.19 <0.01a,c 
Aortic valve area (indexed), cm2/m2 0.65±0.22 0.42±0.10 0.39±0.10 <0.01 a,c 
Mean pressure gradient, mmHg 21±8 30±5 55±24 <0.01a,b,c 
Peak aortic velocity, m/s 3.1±0.6 3.7±0.3 4.8±0.9 <0.01a,b,c 
Dimensionless index 0.34±0.09 0.26±0.05 0.21±0.05 <0.01a,b,c 
Aortic valve calcium score 3 [2,3]  4 [3,4] 4 [4,4] <0.01a,b,c 
Valvuloarterial impedance, mmHg•ml-1•m-2  4.0±1.0 4.8±1.2 4.9±1.3 <0.01a,c 
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End-diastolic volume, mL¶ 93±25 77±25 83±24 <0.01a 
End-diastolic volume (indexed), mL/m2 ¶ 49±12 42±13 45±13 0.09 
End-systolic volume, mL¶ 42±14 31±13 35±14 <0.01a 
End-systolic volume (indexed), mL/m2 ¶ 22±7 17±7 20±7 0.02a 
Stroke volume, mL ¶ 52±13 45±13 45±11 0.02 
Stroke volume (indexed), mL/m2 ¶ 27±6 25±7 25±7 0.27 
Ejection fraction, % ¶ 56±6 60±7 57±9 0.05a 
     
Mild mitral regurgitation, n (%) 7 (11) 4 (14) 7 (21) 0.44 
Mild aortic regurgitation, n (%) 24 (39) 16 (56) 16 (48) 0.34 
Cardiovascular Magnetic Resonance         







     
End-diastolic volume, mL 142±28 117±18 127±35 <0.01a,c 
End-diastolic volume (indexed) (EDVi), 
mL/m2 74±14 65±9 70±17 0.01
a 
End-systolic volume, mL 47±16 39±10 45±22 0.12 
End-systolic volume (indexed), mL/m2 25±8 22±5 25±11 0.28 
Stroke volume, mL 95±18 78±13 83±21 <0.01a,c 
Stroke volume (indexed), mL/m2 50±9 43±7 45±10 <0.01a 
Ejection fraction, % 67±7 67±6 66±9 0.63 
Left ventricular mass (indexed) (LVMi), 
g/m2 86±21 81±18 93±20 0.06 
LVMi/EDVi, g/mL 1.18±0.22 1.25±0.23 1.37±0.30 <0.01c 
 
¶ Estimated using the Teichholz formula 
‡ Planimetered left ventricular outflow tract area was performed in 40 patients.  Four 
patients were classified with large-area high-gradient aortic stenosis 
a P<0.05 between non-severe and small-area low-gradient aortic stenosis  
b P<0.05 between small-area low-gradient and severe aortic stenosis 
c P<0.05 between non-severe and severe aortic stenosis 
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EVALUATION OF AORTIC STENOSIS CLASSIFICATION USING INDEXED 
AORTIC VALVE AREA 
 
We investigated thresholds of severe aortic stenosis using indexed aortic 
valve area, and the effects on classification using an indexed aortic valve area 
of 0.6 cm2/m2, and mean pressure gradient of 40 mmHg. 
 
Using Doppler stroke volume, an indexed aortic valve area of 0.6 cm2/m2 
corresponded to a mean pressure of 18 mmHg (Figure S1A) while an indexed 
aortic valve area of 0.6 cm2/m2 corresponded to a mean pressure gradient of 
27 mmHg with MRI-derived stroke volume (Figure S1B).  The use of indexed 
aortic valve area did not reduce the number of patients with discordant small-
area low-gradient aortic stenosis with either Doppler stroke volume [61 
patients (46%) compared with the 56 patients (42%) using non-indexed aortic 
valve area] or MRI-derived stroke volumes [52 patients (39%) compared with 
the 36 patients (27%) using non-indexed aortic valve area].  These results are 
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EVALUATION OF USING THE DIMENSIONLESS INDEX IN AORTIC 
STENOSIS CLASSIFICATION 
 
Using a dimensionless index (DI) threshold of <0.25 and mean pressure 
gradient of <40mmHg, 26 patients were classified with discordant low-DI low-
gradient aortic stenosis (20%).  This appears to support our conclusion that 
discordant small-area low-gradient aortic stenosis is largely influenced by left 
ventricular outflow tract area (LVOTarea) estimation.   
 
However, this result has to be interpreted with caution.  The use of DI has 
major limitations precisely because it does not take into account the left 
ventricular outflow tract area (LVOTarea), which is the key factor to consider 
when determining the severity of aortic stenosis (Michelena et al., Heart 2012; 
Baumgartner et al., JASE 2009).  This is perhaps best illustrated with an 
example: 
 
 Aortic valve area = LVOTd2 x 0.785 x DI; DI = LVOTVTI/AVVTI 
 
In a patient with a LVOT diameter (LVOTd) of 2.0 cm and DI of 0.25 (severe 
aortic stenosis), this would translate to an aortic valve area of 0.79 cm2 
(severe aortic stenosis).  However, in another patient with LVOTd of 2.5 cm 
and the same DI of 0.25, this increases the aortic valve area to 1.23 cm2 
(moderate aortic stenosis).  This example illustrates that a DI threshold of 0.25 
may not be appropriate in all patients: in patients with large LVOT, a smaller 
DI threshold for severe disease may be needed (Michelena et al., Heart 2012).  
Indeed, amongst the 26 patients with discordant low-DI low-gradient aortic 
stenosis, 9 patients (35%) had an aortic valve area > 1.0cm2 and they had 
larger mean LVOTd (measured on 2D echocardiography) compared to the 
other 17 patients (2.2±0.2 versus 1.9±0.2 cm, P=0.03). 
 
Chin et al., Aortic stenosis classification with MRI 
Online Supplemental Data 
	   8	  
Accurate estimation of the LVOTarea is therefore critical in assessing aortic 
stenosis severity.  Our study highlights the limitations that echocardiography 
has in making such measurements and how improved stroke volume 
estimation can have important implications in the grading of aortic stenosis. 
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BASELINE CHARACTERISTICS OF THE 40 PATIENTS WITH 
PLANIMETERED LEFT VENTRICULAR OUTFLOW TRACT AREA ON 
CARDIOVASCULAR MAGNETIC RESONANCE 
 
In this study, 40 patients with mild to severe aortic stenosis were randomly 
selected and planimetry of the left ventricular outflow tract area (LVOTarea) was 
performed on cardiovascular magnetic resonance.  The purpose is to 
investigate the effects of accurate LVOTarea measurement on stroke volume 
estimation. 
 
The characteristics of these 40 patients were similar to the entire cohort of 


















Age, years 68±12 69±12 0.64 
Males, n (%) 27 (68) 83 (63) 0.56 
Body surface index, m2 1.9±0.2 1.9±0.2 1.00 
Systolic blood pressure, mmHg 151±21 150±21 0.79 
Heart rate, per min 64±10 64±11 1.00 
Mean pressure gradient, mmHg 37±24 32±16 0.13 
Peak aortic jet velocity, m/s 4.0±1.1 3.7±0.8 0.06 
Aortic valve area, cm2 1.0±0.3 1.0±0.4 1.00 
Indexed end-diastolic volume (EDV), mL/m2 75±21 72±16 0.34 
Indexed end-systolic volume, mL/m2 25±12 24±9 0.57 
Indexed stroke volume, mL/m2 50±12 48±10 0.29 
Ejection fraction, % 67±8 67±7 1.00 
Indexed left ventricular mass (LVM), g/m2 95±28 88±21 0.09 
LV mass/EDV, g/mL 1.29±0.28 1.25±0.26 0.40 
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COMPARISON OF DOPPLER, MRI VOLUMETRIC AND PHASE 
CONTRAST STROKE VOLUME ESTIMATION 
 
An exploratory analysis was performed in 10 patients with aortic stenosis to 
compare Doppler, MRI volumetric (cine) and phase contrast stroke volume.  
Through plane phase contrast velocity mapping was positioned orthogonal to 
the ascending aorta at the level of the bifurcation of the main pulmonary 
artery.  An initial velocity encoding level of 100 cm/s was selected and 
increased in increments of 50 cm/s if aliasing occurs.  The total forward flow 
during systole is computed using the Argus software (Siemens AG Healthcare 
Sector, Erlangen, Germany). 
 
The results are shown in Table S4.  In these 10 patients, there was no 
correlation between Doppler indexed stroke volume and MRI-derived indexed 
stroke volume (r=0.32; P=0.37) and between Doppler indexed stroke volume 
and MRI phase contrast indexed stroke volume (r=0.20; P=0.58).  On the 
other hand, MRI-derived stroke volume and MRI phase contrast demonstrated 
excellent correlation (r=0.87; P=0.001; Figure S2A) and agreement 
(2.4mL/m2; 95% CI -6.8 to 11.6 mL/m2; Figure S2B).   
















#1 34 49 41 Severe 
#2 33 33 32 Severe 
#3 45 34 28 Moderate 
#4 35 35 36 Moderate 
#5 46 37 32 Severe 
#6 54 36 29 Severe 
#7 50 48 45 Mild 
#8 45 42 38 Moderate 
#9 36 30 32 Severe 
#10 49 52 59 Mild 
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Valvular heart disease
High-sensitivity troponin I concentrations are a
marker of an advanced hypertrophic response and
adverse outcomes in patients with aortic stenosis
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Aims High-sensitivity cardiac troponin I (cTnI) assays hold promise in detecting the transition from hypertrophy to heart failure
in aortic stenosis. We sought to investigate the mechanism for troponin release in patients with aortic stenosis and
whether plasma cTnI concentrations are associated with long-term outcome.
Methods
and results
Plasma cTnI concentrations were measured in two patient cohorts using a high-sensitivity assay. First, in the Mechanism
Cohort, 122 patients with aortic stenosis (median age 71, 67% male, aortic valve area 1.0+0.4 cm2) underwent cardio-
vascular magnetic resonance and echocardiography to assess left ventricular (LV) myocardial mass, function, and fibrosis.
The indexed LV mass and measures of replacement fibrosis (late gadolinium enhancement) were associated with cTnI
concentrations independent of age, sex, coronary artery disease, aortic stenosis severity, and diastolic function. In the
separate Outcome Cohort, 131 patients originally recruited into the Scottish Aortic Stenosis and Lipid Lowering
Trial, Impact of REgression (SALTIRE) study, had long-term follow-up for the occurrence of aortic valve replacement
(AVR) and cardiovascular deaths. Over a median follow-up of 10.6 years (1178 patient-years), 24 patients died from a
cardiovascularcause and 60patients hadanAVR.PlasmacTnI concentrationswereassociated withAVRorcardiovascular
death HR 1.77 (95% CI, 1.22 to 2.55) independent of age, sex, systolic ejection fraction, and aortic stenosis severity.
Conclusions In patients with aortic stenosis, plasma cTnI concentration is associated with advanced hypertrophy and replacement
myocardial fibrosis as well as AVR or cardiovascular death.
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Keywords Aortic stenosis † High-sensitivity troponin † Left ventricular hypertrophy † Myocardial fibrosis † Cardiac magnetic
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Introduction
Aortic stenosis is the commonest form of valvular heart disease in the
western world, and its prevalence is expected to double in the next
two decades.1 Current guidelines advocate aortic valve replacement
(AVR) in patients with symptoms and severe valve narrowing.2,3
However, there is apoorcorrelation between the severityof stenosis
and symptom onset making the management of asymptomatic
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patients controversial.2 This apparent discrepancy might in part
be explained by heterogeneity in the hypertrophic response to
aortic stenosis, which itself is an independent marker of an adverse
prognosis.4– 6
Hypertrophy occurs in response to the increased afterload
imposed by aortic valve narrowing on the left ventricle. Initially this
restores wall stress and maintains cardiac performance, but decom-
pensation ultimately ensues and patients develop symptoms, adverse
events, and the need for surgery. The transition from hypertrophy
to heart failure is characterized by progressive cardiomyocyte
death and replacement fibrosis.7 Myocardial fibrosis can be detected
using two cardiovascular magnetic resonance (CMR) techniques: late
gadolinium enhancement (replacement fibrosis) and T1 mapping
(diffuse interstitial fibrosis) with data indicating that the former pro-
vides useful prognostic information.5,8 However, to date, a marker of
myocyte cell death has been lacking.
Cardiac troponin is a structural protein present in cardiac muscle,
with plasma troponin concentrations considered a highly specific
marker for myocardial injury.9 Recent advances in assay technology
have greatly improved sensitivity, now allowing quantification of
troponin with a high degree of precision at extremely low plasma
concentrations.10
In this study, we hypothesized that detection of myocardial injury
by high-sensitivity troponin assays may provide an early indicator of
left ventricular (LV) decompensation and be associated with future
adverse events in patients with aortic stenosis.
Methods
Two cohorts of stable patients with aortic stenosis were recruited from
cardiology outpatient clinics across three centres in Southeast Scotland.
First, we determined the association between plasma cardiac troponin I
(cTnI) concentrations and LV functional and structural abnormalities on
cardiac magnetic resonance (Mechanism Cohort), and second, we exam-
ined the prognostic role of plasma cTnI concentrations in patients with
aortic stenosis (Outcome Cohort). The study was conducted in accord-
ance with the Declaration of Helsinki and approved by the local research




Patients with mild to severe aortic stenosis were recruited prospectively.
We excluded patients who had other significant (moderate or severe)
valvular heart disease or cardiomyopathies (acquired or inherited).
Presence of coronary artery disease was defined by previous infarction,
clinical symptoms of angina (in those with mild or moderate aortic sten-
osis), evidence of myocardial ischaemia, or .50% luminal stenosis in
a major epicardial vessel. In addition, thirteen age- and sex-matched
healthy volunteers without clinically significant heart disease were
recruited from the local community.
Outcome Cohort
The Outcome Cohort comprised patients recruited into the Scottish
Aortic Stenosis and Lipid Lowering Trial, Impact of REgression
(SALTIRE) study. The study design and inclusion and exclusion criteria
have been described previously.11 In brief, from March 2001 to April
2002, 155patients with asymptomaticmoderate to severe aortic stenosis
were randomly assigned to receive either atorvastatin 80 mg or placebo
once daily. Patients were excluded if they were already on a statin, if AVR
was planned, or if they had moderate or severe LV systolic impairment.
Only patients with plasma samples available for cTnI analysis were
included in the present analysis.
Blood sampling and analysis
In the Mechanism Cohort, brain natriuretic peptide (BNP) concentration
was analysed with the Triage BNP assay (Biosite, Inc., San Diego, CA,
USA). The inter-assay coefficient of variation was 10% at 28.8 pg/mL,
with a detection range of 5–1300 pg/mL.12 In the Outcome Cohort,
N-terminal proBNP (NT-proBNP) concentration was measured using
the Elecysys 2010 analyzer (Roche Diagnostics Ltd, Lewes, UK). This
assay has ,0.001% cross-reactivity with bioactive BNP, and the inter-
assay coefficients of variation range from 0.9 to 5.5%.13
Plasma cTnI concentrations were determined by the ARCHITECT
STAT high-sensitivity cTnI assay (Abbott Laboratories, Abbott Park, Il,
USA) in both cohorts. The lower limit of detection of this assay is
1.2 ng/L;10 the 99th percentile from a healthy reference population is
26 ng/L.14 Our inter-assay coefficient of variation is 10% at 6 ng/L
(see Supplementary material online).
Echocardiography
All participants underwent a comprehensive echocardiographic assess-
ment to determine the severity of aortic stenosis. Peak aortic jet velocity
and mean pressure gradient were measured by velocity time integral
spectral Doppler, and the aortic valve area derived using the continuity
equation. The severity of aortic stenosis was assessed and classified
according to the European Association of Echocardiography/American
Societyof Echocardiology guidelines.15 Trans-mitral early (E) and latedia-
stolic velocities and deceleration time of early filling velocity were mea-
sured at the tips of the mitral valve leaflets using pulse-wave Doppler.
Early (e′) diastolic velocities of the medial and lateral mitral annulus
were measured using pulse-wave tissue Doppler imaging. Diastolic func-
tion was determined using the E/e′ ratio.
Cardiovascular magnetic resonance
in the Mechanism Cohort
Cardiovascular magnetic resonance was performed using a 3T scanner
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen,
Germany). Short-axis cine images were obtained using a balanced
steady-state free precession sequence from the mitral valve annulus to
the apex (8-mm parallel slices with 2 mm spacing) for the assessment
of LV function and volumes. LV volumes, mass, and ejection fraction
were assessed using dedicated software (Argus Ventricular Function,
Siemens AG Healthcare Sector, Erlangen, Germany), and values were
indexed to body surface area.
Focal myocardial fibrosis was assessed using the late gadolinium
enhancement (LGE) technique, performed 10–15 min following
0.1 mmol/kg of gadobutrol (Gadovist, Bayer Pharma AG, Germany).
Two approaches were used: an inversion-recovery fast gradient echo se-
quence and a phase-sensitive inversion-recovery sequence (performed
in two phase-encoding directions for the exclusion of artefact). The
inversion time was optimized to achieve satisfactory nulling of the myo-
cardium. Assessment for the presence of mid-wall LGE was determined
visually and independently by two experienced operators. The extent of
mid-wall LGE was quantified with QMASS software (Medis Medical
Imaging Systems, Leiden, the Netherlands) using a signal intensity thresh-
oldof .2 standarddeviations above themeanvalue in an adjacentnormal
region of myocardium. Areas of inversion artefact, or contamination by
blood pool or epicardial fat, were excluded.
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Myocardial T1 mapping was performed to investigate diffuse
myocardial fibrosis using the Modified Look-Locker Inversion-recovery
sequence (flip angle 358; minimum TI 100 ms; TI increment of 80 ms;
time delay of 150 ms with a heartbeat acquisition scheme of 3–3–5).16
We have previously described a standardized approach for the analysis
of myocardial extracellular volume fraction (ECV) in patients with
aortic stenosis, demonstrating that it offers improved reproducibility
(+3%) and the ability to identify disease states compared with other
T1 mapping techniques.17 In brief, regions of interest were drawn
around the myocardium on short-axis pre-contrast motion-corrected
myocardial T1 maps and then applied to corresponding 20-min post-
contrast maps with minor adjustments made to avoid partial volume
effects and artefact (OsiriX version 4.1.1, Geneva, Switzerland). Extracel-
lular volume fraction values were calculated according to: ECV ¼
[DR1myocardium/DR1blood2pool] × [1-haematocrit], where DR1 ¼ (1/
post-contrast T1-1/pre-contrast T1). Haematocrit was determined at
the time of CMR.
Computed tomography in the Outcome
Cohort
Computed tomography calcium scoring of the coronary arteries and
aortic valve was performed on ECG-gated non-contrast scans using a
double helix scanner (Twin II Flash, Philips Medical Systems). All images
were analysed by a single operator using the Picker Cardiac Scoring soft-
ware as previously described.11
Follow-up in the Outcome Cohort
Clinical outcomes were obtained and adjudicated by two independent
investigators blinded to plasma cTnI and BNP concentrations. All
in-hospital and community deaths were captured in a comprehensive
national database: the General Register of Scotland. Cardiovascular
death was based on the cause of death stated on the death certificate.
We defined cardiovascular death as death due to myocardial infarction,
sudden cardiac death, heart failure, stroke, death due to cardiovascular
procedures, and death due to other cardiovascular causes. Each death
was classified as cardiac or non-cardiac by two independent investigators
andanydiscrepancyresolvedbyconsensus.All events wereconfirmedby
independent review of each patient’s electronic healthcare record where
available. Surgical AVR (no patients underwent transcatheter aortic valve
implantation in the follow-up period) was determined from individual
patient medical records. All patients in the Outcome Cohort were
managed in the tertiary cardiac centre, where patients are reviewed at
a multi-disciplinary meeting prior to undergoing cardiac surgery. Only
patients with established indications were referred for AVR according
to the European Society of Cardiology recommendations.2,18
Statistical analysis
Baseline characteristics are reported as percentages for categorical
variables, mean+ standard deviation or median [interquartile range],
as appropriate. We used one-way analysis-of-variance to compare con-
tinuous parametric data and the Kruskall–Wallis test for non-parametric
data. Chi-square tests were used for categorical baseline characteristics.
Analyses were performed in R version 2.15.2 (Vienna, Austria) and SPSS
Version 20.0.0 (Armonk, NY, USA: IBM Corp). Statistical significance was
taken as a two-sided P , 0.05.
Mechanism Cohort
We assessed the association of plasma cTnI concentrations with mea-
sures of aortic stenosis and ventricular remodelling using univariate and
multivariable linear regression models. Plasma cTnI concentrations
were log-transformed as this variable was highly skewed.
Outcome Cohort
Kaplan–Meier analysis was performed across tertiles of cTnI concentra-
tions. To accommodate competing risks, the association between time to
AVR or cardiovascular deaths and plasma cTnI concentrations (log-
transformed [base 2]) wasmodelled as a composite endpoint in Coxpro-
portional hazard models.
Furthermore, we examined whether relative change in cTnI concen-
trations at 1 year (cTnI at 1 year—baseline cTnI, both log-transformed)
was associated with increased odds of an event at 3-year and 5-year
follow-up independent of baseline cTnI concentrations (results in Sup-
plementary material online).
Results
We recruited 122 patients into the Mechanism Cohort (71 [65–77]
years, 67% males, aortic valve area 1.0+0.4 cm2) and analysed 131
patients in the Outcome Cohort (69 [62–75] years, 70% males,
aortic valve area 1.1+0.4 cm2) (Tables 1 and 2). Thirteen healthy
volunteers were recruited, who were well matched in terms of age
(65 [57–75] years) and sex (62% male) compared with the other
groups and did not have any history of diabetes mellitus, hyperten-
sion, or coronary artery disease.
Plasma cTnI concentrations above the lower limit of detection of
1.2 ng/L were present in 98% of our patients with aortic stenosis
and increased in both cohorts compared with the healthy volunteers
(Mechanism Cohort 6.6 [3.8–12.0] ng/L; Outcome Cohort 7.6 [5.7–
13.2] ng/L; healthy volunteers 3.2 [1.3–11.0] ng/L). The distribution
of plasma cardiac troponin I concentrations was skewed in a similar
pattern across the two cohorts (see Supplementary material
online). There were 10 patients (8.1%) in the Mechanism Cohort
and 10 patients (7.6%) in the Outcome Cohort with plasma cTnI
concentrations of .26 ng/L (the 99th percentile derived from the
healthy reference population). There was no difference in renal
function across tertiles of cTnI in patients with aortic stenosis.
Mechanism for increased cardiac
troponin I concentrations
In the Mechanism Cohort, patients with aortic stenosis had an
increased LV mass index compared with healthy controls, although
there was no difference in LV volumes or ejection fraction
(Table 1). Furthermore, these patients had higher ECV values
(27.7+ 2.5 vs. 25.9+1.6%, P ¼ 0.01), and 35 patients (28%) had a
mid-wall pattern of LGE: an observation not seen among the
healthy volunteers (Figure 1).
Plasma cTnI concentrations correlated with LV mass index, inde-
pendent of coronary artery disease status (r ¼ 0.50, P , 0.001;
Figure 2). A weaker correlation was also observed between
plasma cTnI concentrations and peak aortic jet velocity (r ¼ 0.32,
P , 0.001). Furthermore, patients with aortic stenosis and mid-wall
LGEhada two-fold increase inplasmacTnI concentrations compared
with those without (9.5 [5.7, 20.3] ng/L vs. 4.3 [3.3, 7.9] ng/L,
P ¼ 0.02; Figure 3).
With univariate analysis, age, mean pressure gradient, mean e′, the
LV mass index, and measures of both diffuse and replacement fibrosis
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were all associated with plasma cTnI concentrations (Table 3; all
P , 0.05). However, only age, LV mass index, and %LGE were inde-
pendently associated with plasma cTnI concentrations (Model 1;
Table 3).
Interestingly, there was no difference in plasma cTnI concentra-
tions between patients with and without coronary artery disease
(6.9 [4.0, 13.5] ng/L vs. 6.2 [3.5, 10.0] ng/L, P ¼ 0.28). This was sup-
ported by data from the Outcome Cohort where no correlation
was observed between the coronary calcium scores and plasma
cTnI concentrations (r ¼ 20.03, P ¼ 0.71).
Prognostic value of cardiac troponin I
concentrations
Patients in the Outcome Cohort were stratified by tertiles of plasma
cTnI concentration (Table 2). In comparison with the lowest tertile,
patients in the highest tertile were older (70+9 vs. 64+12 years,
P ¼ 0.03) and had an increased ventricular mass (393+100 vs.
327+111 g, P ¼ 0.02). However, there were no differences in co-
morbidity, severity of aortic stenosis, or coronary calcium scores
across the tertiles (P . 0.1 for all; Table 2).
Over a median of 10.6 years of follow-up (1178 patient-years), 60
patients had an AVR, 24 died from a cardiovascular cause, and 47 died
fromnon-cardiovascular causes. Ten-yearevent-free survival rate for
AVR or cardiovascular deaths differed across the tertiles of cTnI con-
centrations (log rank test for trend, P ¼ 0.016, Figure 4). Plasma cTnI
concentration was associated with an increased risk of AVR or
cardiovascular deaths in unadjusted analysis (HR 1.65 per two-fold
increment in cTnI concentration; 95% CI, 1.15–2.38, P ¼ 0.007)
with minimal attenuation in the effect estimate after adjusting for
age, sex, and ejection fraction (Table 4). Moreover, this association
persisted after further adjustment for severity of aortic stenosis
(HR 1.77; 95% CI, 1.22–2.35, P ¼ 0.002) as well as the coronary
artery and aortic valve calcium scores (HR 2.10; 95% CI, 1.22–
3.61, P ¼ 0.007).
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Table 1 Baseline characteristics of patients with aortic stenosis in the Mechanism Cohort
Healthy volunteers (n 5 13) Mechanism Cohort (n 5 122) P-value
Clinical characteristics
Age, years 65 [57, 75] 71 [65, 77] 0.13
Male sex, n (%) 8 (62) 82 (67) 0.76
Diabetes mellitus, n (%) 0 14 (11) –
Hypertension, n (%) 0 78 (63) –
CAD, n (%) 0 41 (33) –
SBP, mmHg 148+12 149+20 0.35
NYHA class, n (%)
I 13 (100) 63 (52) –
II 0 35 (28)
III 0 24 (20)
Creatinine, mmol/L 69+8 78+17 0.06
Cardiac troponin I concentration, ng/L 3.2 [1.3, 11.0] 6.6 [3.8, 12.0] 0.03
BNP, pg/mL 10.3 [5.6, 18.1] 26.4 [10.6, 53.9] 0.009
Echocardiography
Vm, m/s 1.4+0.2 3.7+0.9 ,0.001
MPG, mmHg 4+1 32+18 ,0.001
AVA, cm2 2.4+0.7 1.0+0.4 ,0.001
Valvulo-arterial impedance, mmHg/mL/m2 4.5+1.1 4.5+1.2 0.96
Mean e′, cm/s 8.1+2.7 6.2+1.9 0.001
Mean E/e′ 7.9+2.2 14.8+8.1 0.003
Cardiac MRI
Indexed EDV, mL/m2 73+13 72+14 0.71
Indexed ESV, mL/m2 27+7 24+9 0.28
Indexed SV, mL/m2 46+7 48+9 0.68
Ejection fraction, % 64+3 67+7 0.12
Indexed LVM, g/m2 70+14 89+22 0.004
LVM/EDV, g/mL 0.96+0.13 1.26+0.28 ,0.001
ECV, % 25.9+1.6 27.7+2.5 0.01
CAD, coronary artery disease; SBP, systolic blood pressure; BNP, brain natriuretic peptide; Vm, peak aortic jet velocity; MPG, mean pressure gradient; AVA, aortic valve area;
EDV, end diastolic volume; ESV, end systolic volume; LVM, left ventricular mass; ECV, extracellular volume fraction; %LGE, amount of late gadolinium enhancement.
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Mechanism and prognosis associated
with BNP concentrations
Serum BNP concentrations were higher in patients with aortic sten-
osis compared with healthy volunteers (26.4 [10.6,53.9] vs. 10.3
[5.6,18.1] ng/mL, P ¼ 0.009; Table 1). In patients with aortic stenosis,
BNP concentrations increased with age, disease severity, diastolic
dysfunction, LV mass index myocardial fibrosis, the presence of cor-
onary artery disease, and symptoms (all P , 0.05; see Supplementary
material online). However, on multivariable analysis, only age was sig-
nificantly associated with BNP concentrations (P , 0.001; see Sup-
plementary material online).
In the Outcome Cohort, NT-proBNP was not associated with
AVR or cardiovascular deaths in both unadjusted (HR 1.15 per
two-fold increment in NT-proBNP concentration; 95% CI, 0.86–
1.53, P ¼ 0.34) and adjusted analyses (see Supplementary material
online). Importantly, NT-proBNP concentration did not modify the
association between troponin and time to AVR or cardiovascular
deaths (HR 1.60; 95% CI 1.10–2.34, P ¼ 0.01).
Discussion
This is the first dataset to explore mechanisms and outcomes asso-
ciated with cTnI concentrations using a high-sensitivity assay in
patients with aortic stenosis. In more than 250 patients with aortic
stenosis, we have demonstrated that levels are detectable in 98%
of subjects and increased compared with age- and sex-matched
healthy volunteers. Plasma cTnI concentrations were not associated
with the presence of co-existent coronary artery disease or the
severity of valve narrowing on multivariable analysis. Instead,
plasma cTnI concentrations demonstrated a close association with
the magnitude of LV hypertrophy and the presence of mid-wall myo-
cardial fibrosis. Moreover, high-sensitivity plasma cTnI concentration
showed an independent association with long-term risk of AVR or
cardiovascular deaths. We therefore believe that high-sensitivity
plasma cTnI concentrations hold potential as an objective marker
of LV decompensation in patients with aortic stenosis and as a poten-
tial early trigger to AVR.
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Table 2 Characteristics of patients in the Outcome Cohort by tertiles of troponin I concentrations







(n 5 131) (n 5 42) (n 5 45) (n 5 44)
Clinical characteristics
Age, years 67+10 64+12 69+10 70+9 0.03
Male sex, n (%) 91 (70) 24 (57) 32 (71) 35 (79) 0.08
Diabetes Mellitus, n (%) 4 (3) 1 (2) 1 (2) 2 (5) –
Hypertension, n (%) 66 (50) 18 (43) 22 (49) 26 (59) 0.31
CAD, n (%) 22 (16) 6 (14) 7 (16) 9 (21) 0.72
SBP, mmHg 145+20 139+17 148+21 146+19 0.07
NYHA class, n (%)
I 117 (89) 38 (90) 41 (91) 38 (86) 0.53
II 14 (11) 4 (10) 4 (9) 6 (14)
Creatinine, mmol/L 91+21 86+17 92+20 95+25 0.12
NT-pro-BNP, pg/mL 198.0 [113.5, 530.5] 129.5 [76.3, 228.0] 180.0 [89.0, 416.0] 507.0 [181.5, 1103.0] 0.008
Echocardiography
Vm, m/s 3.4+0.7 3.4+0.6 3.4+0.6 3.5+0.7 0.45
MPG, mmHg 26+11 25+10 25+10 28+13 0.35
AVA, cm2 1.1+0.4 1.0+0.4 1.1+0.4 1.0+0.4 0.72
Indexed AVA, cm2/m2 0.5+0.2 0.5+0.2 0.6+0.2 0.5+0.2 0.66
LVM, g 357+107 327+111 350+102 393+100 0.02
Indexed LVM, g/m2 180+50 165+54 172+49 196+49 0.06
Fractional shortening, % 40+8 42+9 42+8 37+6 0.004
Ejection fraction, % 70+10 72+11 72+9 66+8 0.007
LVH, n (%) 109 (95) 34 (81) 36 (80) 39 (89) 0.49
Impaired LVEF ,50%, n (%) 4 (3) 1 (2) 2 (4) 2 (5) 0.84
Computed tomography
Coronary calcium score, log AU 1.6+1.3 1.5+1.3 1.5+1.3 1.8+1.1 0.53
Aortic valve calcium score, log AU 3.6+0.6 3.6+0.5 3.6+0.5 3.7+0.8 0.61
CAD, coronary artery disease; SBP, systolic blood pressure; BNP, brain natriuretic peptide; Vm, peak aortic jet velocity; MPG, mean pressure gradient; AVA, aortic valve area; EDV, end
diastolic volume; ESV, end systolic volume; LVM, left ventricular mass; LVH, left ventricular hypertrophy, based on ASE/EAE sex-specific criteria; LVEF, left ventricular ejection fraction.
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Aortic stenosis is defined not only by the development of progres-
sive valve narrowing but also by the LV hypertrophic response that
ensues. Whilst this initially restores wall stress, decompensation
due to progressive cell death and fibrosis ultimately occurs and
patients transition from hypertrophy to heart failure.4 Because of
the associated adverse prognosis, current guidelines recommend
surgery in patients with severe stenosis and evidence of such decom-
pensation, detected either on the basis of symptom development or
an ejection fractionof ,50%. Unfortunately, symptoms areoften fre-
quently difficult to assess whereas an ejection fraction of ,50%
Figure 1 Comparison of two patients with severe aortic stenosis. Both had similar severity of aortic valve narrowing (peak aortic jet velocity in
Patient A was 4.8 m/s and Patient B 5.1 m/s) and neither had significant coronary artery disease. However, the high-sensitivity troponin I concen-
tration was more than four-fold higher in Patient A (11.9 ng/L) compared with Patient B (2.5 ng/L), consistent with the more advanced hypertrophic
response observed in this patient (left ventricular mass index in Patient A was 114 g/m2 and Patient B was 81 g/m2). Furthermore, Patient A had
evidence of focal mid-wall fibrosis on late gadolinium imaging (LGE) and myocardial T1 mapping (Patient B did not) and more extensive collagen
staining with picrosirius red staining on myocardial biopsy.
Chin et al.Page 6 of 10







occurs late in the disease process and is often irreversible. There is
therefore emerging interest in developing novel, objective biomar-
kers of decompensation for patients with aortic stenosis. Data
from our study suggests that troponin has the potential to be such
a marker.
Todate elevated cardiac troponin has been considered the sine qua
non for the diagnosis of myocardial infarction.19 However, marked
improvements in assay sensitivity now allow quantification of
plasma cTnI concentrations in the majority of the healthy popula-
tion.10 In our study, cTnI was detectable in 98% of patients with
aortic stenosis and exceeded the recommended diagnostic threshold
for myocardial infarction in 7.9%. Patients with stable coronary
disease have been reported to have higher plasma troponin concen-
trations, with elevated levels being associated with long-term cardio-
vascular risk.20 However in our cohort of patients with aortic
stenosis, there were no differences in plasma troponin concentra-
tions between those with and without coronary artery disease.
Instead plasma troponin concentrations were independently asso-
ciated with an advanced hypertrophic response and replacement
myocardial fibrosis. Indeed, the latter occurred over and above the
effects of LV mass, supporting our hypothesis that cTnI release
relates to the myocardial injury that accompanies ventricular decom-
pensation and myocardial fibrosis.
The poor prognosis associated with increased troponin concen-
trations offers further support for this model. At 10 years, more
than a half of patients in the highest tertile of plasma cTnI had under-
gone an AVR or died from cardiovascular disease. Moreover, plasma
cTnI concentrations were associated with AVR or cardiovascular
deaths, independent of the burden of coronary atherosclerosis
(as assessed using coronary calcium scoring) as well as age, sex,
Figure 2 Correlation between indexed left ventricular mass and plasma cardiac troponin I concentrations (log-transformed). Similar correlation
was seen in patients with (A) and without (B) coronary artery disease.
Figure 3 Patients with aortic stenosis and mid-wall late gadolin-
ium enhancement (LGE)had a two-fold increase in cardiac troponin
I concentrations compared with those without LGE and age- and
sex-matched healthy patients.
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systolic ejection fraction, echocardiographic measures of aortic
stenosis severity, and the aortic valve calcium score.
A recent study demonstrated an association between high-
sensitivity cardiac troponin T concentrations and echocardiographic
measures of LV modelling in aortic stenosis.21 Our data confirm and
extend these findings using CMR, which has allowed us to investigate
the remodelling response in greater detail and crucially assess the re-
lationship with myocardial fibrosis, thereby providing additional
mechanistic data. We therefore believe that the plasma cTnI concen-
tration measured by a high-sensitivity assay has considerable poten-
tial as an early biomarker of LV decompensation and as a powerful
prognostic tool in patients with aortic stenosis. Moreover, this test
is inexpensive and easy to perform making any future transition into
routine clinical practice readily achievable. However, considerable
overlap was observed between patients with aortic stenosis and
ourcontrol cohort.This is perhapsunsurprising, givencTnI is released
as a consequence of a wide range of myocardial insults. A future strat-
egy where asymptomatic aortic stenosis patients with elevated or
increasing plasma troponin concentrations subsequently proceed
to CMR for confirmation of myocardial fibrosis and LV
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Univariate and multivariable linear regression analysis to examine association of variables with plasma cardiac
troponin I concentrations







P-value Relative change in
troponin I concentration
(95% CI)




Age, per 10 years 1.32 (1.07–1.44) 0.004 1.49 (1.14–1.80) 0.002 1.36 (1.09–1.72) 0.006
Male sex 1.31 (0.90–1.92) 0.16 0.79 (0.44–1.42) 0.44 0.80 (0.46–1.39) 0.42
Diabetes mellitus 0.92 (0.52–1.61) 0.76
Hypertension 1.21 (0.83–1.74) 0.33
CAD 1.20 (0.82–1.75) 0.35 1.01 (0.58–1.73) 0.96 1.17 (0.72–1.91) 0.53
MPG, per 10 mmHg 1.17 (1.02–1.35) 0.02 0.92 (0.79–1.06) 0.27 0.93 (0.73–1.06) 0.28
Mean e′, cm/s 0.86 (0.78–0.95) 0.002 1.08 (0.93–1.27) 0.30 1.02 (0.88–1.19) 0.78
Indexed LVM,
per 10 g/m2
1.23 (1.15–1.32) ,0.001 1.34 (1.15–1.55) ,0.001 1.41 (1.23–1.62) ,0.001
%LGE, % 1.13 (1.08–1.17) ,0.001 1.11 (1.03–1.19) 0.006
ECV, % 1.15 (1.07–1.23) ,0.001 1.11 (1.00–1.21) 0.05
See Table 1 for abbreviations.
Figure 4 Ten-year event-free survival for composite endpoint of
aortic valve replacement or cardiovascular death by tertiles of
cardiac troponin I concentrations. Patients in the highest tertile
were associated with lower survival rates compared with patients
in the other tertiles (log rank test for trend, P ¼ 0.016).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Hazard ratios predicting time to valve
replacement or cardiovascular death for troponin I
concentrations in adjusted and unadjusted analyses
Model Hazard ratio (95% CI) P-value
Model 1 1.65 (1.15–2.38) 0.007
Model 2 1.61 (1.11–2.35) 0.01
Model 3 1.63 (1.11–2.38) 0.01
Model 4 1.77 (1.22–2.55) 0.002
Model 5 2.10 (1.22–3.61) 0.007
Model 1—unadjusted; Model 2—adjusting for age and sex; Model 3—as model 2
additionally adjusting for systolic ejection fraction; Model 4—as model 2 additionally
adjusting for mean pressure gradient; Model 5—as model 2 additionally adjusting for
coronary and aortic valve calcium score.
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decompensation is therefore attractive. Large-scale prospective
studies are now required to investigate the use of these two biomar-
kers in the management and risk stratification of patients with aortic
stenosis and whether the above approach might identify asymptom-
atic patients who would benefit from early surgery.
In contrast to troponin, BNP did not have prognostic value in our
study. BNP is an endogenous cardiac hormone released in response
to increasing LV wall stress and most commonly used in the assess-
ment of patients with heart failure. It is therefore only likely to be
released late in the transition from hypertrophy to heart failure,
making it of limited value in detecting signs of early decompensation
in asymptomatic patients. Given that this is the group in whom novel
biomarkers of LV decompensation are most likely to be useful, we
believe that troponin holds greater clinical promise than BNP.
Limitations
CMR was not available at the inception of the SALTIRE study. There-
fore, we needed to recruit another patient population to investigate
the mechanism for troponin release in aortic stenosis. However,
plasma cTnI concentrations in the Outcome Cohort also displayed
a close association with LV mass determined by echocardiography
and were unrelated to the burden of coronary atherosclerosis or
the severity of valvular stenosis. Similar mechanisms would therefore
seem to govern cTnI release across both groups. Another limitation
is the lack of more sensitive markers of LV systolic dysfunction in
the Mechanism Cohort, for example CMR tagging techniques.
However, we elected not to perform these due to concerns about
lengthening the scanning protocol in this elderly cohort of patients
and compromising the detection of myocardial fibrosis. Finally, data
on short-term biological variability (the change in concentration
from one occasion to another) are very limited in disease states.
However, we do not anticipate significant short-term variability in
chronic conditions such as aortic stenosis, although this will require
further validation.
Conclusions
In patients with aortic stenosis, plasma cTnI concentrations are a
marker of LV decompensation and myocardial fibrosis that are asso-
ciated with cardiovascular deaths and AVR. High-sensitivity troponin
assays hold major promise as a future clinical tool for patients with
this condition.
Supplementary material
Supplementary material is available at European Heart Journal online.
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HIGH-SENSITIVITY TROPONIN I CONCENTRATIONS ARE 
A MARKER OF AN ADVANCED HYPERTROPHIC 
RESPONSE AND ADVERSE OUTCOMES IN PATIENTS 
WITH AORTIC STENOSIS 
 
ONLINE SUPPLEMENTAL DATA 
	   1	  
1. Distribution of high-sensitivity plasma cardiac troponin I 
concentrations in the Mechanism and Outcome cohorts of patients 
with aortic stenosis 
 
Plasma cardiac troponin I concentrations were above the limit of 
detection in 98% of our patients with aortic stenosis in both cohorts, and 
exceeded the recommended diagnostic threshold for myocardial 
infarction (> 26 ng/L) in 8%.  The distribution of plasma troponin I 
concentrations in the two cohorts was similar (Figure S1). 
 
FIGURE S1 
	   2	  
2. Exploratory analysis of 1 year change in cardiac troponin I 
concentrations and adverse outcomes at 3 and 5 years 
 
Among a subset of patients in whom troponin was measured more than 
once and who were event-free at one year, we explored the association 
between both baseline troponin and change in troponin from baseline to 
year 1 with the odds of valve surgery or death during subsequent follow-
up.  
 
Serial plasma cardiac troponin I concentrations were available for 69 
patients (52%).  Cardiac troponin I (cTnI) concentrations at baseline and 
one year were strongly correlated (r=0.87, P<0.001). Sixteen (23%) 
patients had an event within 3 years and 25 (41%) had an event within 5 
years of follow-up.  Associations in the same direction were evident for 
both 3-year and 5-year events for both baseline troponin (two-fold 
increase OR 1.73 (1.11-2.89), P=0.02 and OR 1.39 (0.95-2.16), P=0.11, 
respectively) and difference in troponin from baseline (2-fold increase OR 
3.19 (1.33-8.62), P=0.01 and 1.58 (0.75-3.47), P=0.23, respectively) 
although the associations met the conventional cut-off for statistical 
significance for 3-year event rates only. 
 
	   3	  
3. Analytical variability of high-sensitivity cardiac troponin I 
assay 
 
Precision profiling of the ARCHITECT STAT high-sensitivity troponin I assay 
was performed in 248 samples across 18 healthy controls.  The inter-assay 
coefficient of variation (CV) for duplicate samples is 10% at 6 ng/L and 20% at 
1.5 ng/L. 
 
	   4	  
4. Mechanism and prognosis of brain natriuretic peptide in 
patients with aortic stenosis 
 
In the Mechanism Cohort, brain natriuretic peptide (BNP) concentration 
was increased in patients with coronary artery disease (Figure S2) and 
worse symptoms (Figure S3); and associated with age, severity of aortic 
stenosis, increased left ventricular mass index, diastolic dysfunction and 
extent of myocardial fibrosis.  However, only age was strongly associated 
with BNP concentration in both models on the multivariable analysis 
(Table S1).  In the Outcome Cohort, N-terminal pro-BNP was not 
associated with adverse cardiac events with both unadjusted and 
adjusted analyses (Table S2).  
 
FIGURE S2 
In patients with aortic stenosis, brain natriuretic peptide (BNP) 




	   5	  
FIGURE S3 
Brain natriuretic peptic (BNP) concentrations were increased across New 
York Heart Association (NYHA) class in patients with aortic stenosis.  Of 
note, all patients in NYHA III had detectable BNP concentrations (range 
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TABLE S2 
Hazard ratios for time to valve replacement or cardiovascular death for N-
terminal pro-brain natriuretic peptide concentrations in adjusted and 
unadjusted analyses 
 
Model Hazard ratio (95%CI) P value 
Model 1* 1.15 (0.86 to 1.53) 0.34 
Model 2† 1.14 (0.80 to 1.60) 0.47 
Model 3‡ 1.13 (0.80 to 1.60) 0.49 
 
*Model 1 – unadjusted; †Model 2 – adjusting for age and sex; ‡Model 3 – 
as Model 2 with additional adjusting for dyspnea (NYHA >1) 
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Aortic stenosis is characterized by progressive valve nar-rowing of and secondary changes in the myocardium.1 In 
response to increased afterload, left ventricular hypertrophy 
(LVH) can develop to maintain wall stress and cardiac func-
tion. Although this process appears to be compensatory in the 
early stages, preclinical studies have suggested that cardiac 
performance can be preserved in the absence of hypertrophy.2,3 
Moreover, the LVH response ultimately decompensates with 
progressive cell death and fibrosis, driving the transition to 
symptoms, heart failure, and adverse cardiovascular events.1,4,5 
There is therefore considerable interest in identifying early, 
objective markers of this decompensation that might identify 
asymptomatic patients who would benefit from early valve 
replacement.
Clinical Perspective on p 1616
ECG strain is a well-recognized marker of LVH. However, 
the exact mechanism underlying the characteristic ST- and 
T-wave abnormalities associated with this pattern is uncertain. 
In this study, we hypothesized that ECG strain is a marker of 
Background—ECG left ventricular hypertrophy with strain is associated with an adverse prognosis in aortic stenosis. We 
investigated the mechanisms and outcomes associated with ECG strain.
Methods and Results—One hundred and two patients (age, 70 years [range, 63–75 years]; male, 66%; aortic valve area, 
0.9 cm2 [range, 0.7–1.2 cm2]) underwent ECG, echocardiography, and cardiovascular magnetic resonance. They made 
up the mechanism cohort. Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) 
and T1 mapping (diffuse fibrosis). The relationship between ECG strain and cardiovascular magnetic resonance was then 
assessed in an external validation cohort (n=64). The outcome cohort was made up of 140 patients from the Scottish 
Aortic Stenosis and Lipid Lowering Trial Impact on Regression (SALTIRE) study and was followed up for 10.6 years 
(1254 patient-years). Compared with those without left ventricular hypertrophy (n=51) and left ventricular hypertrophy 
without ECG strain (n=30), patients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular 
mass index, more myocardial injury (high-sensitivity plasma cardiac troponin I concentration, 4.3 ng/L [interquartile 
range, 2.5–7.3 ng/L] versus 7.3 ng/L [interquartile range, 3.2–20.8 ng/L] versus 18.6 ng/L [interquartile range, 9.0–45.2 
ng/L], respectively; P<0.001) and increased diffuse fibrosis (extracellular volume fraction, 27.4±2.2% versus 27.2±2.9% 
versus 30.9±1.9%, respectively; P<0.001). All patients with ECG strain had midwall late gadolinium enhancement 
(positive and negative predictive values of 100% and 86%, respectively). Indeed, late gadolinium enhancement was 
independently associated with ECG strain (odds ratio, 1.73; 95% confidence interval, 1.08–2.77; P=0.02), a finding 
confirmed in the validation cohort. In the outcome cohort, ECG strain was an independent predictor of aortic valve 
replacement or cardiovascular death (hazard ratio, 2.67; 95% confidence interval, 1.35–5.27; P<0.01).
Conclusion—ECG strain is a specific marker of midwall myocardial fibrosis and predicts adverse clinical outcomes in aortic 
stenosis.  (Circulation. 2014;130:1607-1616.)
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left ventricular decompensation and investigated this associa-
tion using cardiovascular magnetic resonance (CMR) to assess 
the degree of LVH and myocardial fibrosis and high-sensitiv-
ity plasma cardiac troponin I (cTnI) as a marker of myocardial 
injury. Moreover, we aimed to reassess the adverse prognosis 
previously associated with the ECG strain pattern in patients 
with aortic stenosis.6
Methods
Three cohorts were used for the study. In the mechanism cohort, we 
determined the pathophysiology underlying the ECG strain pattern 
using CMR and plasma cTnI concentration in patients recruited from 
the Edinburgh Heart Center. This was then independently validated 
in an external validation cohort from the Royal Brompton Hospital, 
London. Subsequently, in the outcome cohort, we examined the 
prognostic role of ECG strain in patients with aortic stenosis. The 
study was conducted in accordance with the Declaration of Helsinki 
and was approved by the local research ethics committee. Written 
informed consent was obtained from all participants.
Patient Populations
Mechanism Cohort
Patients with aortic stenosis (mild to severe) were recruited pro-
spectively from the Edinburgh Heart Center. We excluded patients 
with other significant valvular heart disease (moderate or severe), 
contraindications to CMR, cardiomyopathies (acquired or inher-
ited), left or right bundle-branch block, concurrent digoxin use, and 
impaired systolic function on CMR (ejection fraction <95th percen-
tile for age and sex).7
Validation Cohort
Between 2011 and 2013, patients with moderate to severe aortic ste-
nosis undergoing CMR were prospectively recruited from the Royal 
Brompton Hospital, London, with the use of similar exclusion criteria.
Outcome Cohort
Patients were initially recruited into the Scottish Aortic Stenosis 
and Lipid Lowering Trial, Impact on Regression (SALTIRE) study 
between March 2001 and April 2002, which comprised 155 patients 
with asymptomatic aortic stenosis who had been randomly assigned 
to either atorvastatin 80 mg or placebo once daily. Patients were 
excluded if already on a statin or if aortic valve replacement (AVR) 
was planned (because of either symptoms or impaired systolic func-
tion).8 For the purposes of this analysis, patients on digoxin or with 
uninterpretable ECGs or bundle-branch block patterns were excluded.
Electrocardiography
A standard 12-lead ECG was obtained for all participants, and inter-
pretation of the ECG was performed independently by 2 observers 
who were blinded to the clinical data and imaging findings. LVH on 
ECG was diagnosed on the basis of the Romhilt-Estes point system 
(≥5 points),9 and ECG strain was defined as ≥1-mm concave down-
sloping ST-segment depression with asymmetrical T-wave inversion 
in the lateral leads (Figure 1A).10
Echocardiography
Transthoracic echocardiography was performed in all participants 
in the mechanism and outcome cohorts. Maximum aortic valve jet 
velocity and mean pressure gradient were measured by velocity–time 
integral spectral tracing and the aortic valve area derived with the 
continuity equation. Multiple acoustic windows with the S51 and 
Figure 1. ECGs and myocardial biopsies in 2 patients with severe aortic stenosis. The ECG for patient A (A) demonstrated left ventricular 
hypertrophy and associated repolarization abnormalities (ST-segment depression and asymmetrical T-wave inversion in the lateral leads) 
characteristic of the ECG strain pattern, whereas the ECG for patient B (B) demonstrated left ventricular hypertrophy without the strain 
pattern. Compared with patient B, patient A had increased left ventricular mass index (169 vs 81 g/m2), increased plasma cardiac troponin 
I concentrations (8.4 vs 2.5 ng/L), and evidence of more extensive myocardial fibrosis on both cardiovascular magnetic resonance and 
histology (picrosirius red staining).
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D2cwc probes (Philips Medical Systems, Best, the Netherlands) were 
assessed. The severity of aortic stenosis was classified according to 
the European Association of Echocardiography/American Society 
of Echocardiography guidelines.11 Transmitral early (E) and late (A) 
diastolic velocities and deceleration time of early filling velocity were 
measured at the tips of the mitral valve leaflets with pulsed-wave 
Doppler. Early (e′) diastolic velocities of the medial and lateral mitral 
annulus were measured with pulsed-wave tissue Doppler imaging. 
Diastolic function was determined from the E/A ratio, deceleration 
time, mean of medial and lateral e′, and E/e′. Midwall fractional 
shortening was estimated as an assessment of intrinsic myocardial 
contractility in the context of LVH.12
Cardiovascular Magnetic Resonance
CMR in the mechanism cohort was performed at 3 T (MAGNETOM 
Verio, Siemens AG, Healthcare Sector, Erlangen, Germany). In 
the validation cohort, CMR was performed at 1.5 T, as previously 
described.13 For the assessment of left ventricular function and mass, 
short-axis cine images from the mitral valve annulus to the apex were 
obtained by use of a balanced steady-state free-precession sequence 
(8-mm parallel slices with 2-mm spacing). The quantification of left 
ventricular function, volumes, and mass was assessed with dedicated 
software (Siemens AG Healthcare Sector, Erlangen, Germany) and 
indexed to body surface area. LVH on CMR was defined as a left 
ventricular mass index (LVMi) >95th percentile using age- and sex-
specific normal ranges.7 Left ventricular longitudinal shortening was 
determined by measuring the difference in mitral annular displace-
ment between end systole and end diastole. The mean value of the 
lateral and septal insertion sites (4-chamber view) and the anterior 
and inferior sites (2-chamber view) was used.
The assessment of focal replacement myocardial fibrosis was 
performed with late gadolinium enhancement (LGE) imaging, 
15 minutes after administration of 0.1 mmol/kg gadobutrol 
(Gadovist/Gadavist, Bayer Pharma AG, Berlin, Germany). Two 
approaches were used: an inversion recovery fast gradient-echo 
sequence and a phase-sensitive inversion recovery sequence, per-
formed in 2 phase-encoding directions to differentiate true late 
enhancement from artifact. The inversion time was optimized to 
achieve satisfactory nulling of the myocardium. Midwall LGE was 
determined visually by 2 independent operators who were blinded 
to the ECG findings. The amount of LGE was quantified with 
QMASS software (Medis Medical Imaging Systems, Leiden, the 
Netherlands) using a signal intensity threshold greater than twice 
the standard deviation above the mean value in a normal region of 
myocardium sampled on the same short-axis image. Areas thought 
to represent inversion artifact or contamination by blood pool or 
epicardial fat were manually excluded.
Table 1. Baseline Characteristics of Patients in the Mechanism Cohort
All Patients  
(n=102)
Patients With Aortic Stenosis
No LVH  
(n=51)
LVH Without  
Strain (n=30)
ECG Strain  
(n=21) P Value
Clinical characteristics
  Age, y
  Male sex, n (%)
  Diabetes mellitus, n (%)
  Hypertension, n %
  Coronary artery disease, n (%)
  Systolic blood pressure, mm Hg
  Bicuspid aortic valve, n (%)










































  Aortic valve area, cm2
  Aortic jet velocity, m/s
  MPG, mm Hg





















  Midwall fractional shortening, mm
  Mitral E/A ratio
  Deceleration time, ms
  Mean e′, cm/s



























  Indexed LV mass, g/m2
  LV mass/EDV ratio, g/mL
  Indexed EDV, mL/m2
  Indexed ESV, mL/m2
  Indexed stroke volume, mL
  Ejection fraction, %
  Longitudinal shortening, mm
  Patients with midwall LGE, n (%)
  Amount of LGE, %



















































Plasma high-sensitivity cTnI concentration, 
ng/L
6.7 (3.6–13.3) 4.3 (2.5–7.3) 7.3 (3.2–20.8) 18.6 (9.0–45.2) <0.001
cTnI indicates cardiac troponin I; ECV, extracellular volume fraction; EDV, end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; LV, left 
ventricular; LVH, left ventricular hypertrophy; MPG, mean pressure gradient; MRI, magnetic resonance imaging; and NYHA, New York Heart Association. 
ANOVA post hoc Bonferroni adjustment: *P<0.05 between no LVH and LVH without strain, †P<0.05 between LVH without strain and LVH with strain, and ‡P<0.05 
between no LVH and LVH with strain.
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Myocardial extracellular volume fraction (ECV) has been demon-
strated to act as a measure of diffuse myocardial fibrosis in a variety 
of cardiac conditions, including aortic stenosis.14–16 Recently, we have 
described a standardized approach to analyze myocardial ECV in 
patients with aortic stenosis, demonstrating excellent intraobserver, 
interobserver, and scan-rescan reproducibility of ±3%.17 In brief, myo-
cardial T1 mapping was performed in the mechanism cohort using 
the modified look-locker inversion recovery sequence: flip angle, 35°; 
minimum TI, 100 milliseconds; TI increment, 80 milliseconds; and 
time delay, 150 milliseconds with a heartbeat acquisition scheme of 
3-3-5.18 Regions of interest were drawn around the myocardium on 
the short-axis, precontrast, motion-corrected myocardial T1 maps 
and copied onto corresponding 20-minute postcontrast maps, with 
minor adjustments made to avoid partial volume effects and artifact 
(OsiriX version 4.1.1, Geneva, Switzerland). ECV was calculated 





×(1−hematocrit), where ∆R1=(1/postcontrast T1−1/precontrast T1). 
Hematocrit was sampled at the time of CMR.
High-Sensitivity Plasma cTnI Assay
Plasma cTnI concentrations were determined in patients in the mech-
anism cohort as a marker of myocyte injury with the ARCHITECT
STAT
 
high-sensitive troponin I assay (Abbott Laboratories, Abbott Park, 
IL). Previous data have shown that high-sensitivity plasma cTnI con-
centrations correspond to the magnitude of the hypertrophic response 
and extent of myocardial fibrosis in patients with aortic stenosis.19,20 
The lower limit of detection for this assay is 1.2 ng/L, and the 99th 
percentile from a healthy reference population of 26 ng/L, with a 10% 
interassay coefficient of variation at 4.7 ng/L.21 Concentrations lower 
than the detection limit were assigned a value of 1.2 ng/L.
Calcium Scoring in the Outcome Cohort
ECG-gated noncontrast computed tomography scans of the coronary 
arteries and aortic valve were performed in all patients in the outcome 
cohort with a double-helix scanner (Twin II Flash, Philips Medical 
Systems). Coronary artery and aortic valve calcium scores were 
determined by a single operator using the Picker Cardiac Scoring 
software.8
Long-Term Follow-Up in the Outcome Cohort
Clinical outcomes were obtained in the outcome cohort and adju-
dicated by 2 independent investigators blinded to the clinical and 
ECG data. In-hospital and community deaths were captured from 
the General Register of Scotland. Cardiovascular death was defined 
as death resulting from myocardial infarction, sudden cardiac death, 
heart failure, or stroke; death related to cardiovascular procedures; 
and death resulting from other cardiovascular causes. Each death 
was classified by the 2 independent investigators, and any discrep-
ancy was resolved by consensus. Furthermore, all events, including 
surgical AVR (no patients had transcatheter aortic valve implanta-
tion during follow-up), were confirmed by independent review of 
each patient’s healthcare record. All patients in the outcome cohort 
were managed in our tertiary cardiac center and reviewed at a mul-
tidisciplinary meeting before undergoing AVR. Only patients with 
established indications as per contemporary guidelines were referred 
for AVR.22,23
Statistical Analysis
Continuous variables were presented as mean±SD or median 
(interquartile range) as appropriate. The distribution of all continu-
ous variables was assessed for normality with the Shapiro-Wilk 
test. Comparison of continuous variables was performed with the 
Student t test or 1-way ANOVA with post hoc Bonferroni adjust-
ment when appropriate. The assumption of homogeneity of vari-
ances was tested with the Levene test. For nonparametric data, the 
Mann-Whitney U or Kruskal-Wallis test was used. Categorical 
variables were expressed as percentages and compared by use of 
the χ2 test for trend. All statistical analyses were performed with 
Table 2. Baseline Characteristics of Patients in the External Validation Cohort
All Patients  
(n=64)
Patients With Aortic Stenosis
No LVH  
(n=48)
LVH Without  
Strain (n=5)
ECG Strain  
(n=11) P Value
Clinical characteristics
  Age, y
  Sex, males, n (%)
  Diabetes mellitus, n (%)
  Hypertension, n %
  Coronary artery disease, n (%)
  Systolic blood pressure, mm Hg
  Bicuspid aortic valve, n (%)
  NYHA class III and IV, n (%)
  Race, n (%)
   White



















































  Planimetered aortic valve area, cm2
  Indexed LV mass, g/m2
  LV mass/EDV ratio, g/mL
  Indexed EDV, mL/m2
  Indexed ESV, mL/m2
  Indexed stroke volume, mL
  Ejection fraction, %









































EDV indicates end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; LV, left ventricular; LVH, left ventricular hypertrophy; 
MRI, magnetic resonance imaging; and NYHA, New York Heart Association. 
*The remaining patient had a large infarct.
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GraphPad Prism (GraphPad Software Inc, San Diego, CA), R ver-
sion 2.15.2 (Vienna, Austria), and SPSS version 20.0.0 (IBM Corp, 
Armonk, NY). A 2-sided value of P<0.05 was considered statisti-
cally significant.
Mechanism Cohort
In the mechanism cohort, the association between ECG strain and left 
ventricular mass and aortic stenosis severity was assessed with multi-
variable linear regression analysis to adjust for potential confounders. 
Furthermore, we assessed determinants associated with ECG strain 
using univariate and multivariable logistic regression.
Outcome Cohort
In the outcome cohort, time-to-event curves in patients with and with-
out ECG strain were estimated with the Kaplan–Meier method and 
compared by use of the log-rank test. To accommodate for competing 
risks, the association between time to AVR or cardiovascular death 
and ECG strain was modeled as a composite outcome in Cox propor-
tional hazards models. The assumption for proportional hazards was 
assessed using the log (−log[survival]) versus log(survival time) plots 
and by examining the Schoenfeld residuals.
Results
One hundred and two patients with aortic stenosis (age, 70 
years [interquartile range, 63–75 years]; male, 66%; aortic 
valve area, 0.9 cm2 [interquartile range, 0.7–1.2 cm2]) were 
recruited into the mechanism cohort, and an additional 64 
patients were recruited into the validation cohort (age, 76 
years [interquartile range, 69–84 years]; male, 69%; aor-
tic valve area, 0.9 cm2 [interquartile range, 0.7–1.0 cm2]; 
Tables 1 and 2). After the exclusion of patients with unin-
terpretable ECGs or bundle-branch block and those receiv-
ing digoxin therapy (n=15), 140 patients from the SALTIRE 
study were analyzed as part of the outcome cohort (age, 69 
years [interquartile range, 62–75] years; male, 70%; aor-
tic valve area, 1.0 cm2 [interquartile range, 0.7–1.3 cm2]; 
Table 3). All patients in the mechanism and outcome cohorts 
were white. In the validation cohort, 92% were white and the 
remainder were South Asian. There were no observed racial 
differences with respect to the presence of LVH or strain on 
the ECG (P=0.95; Table 2).
Mechanisms Underlying ECG Strain
Fifty-one patients in the mechanism cohort fulfilled the ECG 
criteria for LVH, demonstrating high predictive values for the 
presence of CMR-defined LVH (positive predictive value, 
96%; negative predictive value, 89%). Of these, 21 patients 
had the strain pattern on their ECGs. These patients with ECG 
strain had the highest LVMi and most severe aortic stenosis 
compared with the other patient groups (those without LVH 
on their ECG and those with LVH but no ECG strain; Table 1), 
even after adjustment for age, sex, and systolic blood pressure 
(P<0.001 for both). Moreover, compared with other groups, 
these patients had increased end-diastolic volumes (P<0.01), 
worse diastolic function (P<0.001), and more severe symp-
toms (P<0.001; Table 1). Despite similar left ventricular ejec-
tion fractions, patients with LVH and ECG strain also had the 
worst longitudinal function (Figure 2) and midwall fractional 
shortening (Table 1).
Interestingly, all patients with LVH and ECG strain had focal 
midwall fibrosis (positive and negative predictive value, 100% 
and 86%, respectively; Figure 3B), strongly supporting ECG 
strain as a specific marker of replacement myocardial fibrosis. 
Moreover, these patients had more extensive diffuse myocar-
dial fibrosis (ECV, 30.9±1.9% versus 27.2±2.9% in patients 
with LVH and no ECG strain versus 27.4±2.2% in patients 
without LVH; P<0.001; Figure 3A) and myocardial injury 
as assessed by high-sensitivity plasma cTnI. Indeed, plasma 
cTnI concentrations were >4-fold higher in patients with strain 
than in the other patient groups (18.6 ng/L [interquartile range, 
Table 3. Characteristics of Patients in the Outcome Cohort
All Patients  
(n=140)
Patients With Aortic Stenosis
No ECG  
Strain (n=120)
ECG Strain  
(n=20) P Value
Clinical characteristics
  Age, y
  Male sex, n (%)
  Diabetes mellitus, n (%)
  Hypertension, n (%)
  Coronary artery disease, n (%)


























  Aortic valve area, cm2
  Peak aortic jet velocity, m/s
  MPG, mm Hg
  Ejection fraction, %






















  Coronary calcium score, log AU









Plasma high-sensitivity cTnI concentration, 
ng/L
7.5 (5.7–13.4) 6.9 (5.3–11.4) 17.3 (10.5–29.6) <0.001
AU indicates arbitrary units; cTnI, cardiac troponin I concentration; LVMi, left ventricular mass index; and MPG, mean pressure 
gradient.
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9.0–45.2 ng/L] versus 7.3 ng/L [interquartile range, 3.2–20.8 
ng/L] in patients with LVH and no ECG strain versus 4.3 ng/L 
[interquartile range, 2.5–7.3 ng/L] in patients without LVH; 
P<0.001; Figure 2D). Three patients with ECG strain had both 
an infarct and midwall pattern of fibrosis on LGE, and our find-
ings remained unchanged even after their exclusion.
On univariate analysis, ECG strain was associated with 
an increased LVMi, more severe aortic stenosis, increased 
replacement and diffuse myocardial fibrosis, and diastolic 
dysfunction (all P<0.01; Table 4) but was not associated with 
the presence of coronary artery disease (odds ratio, 1.88; 
95% confidence interval, 0.68–5.18; P=0.22). However, only 
increased myocardial fibrosis (either amount of LGE or ECV) 
and the severity of aortic stenosis maintained an independent 
association on multivariate analysis, with increased LVMi, 
increased myocardial injury, and diastolic dysfunction all 
dropping out of the model (models 3 and 4 in Table 4).
Myocardial histology was available in 2 patients who under-
went AVR and biopsy, supporting increased myocardial fibro-
sis in patients with LVH and ECG strain (Figure 1). However, 
not all patients with myocardial LGE had a strain pattern on 
the ECG. Indeed, of the 32 patients with myocardial LGE, 11 
patients (34%) did not have any evidence of ECG repolariza-
tion abnormalities. Interestingly, these patients had ≈40% less 
replacement fibrosis on LGE compared with patients who had 
ECG strain (5.6% [interquartile range, 4.3%–7.5%] versus 
9.5% [interquartile range, 7.5%–14.2%]; P=0.002), with no 
differences in the distribution of midwall LGE between these 
groups (P=0.78; see Distribution of Midwall Fibrosis in the 
online-only Data Supplement).
Validation Cohort
In the external validation cohort, similar findings were dem-
onstrated (Table 2). There were 11 patients with ECG strain, 
of whom 10 had isolated midwall fibrosis and 1 had extensive 
Figure 2. Despite similar normal-range ejection fractions (A), patients with left ventricular hypertrophy (LVH) and ECG strain had the 
most impaired longitudinal shortening (B) and diastolic function (C). High-sensitivity plasma cardiac troponin I concentrations were 4-fold 
higher in patients with ECG strain compared with patients without LVH on ECG (D). Results are presented in box-and-whiskers plot 
(Tukey method).
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fibrosis from a large myocardial infarct to explain the ECG 
changes. Conversely, 15 patients had midwall fibrosis but no 
ECG strain. In this cohort of patients with moderate to severe 
aortic stenosis, the positive and negative predictive values of 
LVH with ECG strain for midwall fibrosis were 91% and 72%, 
respectively. Patients with ECG strain were again observed 
to have an advanced hypertrophic response associated with 
increased LVMi and reduced myocardial performance (Table 2).
Prognostic Value of ECG Strain
In the outcome cohort, 20 patients (14%) had LVH with strain 
on ECG. Consistent with the mechanism cohort, patients with 
ECG strain had more severe aortic stenosis, increased LVMi, 
and elevated plasma cTnI concentrations compared with those 
without strain (Table 3). Of note, these elevated cTnI con-
centrations in patients with ECG strain were similar to those 
observed in the mechanism cohort (P=0.85). Over 10.6 years 
of follow-up (1254 patient-years), 63 patients had an AVR 
and 22 patients died of a cardiovascular cause of a total of 
36 deaths. ECG strain was associated with a lower 10-year 
event-free survival rate for AVR or cardiovascular death 
(log-rank test, P<0.0001; Figure 4). Indeed, this association 
persisted even after adjustment for traditional markers of an 
adverse outcome, including systolic ejection fraction, severity 
of aortic stenosis, LVMi, and aortic valve calcium score (haz-
ard ratio, 2.67; 95% confidence interval, 1.35–5.27; P<0.01; 
see Univariate and Adjusted Cox Models Predicting Time to 
Adverse Events in the online-only Data Supplement). 
Discussion
This is the first CMR study to investigate the mechanisms 
underlying the ECG strain pattern in patients with aortic steno-
sis, demonstrating that it is a highly specific marker of midwall 
myocardial fibrosis. Moreover, ECG strain was associated with 
increased myocardial injury and impaired left ventricular per-
formance and was an independent predictor of cardiovascular 
death or AVR. Our data therefore indicate that ECG strain is a 
powerful biomarker of left ventricular decompensation in aor-
tic stenosis, with the ability to identify an at-risk population 
who may benefit from earlier valve replacement.
Currently, AVR is recommended in patients with severe aor-
tic stenosis who have symptoms or evidence of left ventricular 
decompensation with an ejection fraction <50%.23 However, 
symptoms are often subjective, particularly in the elderly, and 
Figure 3. Patients with the strain pattern on the ECG had increased extracellular volume fractions, suggestive of increased diffuse 
myocardial fibrosis (A). Furthermore, all patients with ECG strain had a midwall pattern of late gadolinium enhancement (B). Of note, about 
a third of patients with midwall late gadolinium enhancement did not have ECG strain. The corresponding myocardial T1 map (A) and late 
gadolinium enhancement image (B) of a patient with ECG strain demonstrated evidence of focal myocardial fibrosis in the midcavity lateral 
wall. The extracellular volume fraction of the midcavity slice in this patient was 30.2%. LVH indicates left ventricular hypertrophy.
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a reduced ejection fraction is frequently a late manifestation 
and is not necessarily reversible. There is therefore interest in 
exploring alternative, earlier, and more objective markers of 
ventricular decompensation in aortic stenosis.5
Previous echocardiographic studies have demonstrated 
that ECG strain is associated with an advanced hypertrophic 
response,24 and it has been hypothesized that the characteris-
tic repolarization abnormalities relate to coronary perfusion 
abnormalities, even in the absence of coronary artery dis-
ease.25–28 Our study adds to these data, demonstrating a close 
association between ECG strain and myocardial injury and 
fibrosis. Indeed, across 2 independent cohorts, midwall myo-
cardial fibrosis was present in 31 of the 32 patients with strain 
on their ECGs, and the remaining subject had an extensive 
infarct to explain the ECG changes. Moreover, patients with 
strain had evidence of higher plasma cTnI concentrations and 
worse myocardial function. It has been established that myo-
cardial ischemia, cell death, and fibrosis are all key features 
that characterize the transition from hypertrophy to heart fail-
ure in aortic stenosis. Our study would therefore support ECG 
strain as a useful marker of left ventricular decompensation in 
patients with this condition.
In our outcome cohort, we have demonstrated that ECG strain 
acts as a strong independent predictor of AVR or cardiovascular 
death, over and above established prognostic markers such as 
systolic ejection fraction, severity of aortic stenosis, LVMi, and 
aortic valve calcium score. Indeed, patients with ECG strain 
had a >2-fold increase risk in adverse events compared with 
patients without ECG strain. This is in agreement with previous 
studies that have demonstrated an adverse prognosis associated 
with ECG strain.6,29,30 However, our study provides much longer 
periods of follow-up than have been described previously.








OR (95% CI) P Value OR (95% Cl) P Value OR (95% Cl) P Value OR (95% Cl) P Value
Age, per 10 y 0.91 (0.61–1.36) 0.56 0.88 (0.38–2.03) 0.76 … … … …
Male sex 1.69 (0.56 -5.10) 0.35 0.54 (0.07–3.93) 0.54 … … … …
Coronary artery disease 1.88 (0.68–5.18) 0.22 … … … … … …
MPG, per 10 mm Hg 1.80 (1.31–2.48) <0.001 1.88 (1.02–1.13) <0.01 1.93 (1.04–3.60) 0.03 2.10 (1.22–3.60) 0.01
LVMi, per 10 g/m2 2.10 (1.49–2.95) <0.001 1.95 (1.14–3.35) <0.01 1.30 (0.63–2.66) 0.47 1.77 (0.97–3.22) 0.06
Amount of LGE, % 1.75 (1.35–2.27) <0.001 … … 1.73 (1.08–2.77) 0.02 … …
ECV, % 1.86 (1.38–2.47) <0.001 … … … … 1.55 (1.04–2.31) 0.03
High-sensitivity cTnI* 3.14 (1.73–5.71) <0.001 3.30 (1.24–8.80) 0.02 3.18 (0.62–16.26) 0.16 2.43 (0.83–7.10) 0.11
Mean e′ 0.51 (0.34–0.75) <0.01 … … 1.71 (0.38–7.54) 0.71 0.95 (0.46–1.94) 0.88
CI indicates confidence interval; cTnI, cardiac troponin I; ECV, extracellular volume fraction; LGE, late gadolinium enhancement; LVMi, left ventricular mass 
index; MPG, mean pressure gradient; and OR, odds ratio. 
*Log-transformed.
Figure 4. Kaplan–Meier estimates of time to 
event by status of ECG strain in the outcome 
cohort. Patients with ECG strain had significantly 
lower event-free survival compared with patients 
without ECG strain. LVH indicates left ventricular 
hypertrophy.
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There are clear potential advantages of using ECG strain 
as a marker of left ventricular decompensation in aortic ste-
nosis. A 12-lead ECG is readily available, cheap, and rapidly 
interpretable. However, although ECG strain is an extremely 
specific marker for myocardial fibrosis, it is less sensitive. 
Indeed, in our mechanism cohort, >30% of patients with 
replacement myocardial fibrosis did not have strain on the 
ECG. Importantly, these patients had 40% less replacement 
fibrosis compared with those with strain, suggesting that strain 
is a relatively late manifestation and that CMR offers even 
more sensitive detection of myocardial fibrosis and left ven-
tricular decompensation.
Our data suggest that patients with ECG strain who are 
asymptomatic would derive long-term benefit from early AVR 
as a result of the prevention of progressive myocardial fibro-
sis and injury that would otherwise develop while the patient 
waited for the onset of symptoms. The stage is now set for ran-
domized, controlled studies to investigate this strategy, exam-
ining the clinical utility of the ECG strain pattern in guiding 
early AVR alongside other novel and more sensitive markers 
of left ventricular decompensation, including high-sensitivity 
cTnI concentrations20 and midwall LGE.13
Limitations
In this study, separate cohorts were used to investigate 
the mechanism and prognosis of patients with ECG strain 
because CMR was not available in the original SALTIRE 
study. We therefore cannot directly confirm that ECG strain 
was similarly related to myocardial fibrosis in the outcome 
study. However, ECG strain in this population demonstrated 
the same associations with increased LVMi, aortic steno-
sis severity, and plasma cTnI concentrations, as observed in 
the mechanism cohort. Moreover, in our validation cohort, 
the same clear association between ECG strain and midwall 
LGE was also observed. We are therefore confident that 
ECG strain acts as a specific marker of midwall myocardial 
fibrosis and left ventricular decompensation in the predomi-
nantly white patients investigated in this study, although 
further studies are required for confirmation in different 
ethnic groups.
Conclusions
In patients with aortic stenosis, ECG strain is a specific marker 
of midwall myocardial fibrosis and an independent predictor 
of cardiovascular death or AVR. Future research should now 
examine whether the ECG strain should be used as a marker of 
left ventricular decompensation to guide early AVR in asymp-
tomatic patients.
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CLINICAL PERSPECTIVE
Aortic stenosis is a condition that affects not only the valve but also the myocardium. The transition from compensatory 
left ventricular hypertrophy to heart failure appears to be the key factor in determining the development of symptoms and 
adverse events. Assessment of this transition is currently limited, and interest surrounds the development of novel biomark-
ers of left ventricular decompensation. In a cohort of 102 patients with aortic stenosis, we have demonstrated that ECG 
left ventricular hypertrophy with strain is a highly specific marker of left ventricular decompensation and, in particular, of 
replacement myocardial fibrosis as assessed with cardiovascular magnetic resonance, a finding validated in an independent 
external cohort of 64 patients. Moreover, we have confirmed ECG strain as an independent predictor of cardiovascular 
mortality or aortic valve replacement in 140 asymptomatic patients recruited from the Scottish Aortic Stenosis and Lipid 
Lowering Trial Impact on Regression (SALTIRE) study. Our data indicate that a 12-lead ECG, which is readily available, 
cheap, and rapidly interpretable, can identify high-risk patients with aortic stenosis who potentially might benefit from early 
valve replacement.





DISTRIBUTION OF MID-WALL FIBROSIS  
 
Mid-wall fibrosis was predominantly found in the basal and mid-cavity (92% 
and 100% of all segments with late gadolinium enhancement in patients with 
and without ECG strain, respectively).  Whilst late gadolinium enhancement 
was observed more commonly in the septum, inferior and inferolateral than 
anterior segments, the distribution was not different between those with and 




UNADJUSTED AND ADJUSTED COX MODELS PREDICTING TIME TO 
ADVERSE EVENTS 
 
Further analyses were performed to determine the prognostic value of 
electrocardiographic strain in patients with aortic stenosis, adjusting for 






Values presented are hazard ratios for the presence of LVH strain in 
predicting time to aortic valve replacement or cardiovascular death 
Model 1 = unadjusted 
Model 2 = adjusted for sex and age 
Model 3 = adjusted as in Model 2 and aortic valve calcium score 
Model 4 = adjusted as in Model 2, systolic ejection fraction and coronary 
artery calcium score 
Model 5 = adjusted for aortic valve calcium score, mean pressure gradient, 
systolic ejection fraction and left ventricular mass index 
 
